Our data further demonstrate the complex genetics associated with leiomyosarcomas. As a class, tumor suppressor genes were the most commonly mutated loci, including TP53, mutated in 36% of cases (9/25). The loss of key tumor suppressor genes is consistent with our observations that CNV was present in 85% of leiomyosarcomas. While no common therapeutically targetable gene was identified across these cases, future large cohort sequencing studies of leiomyosarcomas may provide a means for the molecular classification of these tumors and identify new treatment paradigms. Chang-Tsu Yuan, Yung-Ming Jeng, Sheng-Yao Su, Cher-Wei Liang, Chung-Yen Lin, Shu-Hwa Chen, Cheng-Han Lee, Jodi Carter, Chen-Tu Wu, Andrew Folpe, Jen-Chieh Lee. National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Academia Sinica, Taipei, Taiwan; University of Alberta and Royal Alexandra Hospital, Edmonton, AB, Canada; Mayo Clinic, Rochester, MN. Background: Phosphaturic mesenchymal tumors (PMT) are unusual soft tissue and bone tumors that typically cause hypophosphatemia and tumor-induced osteomalacia through secretion of phosphatonins such as fibroblast growth factor 23 (FGF23). PMT has recently been accepted by the World Health Organization as a formal tumor entity. The genetic basis and oncogenic pathways underlying its tumorigenesis remain obscure. Design: Four PMT samples were subjected to RNA sequencing in search of possible fusion transcripts, which would be confirmed by genomic DNA PCR, RT-PCR and western blotting. Fluorescence in situ hybridization (FISH) was performed on a total of 15 cases to check the presence of the fusion gene. Results: Three of the four cases were found harboring a novel FN1-FGFR1 fusion gene by RNA sequencing, which was confirmed by DNA PCR and RT-PCR. Western blotting corroborated the presence in two cases of the chimeric FGFR1 protein with increased sizes. FISH showed 6 cases with FN1-FGFR1 fusion, out of an additional 11 PMTs. Overall, 60% (9/15) harbored this fusion.
Study cases (n=19) Control cases (n=50) p
Largest Tumor size (median) cm 1.8 1.1 0.048
Cumulative size (median) cm 3.5 1.8 0.003
LVI % 95 18
Nodal metastasis % 74 18
In addition, a higher percentage of study cases presented with ≥5 tumor foci compared to controls (42% and 2%, respectively; p=0.0002). Among controls, the majority of patients had only 2 tumor foci (58%). There was a greater percentage of patients with grade III tumors among study cases compared to control cases (63% and 26%, respectively; p=0.0088). There was no statistical difference between the groups with respect to age and biomarkers.
Conclusions:
There is an aggressive subset of MBC that often presents with 5 or more tumor foci/satellite nodules and a higher rate of nodal metastasis. The aggressive behavior of these cases may be cautiously attributed to their proclivity for LVI in a phenomenon akin to 'satellite' and 'in-transit metastasis' in melanoma.
Histogram of Hosoya Indices for Assessing Similarity Across Subgraph Populations: Breast Cancer Prognosis Prediction From Digital Pathology
Sahirzeeshan Ali, Ajay Basavanhally, Shridar Ganesan, Anant Madabhushi. Case Western Reserve University, Cleveland, OH; Rutgers University, Piscataway, NJ. Background: Spatial arrangement of nuclei in digitized pathology images has been shown to be strongly associated with disease aggressiveness and patient outcome for a number of different cancers. There might be recurring structural patterns that are linked to disease outcome. Several researchers have shown that by constructing a graph network, built using nuclei as vertices may actually be a reflection of the underlying molecular biology of the tumor. What remains unexplored however, is identifying similar subgraph structures that are recurring across the population and their effect on overall tumor morphology. Hosoya index (HI) was originally introduced as a measure of chemical bonds. We sought to leverage HI to measure structural similarities of graphs (bonds) across the populations that are indicative of recurrence in breast cancer tissue images. Design: Using a tissue microarray cohort of 74 early-stage estrogen receptor positive (ER+) breast cancer (BCa) patients (diagnosed with invasive ductal carcinoma) were divided into two groups corresponding to patients who experience lifetime distant recurrence (N=23) and those who did not (N=51). All TMA cores were digitized at 20x magnification (0.33 um/pixel spatial resolution). Each nucleus was identified via a computerized image analysis algorithm. Then, using a novel cell graph that encodes a link between a pair of nodes based on proximity, a series of graphs are constructed on a TMA. From each of the resulting graphs, a signature is created based on the distribution of HI value measured on each of the graph in the TMA core. A random forest classifier is developed, trained and validated on these signatures over 10 runs of 3-fold cross validation using subsets of the cases for independent training and testing. Our hypothesis was that there are recurring bonds (as measured by HI signature) across the patient population that is predictive of life-time recurrence in BCa histopathology. Results: For the ER+ BCa dataset, our method was able to predict recurrence with an accuracy of 79.7%. Conclusions: Cases with non-classical HER2 amplification or equivocal results are typically ER positive, higher grade cancers. Co-amplified cases have the highest rates of aggressive characteristics. These results support the current classification scheme for HER2 FISH, with case-by-case correlation with additional clinical-pathologic factors when evaluating whether to offer HER2 targeted therapies.
Anomalous Expression of Cytokeratin and p63 in the Stroma of Phyllodes Tumor: A Comparison With Spindle Cell Metaplastic Carcinoma
Meenakshi Bansal, David Hicks, Qi Yang, Xi Wang. University of Rochester Medical Center, Rochester, NY. Background: The stromal expansion and overgrowth in phyllodes tumors may cause diagnostic confusion with spindle cell metaplastic carcinomas, especially on core biopsies. Immunohistochemical stain for cytokeratin and p63 has been applies to distinguish them. However, Chia et al recently reported focal patchy cytokeratin stains in as many as 28% of phyllodes tumors. Design: Twenty one phyllodes tumors (12 benign, 1 borderline, 9 malignant) were identified in department file from 2005 to now. Four tumor blocks were selected from each case. Immunohistochemical stain for cytokeratin cocktail (including AE1/ AE3 and Cam 5.2) and p63 were performed. In addition, 22 metaplastic carcinoma composed entirely or mostly of spidnle cells were identified in file from 1997 to now. Immunohistochemistry profile was available for 15 of the 22 cases. Patient's age, tumor size and lymph node status were abstracted from the pathology report. Results: Cytokeratin cocktail and p63 were focally (5% of the tumor cells) expressed in the stroma of the 2 of 9 (22%) malignant phyllodes tumors in a scattered/patchy pattern, while the stroma of benign and borderline phyllodes tumors was not stained with these markers. On the other hand, cytokeratin was negative in the spindle cells of metaplastic carcinomas in 3 of 15 cases, very focally positive in another 3 cases, while p63 was negative in one case and very focally positive in another case. Clinically, phyllodes tumor was diagnosed in the youger age group (mean age 41, ranging from 13 to 83) with larger tumor size (mean size 6.6 cm, ranging from 1.5 cm to 14 cm), compared with spindle cell metaplastic carcinoma (mean age 62.7, ranging from 42 to 87; mean size 3.4 cm, ranging from 1.0 to 10 cm). Two cases of the malignant phyllodes tumor had lymph node sampled and they are negative, while 4 of the 19 metaplastic carcinoma cases with lymph node sampled had metastatic disease in the lymph node (s). Conclusions: Anomalous expression of cytokeratin and p63 could be present in the stroma of malignant phyllodes tumor, whereas spindle cell metaplastic carcinoma occasionally could be cytokeratin negative or very focal, even though p63 negativity is rare. Caution should be exercised when one is relying on those markers to make differential diagnosis, especially on core biopsies. Other clinical/pathological informations may have reference value.
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Impact of the 2013 ASCO/CAP Guideline Recommendations for HER2 Testing of Invasive Breast Carcinoma: A Focus on Tumors Assessed as Equivocal for HER2 Gene Amplification By FISH Gillian Bethune, Daniel Veldheijzen van Zanten, Tallal Younis, Daniel Rayson, Kara Thompson, Penny Barnes. Dalhousie University, Halifax, NS, Canada. Background: HER2 testing is routinely performed on primary invasive breast cancers. An update to the 2007 ASCO-CAP HER2 testing guidelines includes changes to HER2 in situ hybridization (ISH) interpretation criteria. The current 'equivocal' category places emphasis on mean HER2 copy number and is now defined as a HER2 count between 4.0 and <6.0, and a HER2:CEP17 ratio of <2.0, with additional testing recommended for such cases. We conducted a single center retrospective review of a consecutive cohort of primary breast carcinomas with available HER2 results to assess the impact of updated guidelines on HER2 classification, laboratory resources, and to better understand the pathobiology of tumors that are equivocal for HER2. Design: FISH records were reviewed for all primary breast cancers that underwent dual-probe HER2 FISH testing from [2007] [2008] [2009] [2010] [2011] [2012] [2013] . We classified each case using both 2007 and 2013 guidelines and identified a subset that were initially reported as HER2 negative but are deemed equivocal by 2013 guidelines. Traditional pathologic factors of this subset were compared to HER2 negative (n=311) and positive (n=144) control cases. Results: A total of 904 HER2 FISH tests were completed, most of which were performed for equivocal HER2 immunohistochemistry. 90.6% (819 cases) had no change in HER2 classification. Of the 85 (9.4%) cases with a classification change, 66 (7.3%) went from HER2 negative to equivocal, 15 cases (1.7%) were reclassified as HER2 positive, and 4 cases from HER2 equivocal to negative. Tumors reclassified from HER2 negative to equivocal were predominantly ER positive (90%). The three HER2 groups were significantly different with respect to tumor size (p<0.0001), Nottingham grade (p<0.0001), lymphatic/vascular invasion (p<0.0001), and lymph node status (p=0.0063). The differences were driven by comparisons between HER2 positive and negative control groups, with the study group showing intermediate features between both control groups.
Conclusions:
The updated HER2 testing guidelines will result in the reclassification of approximately 9.5% of primary breast cancers with uncertainty regarding the clinical impact of this reclassification in the majority of cases. Resource utilization will increase as a result of the recommendation for retesting. Further work is needed to better elucidate the clinical-pathologic behavior of this novel group of HER2 'equivocal' primary breast cancers. Daniel Carvajal-Hausdorf, Kurt Schalper, Lajos Pusztai, Amanda Psyrri, Konstantine Kalogeras, Vasiliki Kotoula, George Fountzilas, David Rimm. Yale University, New Haven, CT; Attikon University Hospital, Athens, Greece; Aristotle University of Thessaloniki, Thessaloniki, Greece. Background: The ASCO/CAP guidelines consider chromogen-based immunohistochemistry (IHC) as the primary assay to determine HER2 status in breast cancer. Studies have shown that antibodies targeting the intracellular [ICD] or extracellular domains [ECD] ) of HER2 are equivalent when the chromogenic method is used. Here we differentially quantified HER2 ICD and ECD expression, and assessed the prognostic value of domain specific HER2 results in patients who received adjuvant Trastuzumab therapy. Design: We measured HER2 protein expression with quantitative immunofluorescence (QIF) and IHC in a HER2 standardization tissue microarray (TMA) using previously shown ICD and ECD antibody assays. Population-based cut-points were generated using Joinpoint software without considering outcome. HER2 IHC and FISH results were used as reference to determine sensitivity and specificity of the domain specific results. We assessed the prognostic value of ICD and ECD expression in 180 patients from a clinical trial of adjuvant chemotherapy followed by Trastuzumab (HeCOG 10/05). Results: : HER2 ICD and ECD expression by QIF showed similar sensitivity and higher specificity to predict HER2 gene amplification than IHC. In the HeCOG 10/05 trial specimens. 15% of cases showed discordant results for ICD and ECD expression. High ECD was significantly associated with longer disease-free survival (DFS) (logrank P=0.049, HR=0.31, 95% CI: 0.144-0.9970.144-0.997), while ICD status was not. Among patients with low ECD, there was no difference in DFS by ICD status. However, when ICD was high, high ECD was significantly associated with longer DFS (log-rank P=0.027, HR=0.23, 95% CI: 0.037-0.82) compared to low ECD.Neither ICD nor ECD showed prognostic value in the 462 patients that were traditionally classified as HER2 negative and did not receive trastuzumab. Conclusions: Performance to predict HER2 amplification is affected by domain and detection technique. Quantitative measurements of HER2 ICD and ECD expression in breast cancer suggest a subclassification of HER2 positive tumors. Trastuzumab-treated patients with high ECD have better DFS than patients with low ECD. Elevated ICD alone has no prognostic value. This observation raises the possibility of differential benefit from trastuzumab therapy based on HER2 ECD expression.
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Measurement of Domain Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer
Prolactin Levels, Expression of Downstream Signals in the Prolactin Receptor Pathway and Breast Cancer Risk: A Nested CaseControl Study From the Nurses' Health Study
Dilys Chen, Megan Rice, Shelley Tworoger, Charles Clevenger, Rulla Tamimi, Susan Hankinson, Laura Collins. Beth Israel Deaconess Medical Center, Boston, MA; Harvard School of Public Health, Boston, MA; Virginia Commonwealth University, Richmond, VA; University of Massachusetts, Amherst, MA. Background: Prolactin is a potent mitogen for the development of breast carcinoma through its transmembrane receptor (PRLR) and downstream signaling pathways: PI3K/MEK/AKT and JAK2/STAT5. Prolactin, when bound to PRLR, activates the JAK kinases resulting in STAT5 phosphorylation (pSTAT5) localizing it to the nucleus. pSTAT5 modulates expression of key target genes involved in growth, differentiation and survival and has been shown to have a role in resistance to antiestrogen therapy. While circulating prolactin has been related to breast cancer risk, it is not known whether this varies by tumor expression of proteins in the signaling pathway. Design: We used conditional logistic regression to examine the association between prediagnostic circulating prolactin levels (>vs< median of 11 ng/mL) and breast cancer risk by tumor expression of markers in the PRLR pathway in a case-control study nested within the Nurses' Health Study. The analysis included 787 women with breast cancer and 1226 controls matched on age, fasting status and timing of blood collection. PRLR, pSTAT5 and pJAK2 expression was evaluated on immunostained breast cancer TMAs. For PRLR and pSTAT5, cores were scored from 0-3+ for cytoplasmic(c) and nuclear(n) staining intensity; a case was considered + if >1 core was scored ³2+ except c-pSTAT5 which was scored + if any core was ³1+ due to small numbers of cores scored ³2+. pJAK2 was scored + if >1% of nuclei expressed the biomarker. Results: The % positive cases are: c-PRLR=23%, n-PRLR=26%, c-pSTAT5=74%, n-pSTAT5=25% and pJAK2=81%. Women with higher plasma prolactin levels had a 2-fold increase in risk of n-pSTAT5+ tumors compared to women with lower levels (OR=2.0, 95%CI:1.3-2.9). However, there was no association between prolactin levels and n-pSTAT5 negative tumors (OR=1.05, 95%CI:0.8-1.3). There were no differences in the association between prolactin levels and breast cancer risk by PRLR, c-pSTAT5 or pJAK2 expression. Conclusions: Our findings suggest elevated plasma prolactin levels may preferentially increase risk of breast tumors with high pSTAT5 expression. Confirmation of these results is needed, as well as an evaluation of whether women with elevated prolactin levels and pSTAT5+ tumors may show less resistance to antiestrogen therapy than those with pSTAT5 negative tumors (Peck, JCO 2011) . Hui Chen, Rajesh Singh, Lei Huo, Xinyan Lu, Alex Bousamra, Ronald Abraham, Meenakshi Mehrotra, Bal Mukund Mishra, Shumaila Virani, Sinchita Roy Chowdhuri, Mark Routbort, Ken Aldape, Russell Broaddus, Aysegul Sahin, Keyur Patel, Rajyalakshmi Luthra. University of Texas MD Anderson Cancer Center, Houston, TX. Background: Breast cancer is the second leading cause of cancer related death in women. Recent advances allowed the identification of common targetable genomic alterations. Fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR) have been implicated as therapeutic targets in various cancer types. However, copy number aberrations in these genes remain under-characterized in breast cancer. Here, we explore FGFR1 and EGFR amplification in breast carcinomas using molecular inversion probe array (MIP). Design: We selected 43 invasive adenocarcinoma of breast from the archives of MD Anderson Cancer Center (2011 -2014 . Based on hormonal receptor (HR) expression by immunohistochemistry and HER2 amplification by fluorescence in situ hybridization, the cases were classified into 4 groups: HR+/HER2-(n=15), HR+/HER2+ (n=14), HR-/HER2+ (n=8), and HR-/HER2-(n=6). After manual micro-dissection of tumors from formalin-fixed, paraffin-embedded tissue (FFPE), genomic DNA was extracted and subjected to MIP by OncoScan FFPE Assay kit and OncoScan Console software (Affymetrix, Santa Clara, CA). Copy number analysis of FGFR1 and EGFR was performed by Nexus Express for OncoScan (BioDiscovery, El Segundo, CA). We defined gene amplification with a designated cut-off of 4.0 for high copy number gains. Four selected cases were also analyzed for FGFR1 amplification by next generation sequencing (NGS) using Ion Torrent PGM and 50 gene hotspot panel (LifeTechnologies, Carlsbad, CA) . Results: Ten of 43 cases (23%) showed FGFR1 amplification (copy number: 4.0-22) and 11 of 43 cases (26%) displayed EGFR amplification (copy number: 4-7). The results are summarized in Table 1 . Interestingly, we observed co-amplification of FGFR1 and EGFR only in HER2+ cases (6/22) but not in HER2-cases (0/21; p=0.02). In the 4 cases with FGFR1 amplification but without EGFR amplification, FGFR1 and EGFR copy number status was also confirmed by NGS analysis. Conclusions: In our HER2+ cohort, there is correlation between FGFR1 amplification and EGFR amplification. In contrast, no co-amplification of FGFR1 and EGFR is detected in HER2-cases. These findings suggest that breast tumors can be further subtyped with different implications for targeted therapy. (FISH) or IHC has been standard of practice. Recently, DISH assay was approved by the FDA for HER2 testing. Although both in-situ methods (FISH and DISH) are performed on paraffin tissue, DISH utilizes light microscopy in assessment of HER2/CEP17 signals. While comparative data on DISH with other tests (FISH and IHC) have been published; the experience of DISH assay as a routine test has not been widely published. The aim of this study is to evaluate the performance of DISH in our laboratory as a routine test. Design: Dual ISH staining results in visualization of HER2 as discrete black signals and CEP17 as red signals in normal (serving as internal positive controls) as well as in tumor nuclei using standard light microscopy. Four (4) -mm tissue specimen sections were used on the Benchmark XT staining platform (Ventana Medical Systems, Tucson, AZ). Statistical analysis was performed with calculation of P value using Graph Pad Prism 6 software. Results: From January 2013 -August 2014, the DISH assay was performed on 490 breast cancer tissues (including 30 cases for initial validation). Five (5) cases were excluded due to absence of microinvasive carcinoma. 11% (49/452) were amplified; 2% (7/452) showed borderline amplification; 87% (396/452) were non-amplified (NA) Among the NA cases, 2% (6/396) showed aneusomy. In a subset of cases (validated and heterogeneous cases reflexed to FISH) the comparison of DISH to FISH ratio showed a high concordance rate (P value = 0.2451}; although DISH showed lower HER2 copy numbers. Technical difficulties were encountered in 3% (13/452) cases and were repeated and reflexed to an alternate test (FISH/IHC).
FGFR1 and EGFR Amplification in Breast Cancer
Conclusions:
We report the experience of HER2 DISH assay which undeniably has additional advantages. Reflex testing to IHC/FISH is recommended in presence of heterogeneity of signals, staining issues as well as clusters. DISH appears to identify CEP17 anomalies (aneusomy), however this needs to be confirmed by additional FISH test. Caution should be applied in decalcified specimens as DISH fails in majority of cases. Identifying these disparities (with strict adherence to ASCO/CAP clinical practice guidelines) would assist in successful implementation in the routine workflow.
Intraoperative Touch Prep Evaluation of Sentinel Lymph Nodes in Breast Carcinoma
Margaret Compton, Emily Reisenbichler. Vanderbilt University Medical Center, Nashville, TN. Background: Axillary lymph node status is an independent prognostic indicator in breast cancer. Intraoperative identification of macrometastatic carcinoma in sentinel lymph nodes allows axillary dissection at the time of primary tumor excision. Intraoperative lymph node evaluation by touch prep analysis preserves all diagnostic tissue and maintains cytologic features for permanent section analysis. Design: Consecutive cases of breast carcinoma surgical cases with sentinel lymph node evaluation were identified by pathology report search over a 2 year period. The clinical, radiologic and pathologic data was collected. Patients receiving neoadjuvant chemotherapy were excluded. Results: Sentinel lymph nodes were excised in 414 patients. 516 touch preps were performed on 213 patients (Table 1) Although lymph nodes were evaluated intraoperatively more frequently in patients undergoing mastectomy than those undergoing lumpectomy, there was no statistical difference in the rate of lymph node metastasis. Patients with intraoperative evaluation of lymph nodes underwent a second surgery for completion axillary dissection less frequently, but the difference was not statistically significant. "Positive" touch preps were seen in nodes with both micro-and macrometatases on final evaluation resulting in specificity, sensitivity, negative predictive and positive predictive values of 99, 60, 96 and 88% respectively for identifying macrometastases ( Conclusions: Touch prep analysis of lymph nodes showed low sensitivity for the detection of macrometastases, did not reduce the rates of re-operation and could not distinguish micro-from macrometastases.
Systematic Review of Clinical, Pathologic and Radiologic Parameters in Breast Atypia: Completeness of Lesion Excision at Biopsy and Atypia Subtype Are Predictive of Rate of Upgrade To Malignancy on Excision
Niamh Conlon, Sandra Brennan, Anne Eaton, Adriana Corben, Lee Tan. Memorial Sloan Kettering Cancer Center, New York, NY. Background: Management of biopsy (Bx)-proven breast atypia is controversial due to difficulties in diagnostic reproducibility and fear of patient overtreatment in light of the low risk of underlying life-threatening malignancy. We aimed to design a predictive clinical nomogram for breast atypia, incorporating a 3-tiered grading system for atypia severity. Design: We undertook review of all relevant histology & radiology of 227 patients with atypia on breast Bx and subsequent in-house excision (2008) (2009) (2010) (2011) . Bx lesions were assessed for 27 separate parameters (8 clinical, 10 radiologic, 9 pathologic) and univariate (UV) & multivariate (MV) statistical analyses performed. An atypia grading system (AGS) ("reactive/borderline atypical" [AGS1], "atypical NOS" [AGS2] and "atypical/borderline DCIS" [AGS3]) was designed and an inter-pathologist reproducibility study performed. Results: 78% of patients had a Dx of ADH. 52% had either personal (PHx) or first-degree family history (FHx) of breast cancer. 45 patients (19%) had an upgrade to malignancy at excision; 35 had DCIS only. All 10 invasive tumors were T1N0. On UV analysis, PHx/FHx (OR 2.18,p =0.03), age (OR 1.45, p=0.04), atypia subtype (ADH vs FEA; OR 4.94, p=0 .01), AGS (AGS1 vs AGs2: OR 0.32; AGS3 vs AGS2: OR 6.56, p<0.001), completeness of lesion removal at Bx (OR 2.54, p=0.008) and needle gauge (£11G vs >11G; OR 3.98, p=0.02) were statistically significant. A reproducibility study showed only moderate agreement between 4 pathologists for AGS (κ=0.4); thus AGS was not carried forward to MV analysis, where only 2 factors proved significant (completeness of excision and atypia subtype). Conclusions: Of 27 parameters assessed, only completeness of lesion removal at Bx and atypia subtype showed a significant change in rate of malignant upgrade at excision. A novel AGS showed insufficient interobserver agreement to form the basis of a clinical nomogram. The predominant upgraded Dx at excision was DCIS. Variations in radiologic and pathologic practice mean that the design of a universally applicable nomogram for breast atypia management is extremely challenging. Multidisciplinary assessment of the individual risk/benefit ratio of excision in each case is likely to most benefit patients.
146
Effect (RS) . The National Cancer Control Programme (NCCP) approved use of this test in all ER positive, early stage invasive breast cancer patients in Ireland in November 2011. This study investigated the impact of the RS on the decision to treat an Irish breast cancer cohort with adjuvant chemotherapy. Design: 300 patients with node-negative, ER positive, Her2 negative invasive breast cancer with RS results from November 2011-January 2013 were identified from the pathology databases of two Irish hospitals. Clinicopathological details including age at diagnosis, tumor histology, size, grade and presence of lymphovascular invasion were collated. Treating oncologists were asked to review clinicopathological parameters and submit adjuvant chemotherapy decision with and without knowledge of RS. Adjuvant chemotherapy decisions pre and post OncotypeDX RS results were compared. Results: 59.7% (n=179) of patients had a low RS, 40% (n=90) had intermediate RS and 10.3% (n=31) had high RS. Pre OncotypeDX testing, 74% (n=222) were considered potential candidates for adjuvant chemotherapy. With knowledge of the RS, 77.7% (n=233) of patient were not offered chemotherapy and 22.3% (n=67) were recommended to receive chemotherapy. A change in treatment decision was seen in 57% (n=171) (p value=0.000). The medical oncologist's decision to recommend chemotherapy and endocrine therapy was changed to endocrine therapy only in 54.3%(n=163). 70% of these patients had a 'low risk' RS. 2.7% (n=8) of patients originally considered for hormonal therapy alone were recommended chemotherapy with knowledge of RS. Conclusions: RS had a significant impact on clinical practice. Compared with traditional clinicopathological assessment, incorporation of the RS result was associated with treatment recommendation changes for 57% of patients, with decision to omit chemotherapy in the majority of these patients. OncotypeDX RS results in an overall reduction in use of adjuvant chemotherapy. expression have a more aggressive behavior. Triple negative breast cancers (TNBC) are associated with poor outcomes and chemoresistance. The aim of this study was to evaluate the expression of MCT1 in a broad group of invasive ductal carcinomas (IDC). Digital pathology was employed for the interpretation of the stains. Design: MCT1 expression was evaluated in IDC by immunohistochemistry on formalinfixed paraffin-embedded tissue micro-arrays. Human tissue was obtained from the tumor bank of the Department of Pathology under a protocol approved by the IRB. Of the178 cases analyzed, 110 cases were estrogen receptor and/or progesterone receptor positive (ER+ and/or PR+), 48 were HER2+, and 55 were TNBC. MCT1 expression was quantified by digital pathology with Aperio software. The intensity of the staining was measured on a continuous 0 (black) to 255 (bright white) scale using a co-localization algorithm. Statistical analysis was performed using a linear mixed model. Results: MCT1 expression was higher in TNBC compared to ER+ and/or PR+ with an average difference in intensity of 21.2 [17.9 -24 .5] (p < 0.001) and, it was also higher in TNBC compared to HER2+ with an average difference in intensity of 20.9 [16.8 -25 .1] (p < 0.001). We selected a cut-off value of 181.2 based on R.O.C., which revealed that 91% (50 out of 55) of TNBC had positive MCT1 staining compared to 29% (32 out of 110) of ER+ and/or PR+ and 31% (15 out of 48) of HER2+ IDC. Conclusions: MCT1, which is a marker of high catabolite uptake and mitochondrial metabolism, is found highly expressed in TNBC compared with non-TNBC. The hypermetabolic status of the TNBC may contribute to their aggressive behavior and chemoresitance. MCT1 expression as detected with digital image analysis may be useful to design clinical trials using MCT1 inhibitors. A small subset of TNBC (9%) showed low expression of MCT1 demonstrating heterogeneity in the metabolic characteristic of these tumors.
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Clinical Impact of ER/PR Levels in Patients With Luminal A and B/ HER2-Negative Breast Carcinoma Ana Culianez, Erica Rivero, F Aranda, Maria Niveiro, Francisco Javier Segui, Gloria Peiro. General University Hospital of Alicante, Alicante, Spain. Background: Patients with breast carcinoma(BC) with positive estrogen and/or progesterone receptors(ER/PR) have better prognosis than those with negative tumors. Novel multigene assays allow the stratifi cation of patients at different risk,but they are expensive and of limited availability.According to ASCO/CAP,tumors with>1% positive nuclear staining by immunohistochemistry(IHC) for ER should be considered positive.Different expression levels may refl ect the observed differences in survival. Therefore,the aim of our study in a large series of patients with BC diagnosed and treated at the same institution was to determine an ER/PR cut-off to select potential subgroups with different prognosis. Design: We selected 893 patients with ER/PR-positive BC.Median clinical follow-up was 92 months (range 6-414).All slides were reviewed and formalin fi xed paraffi nembedded block tissues were selected containing the highest amount of tumor.IHC was performed for ER,PR and HER2. The results of ER and PR were stratifi ed in three groups according to nuclear percentages of positivity: >5% vs>10% vs>20%.HER2 status was confi rmed by FISH/CISH in all 2+ and <10% 3+ cases.The results were statistically correlated with clinical-pathological factors and outcome.A p-value<0.05 was considered signifi cant. Results: We found ER<5% positive in 1%(9/893) of the tumors,<10% in 3.36%(30/893) and<20% in 6%(54/893) and for PR 3.9%(35/893),19% 169/893) and 23.4%(209/893) respectively.A higher signifi cant correlation was detected with older ages,smaller tumor size,histological grade1,no necrosis and LVI,when ER and PR positivity cutoffs were established at 20% compared with 10% vs 5% (all p<0.05; Chi-square and Fisher tests).Survival analysis showed that the 5% cut-off defi ned better a group of patients with higher rate of recurrence:for ER <5%,only 60% did not recur vs 81% in >5% (p=0.006);and for PR, 60% vs 83% patients were free of disease (p<0.000). Similarly,only 60% of the patients were alive at last follow-up if ER <5% vs 86% in cases with >5% (p=0.005).For PR results, 63% of the patients were alive vs 88% with higher tumor levels (p<0.000) (Kaplan-Meier;log-rank test). Conclusions: Our fi ndings in a large series of patients with Luminal A and B/HER2-negative BC show that tumors with ER/PR-positive in>20% nuclei are related with good clinical-pathological factors.Nevertheless,the 5%cut-off level defi nes better a distinct subset of ER/PR patients with higher risk of recurrences and/or mortality.Therefore, those patients would benefi t of additional chemotherapy.
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CD34-Negative Mammary Myofi broblastoma -A Study of Eight cases
Timothy D 'Alfonso, Shivakumar Subramaniyam, Juan Miguel Mosquera, Theresa MacDonald, Yifang Liu, Mark Rubin, Sandra Shin. Weill Cornell Medical College, New York, NY. Background: The various morphologic variants of mammary myofi broblastoma (MM) hinder rapid identifi cation of these tumors. However, their consistent immunoreactivity for CD34, regardless of their morphologic appearance, greatly aids in confi rming the diagnosis. More recently, CD34 positive tumors including MM have been found to harbor monoallelic deletion of 13q14. The purpose of this study is to better characterize a rare subset of MMs that lacks CD34 expression. Design: Eight cases of MM with reported negative CD34 immunoreactivity were identifi ed in our surgical pathology and breast consultation fi les. For each case, the morphologic features and corresponding CD34, estrogen receptor (ER), and desmin immunostains were reviewed (TMD,SJS). In addition, a dual-color interphase FISH assay was performed on unstained paraffi n slides to assess loss of the 13q14 region using the LSI RB1 probe and a control probe on chromosome 13 for each case. Results: Seven tumors occurred in women; 1 occurred in a man (ages 41-85 years, median 49). Tumor size ranged from 0.4 to 2.5 cm (mean, 1.4 cm). Five tumors showed classic MM features -bland uniform spindle cells growing in fascicles with intervening bands of collagen and variable amounts of fat ( Figure 1A ). Of these, 1 case showed no staining for CD34 and 3 showed weak focal (<5% cells) staining ( Figure 1B) . The remaining case was dimorphic where ¾ of the tumor was of the myxoid variant and ¼ showed classic features. The myxoid areas were negative for CD34, whereas the classic areas were strongly positive. Of these 5 tumors, 1 showed deletion of 13q14 by FISH. 3 additional cases showed smooth muscle differentiation by morphology and immunohistochemistry and as such, were classifi ed as the leiomyomatous variant. One of these did not show deletion by FISH; FISH is pending for the remaining 2 cases. 8/8 (100%) tumors showed positive staining with ER, 7 of which were moderate-strong and diffuse. Additionally, 7/8 (88%) showed diffuse staining with desmin.
Conclusions:
MMs that lack or show weak, focal CD34 immunoreactivity can either show classic morphologic features or represent variants, particularly the leiomyomatous or myxoid types. These rare examples can further harbor deletion of 13q14 despite lacking CD34 expression.
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Cystic (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) for breast specimens with "granulomatous mastitis" and "abscess" was conducted. All such cases were subjected to histopathological review. Only cases that exhibited characteristic features of CNGLM were included. Acid-fast bacilli (AFB), fungal (GMS), and Gram stains were performed on all cases. All pertinent imaging studies were reviewed by a breast radiologist.
Results: Eleven cases of CNGLM were identified. All patients were women who had presented with a palpable breast mass (age, range: 25-49 years, median: 34) . Two patents had bilateral metachronous disease. Seven were parous, and 6 had breastfed. Imaging studies in 11 patients showed irregular masses (1.7-5.7 cm) with a BI-RADS score of 5 (highly suggestive of malignancy) in 2 patients. CNGLM showed lobulocentric suppurative granulomas with epithelioid histiocytes, Langhans giant cells, and mixed inflammatory cell infiltrate ( Figure 1A ). Clear vacuoles surrounded by neutrophils contained Gram-positive bacilli in 5/11 cases ( Figure 1B ). AFB and GMS stains, and all microbiological culture studies, were negative in all cases. Signs and symptoms worsened (with erythema, draining sinus) following initial needle core biopsy in 4 patients. Six patients were treated with antibiotics, 5 patients were treated with both antibiotics and surgery, and 1 was treated surgically. The disease process resolved in 1 to 6 months.
Conclusions: CNGLM presents as a unilateral irregular mass with characteristic histopathology. The mass may radiologically mimic malignancy. Needle core biopsy can aggravate symptoms. Gram-positive bacilli can be demonstrated in some cases. Microbiology cultures are often negative which may be due to the fastidious nature of these organisms. The disease resolves in a few months with conservative management.
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Positive GATA-3 and FOXA1 Expression Is Useful To Differentiate Breast Carcinoma From Other Carcinomas Drew Davis, Momin Siddiqui, Gabriela Oprea-Ilies, Adeboye Osunkoya, Cynthia Cohen, Xiaoxian Li. Emory University School of Medicine, Atlanta, GA. Background: It is important to differentiate breast cancers from other carcinomas in daily practice, as morphology may overlap, especially in the metastatic setting. GATA-3 has been shown to be a useful marker to identify breast carcinoma. However, few studies have examined the extent of GATA-3 reactivity in other carcinomas. Likewise, the expression of FOXA1, an essential protein in the estrogen receptor pathway, has not been well studied in breast and other carcinomas. We examined GATA-3 and FOXA1 expression in breast and 11 other different types of carcinomas. Design: Tissue microarrays composed of ER+/Her2-, Her2+ and triple negative breast carcinomas, melanoma and other adenocarcinomas including hepatocellular, colonic, pancreatic, gastric, endometrial, lung, prostatic, renal cell, urothelial, and ovarian serous carcinoma were analyzed. Immunohistochemical studies were performed using GATA-3 primary antibody (1:50 dilution, Biocare, CA) and FOXA1 primary antibody (1:50 dilution, Millipore, CA). The primary antibodies were detected with EnVision+ dual link kit (Dako). Any nuclear staining of GATA-3 or FOXA1 was considered positive. Results: 1) Among the carcinomas stained with GATA-3: 115 of the 119 (96.6%) ER+/ Her2-, 66 of 80 (82.2%) Her2+, and 13 of 51 (25.5%) triple negative breast carcinomas were positive. Of other carcinomas stained for GATA-3, 56 of 79 (70.9%) urothelial carcinomas were positive and none of the remaining carcinomas were immunoreactive. 2) Among the carcinomas that stained for FOXA1: 127 of 132 (96.2%) ER+/Her2-breast carcinomas, 80 of 97 (82.5%) Her2+ breast carcinomas, 7 of 57 (12.3%) triple negative breast carcinomas, 42 of 48 (87.5%) prostatic adenocarcinomas and 4 of 75 (5.1%) urothelial carcinomas were positive. None of the other carcinomas were immunoreactive. Conclusions: Our data show a relatively high specificity of GATA-3 expression in ER+/ Her2 negative and Her2+ breast carcinoma and urothelial carcinoma. High specificity of FOXA1 staining in ER+/Her2-breast carcinoma, Her2+ breast carcinoma and prostatic adenocarcinoma was observed. Combination of GATA-3 and FOXA1 staining is useful to differentiate breast carcinoma from other carcinomas including urothelial carcinoma. The relatively low expression rate of GATA-3 in triple negative breast carcinoma limits its application in the diagnosis of triple negative breast cancers. FOXA1 may be a useful marker to differentiate urothelial from prostatic adenocarcinoma; it is of little utility in the diagnosis of triple negative breast carcinomas.
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Influence of "In Vitro" and "In Vivo" Contexts on the Expression of Cancer Stem Cell Markers in Breast Cancer-Derived Cell Lines Valeria De Souza, Philipi De Souza, Paulo Latuff-Filho, Carlos Nascimento, Marina Resende, Andre Renno, Gilberto Franchi-Jr, Fernando Soares, Jose Vassallo, Rafael Rocha, Andre Schenka. UNICAMP, Campinas, SP, Brazil; A.C.Camargo Cancer Center, São Paulo, Brazil. Background: Recently, in a new paradigm of carcinogenesis, cancer stem cells (CSCs) have been regarded as responsible for the origin, morphologic heterogeneity, selfrenewal and therapeutic resistance of malignant neoplasms. As such, they have become an important target in pathophysiological/pharmacological studies of cancer. Currently, one of the main obstacles to the study of CSCs is the lack of reliable biomarkers. Although there seems to be some consensus regarding what should be considered typical CSC markers in in vitro studies, there is very poor agreement when these are contrasted to in vivo studies based on human tumor tissue. Design: Using three distinct breast cancer-derived cell lines, we investigated the expression of CSC markers in two biological contexts reflecting differences in microenvironment (in vitro vs. in vivo), and in two immunophenotyping techniques (flow cytometry vs. immunocytochemistry).The expression of CD24, CD44, CD133, EpCAM and ALDH1/ALDEFLUOR was assessed in cell and tissue samples (orthotopic xenotransplants from NOD/SCID mice) of MCF-7, MACL-1 and MGSO-3 cell lines, using flow cytometry and immunocytochemistry (n= 5 samples/group). Results: Data provided by flow cytometry was not found to be reliable, since most CSC markers were negative in this technique, regardless of cell line or context. Data provided by immunocytochemistry showed marked variability in the prevalence of positive samples for EpCAM, CD24, CD44, CD133 and ALDH-1 across cell lines and biological context. In in vitro samples (cell-blocks), EpCAM presented the greatest frequency of positive samples (50-80% across cell lines) and of positive cells per sample (mean frequency of positivy: 75%). By contrasting cell-blocks with xenografts, however, we found a significant decrease in the frequency of positive cases (p<0.01; Fisher's Exact Test) and of positive cells per sample (p<0.001; Paired T test) in tissue samples, for most CSC markers. The only exception was EpCAM in MCF-7 cell line, which was increased in xenografts. Conclusions: Our data confirm the role of microenvironment in the maintenance of CSCs, further indicating that it may be an important source of variability in the expression of CSC markers across independent studies. In addition, our results suggest that immunocytochemistry may be more reliable than flow cytometry in the detection of cancer stem cells by immunophenotyping, in both cell and tissue samples.
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Cancer Stem Cells (CSCs) Are Increased in Pregnancy Associated Breast Carcinomas (PABC) Sagar Dhamne, Tracy Lundberg, Luis Blanco, Kalliopi Siziopikou. Northwestern University, Feinberg School of Medicine, Chicago, IL. Background: Cancer stem cells (CSCs) have been shown to play an important role in initiation and progression of human malignancies including breast carcinomas. In breast cancer they are thought to be associated with higher grade tumors, triple negative (TN) or HER2 phenotype and poor prognosis. Pregnancy associated breast carcinoma (PABC) arises during or after pregnancy, is often TN and is also associated with poor prognosis. However, to date, CSCs in PABC have not been adequately evaluated. In this study we examined the expression of ALDH1, CD44 and CD24 CSC markers and correlated their expression with molecular and histologic characteristics of PABC. Design: Our patient population consisted of 23 patients diagnosed with pregnancy associated breast cancer during or within 2 years of pregnancy (mean age: 35.8, range: 26-48) . Age-matched nulliparous women with a diagnosis of breast cancer served as controls (mean age: 37.5, range: 29-51). Tumors were immunohistochemically stained for ALDH1, CD44 and CD24. Pathologic characteristics included histologic type, tumor grade, tumor size, presence of lymphatic vascular invasion, lymph node status, and breast tumor markers (ER, PR, HER2, p53). Results: Six (26.1%) PABC cases but only 1 (6.7%) control case showed ALDH1 expression. Of interest, all the ALDH1+ tumors were high grade. In the ALDH1+ PABC group, 3 (50%) tumors were TN, 2 (33.3%) HER2 and only 1 (16.7%) of luminal subtype. In contrast, the majority of the ALDH1 negative cases were of luminal subtype; 10 (58.8%) in the PABC group and 14 (100%) in the control group. Five (83.3%) of the ALDH1+ PABC cases had lymph node metastasis and 3 (50%) had lymphovascular invasion (LVI) compared to 8 (47%) cases of lymph node metastasis and 5 (29.4%) in ALDH1-population in PABC. The CD44+/CD24 -/Low phenotype was seen in 8 (34.7%) cases of PABC and 6 (40%) cases in the control group; however, no correlation was seen with any clinical or histologic parameters. Conclusions: 1. More than a quarter of PABCs express ALDH1. 2. ALDH1+ PABC tumors tend to be high grade, with TN or HER2 phenotypes and are more likely to have lymph node metastasis and LVI. The results of our study suggest that CSCs are present in PABC in increased numbers and their presence may contribute to the poor prognosis in PABC. Additional studies are underway to expand these findings and further characterize the role of CSCs in these challenging breast tumors.
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Pathological Features of Atypical Ductal Hyperplasia Diagnosed on Core Needle Biopsy Predictive for Upgrade on Excision
Elena Diaconescu, Fang-I Lu. University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Background: Atypical ductal hyperplasia (ADH) is defined as the proliferation of monomorphic, evenly placed epithelial cells involving terminal ducto-lobular units (TDLU) that does not meet the criteria for low-grade DCIS, due to partial involvement of TDLU, or complete involvement of only a limited number of TDLU. Current treatment of ADH diagnosed on core needle biopsy (CNB) consists of surgical excision (SE) to exclude DCIS or invasive carcinoma. Our goal is to identify pathological features of ADH on CNB that predict upgrade to carcinoma on SE. Design: We performed a retrospective review of cases diagnosed as ADH on CNB between January 2009 and January 2011. A total of 50 cases from 47 patients were identified and analyzed for histological features that may be predictive of carcinoma upgrade. Variables analyzed included nuclear features, presence of mitoses and calcifications, architectural subtype, size of the largest focus of ADH, number (#) of cores positive for ADH, # of foci of ADH, and percentage (%) of cores positive for ADH. Two-tailed Student's t-test was performed to identify statistically significant differences between means and the Chi Square test was used for categorical variables. Results: A total of 18 cases (36%) were upgraded to carcinoma on subsequent surgical excision. 10 (56%) of these cases were upgraded to DCIS and 8 (44%) were upgraded to invasive carcinoma. Our findings are summarized in the following Background: For patients with multiple synchronous invasive breast carcinomas, CAP/ ASCO guidelines recommend estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu analysis on "at least one of the tumors, preferably the largest." In practice request for testing additional foci is variable. Design: Cases of multifocal ipsilateral invasive breast carcinoma, defined as discrete foci with intervening benign tissue (N=157; 6/04-6/14), were assessed for number of foci, clinicopathologic features and treatment. ER/PR were defined as negative (<1%), weak (1-10%) and positive (>10%). HER-2/neu was defined as negative, equivocal and positive by staining &/or FISH per CAP/ASCO guidelines. Results: 102 (65%) had 2 and 55 (35%) had >2 foci of invasive carcinoma (range 2-9). 92 (58.6%) were T1 and 65 (41.4%) were T2/T3. Categorical differences for cases with >1 focus tested and frequency of testing >1 focus and clinical significance (treatment change) by year are shown below. Cases with clinical significance (6/60, 10%) had low ER/PR% (1), equivocal HER-2/neu (1), different histology (2) and grade (3).
Conclusions:
Receptor testing for additional foci in multifocal breast carcinoma is increasing, with minimal change in patient management. Clinically-significant differences in receptor profiles were only identified in cases with low ER/PR expression, equivocal HER-2/neu and different histology &/or grade; in these cases testing additional foci appears warranted.
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Massively Background: Infiltrating epitheliosis (IE) is a rare complex sclerosing lesion, characterized by infiltrating ducts and duct-like structures immersed in a scleroelastotic stroma and filled with cells having architectural and cytological patterns reminiscent of those of usual ductal hyperplasia (UDH). The histologic features of IE and the lack of myoepithelial cells, particularly at the periphery of the lesions, raise the concern that IE may constitute a form of low-grade infiltrating neoplasm. In this study we sought to define the molecular characteristics of this unique lesion. Design: Cases of IE were retrieved from the consultation files of one of the authors (IOE). Only samples independently classified by three pathologists as IE were included. Nine IEs, adjacent breast lesions (1 UDH, 1 papilloma, 1 micropapillary DCIS, and 2 low-grade adenosquamous carcinomas), and corresponding normal breast tissue from each case were microdissected, and subjected to massively parallel sequencing analysis targeting all coding regions of 254 genes recurrently mutated in breast cancer or involved in DNA repair-related pathways. Results: Recurrent mutations in PI3K pathway genes were found in all 9 cases of IE. Specifically, 8 of 9 cases harbored PIK3CA hotspot mutations (the H1047R mutation in 6 cases, E545K in 1 case, and E542K in 1 case). The PIK3CA wild-type case displayed a PIK3R1 (KL379K) codon deletion. In a case with IE, micropapillary DCIS, and lowgrade adenosquamous carcinoma the same PIK3CA (H1047R) and SF3B1 (K700E) hotspot mutations were found in all components. In a case of IE, a papillary lesion and a low-grade adenosquamous carcinoma, the first two components shared the same PIK3CA mutation (H1047R); whereas the low-grade adenosquamous carcinoma did not harbor any somatic mutation in the genes analyzed. Conclusions: Recurrent somatic mutations affecting PI3K pathway genes were identified in all IEs, providing direct evidence that these lesions are clonal and neoplastic rather than hyperplastic. In one case, the IE may have constituted the substrate from which the DCIS and adenosquamous carcinoma originated. The landscape of somatic genetic alterations found in IEs is similar to that of radial scars/complex sclerosing lesions, suggesting that IEs may represent one end of the spectrum of these lesions.
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Metaplastic (hormonal, chemo-and radiation) and survival data was extracted from the clinical reports. The clinical and pathological data for 558 TN cases was extracted from the breast cancer database. Results: There were 20 (38.6%) MP, 15 (28.8%) SCC, 10 (19.2%) SHG, 2 (3.8%) SLG, 2 (3.8%) LGAS, and 3 (5.8%) mixed. ER was positive in 6 (12.5%), PR in 7 (14.6%) and HER2 in 3 (6.5%) cases. The number of patients who died from disease was 13 (26.5%) with MC and 96 with TN (20.9%) (p=<0.001) (figure1). The median follow up was 38.6 and 157.8 months respectively. Only postmenopausal status was predictive of death due to disease (p=0.036). There was no significant survival difference between MP, SCC or SHG. However, two patients with LGAS and 2 with SLG had no tumor recurrence or death due to disease after follow up time from 3-years to 16-years.
Conclusions:
We present a relatively large number of cases with a long clinical followup. We found that metaplastic carcinoma is more aggressive than TN cancers. Two WHO-recognized MC subtypes, SLG and LGAS, should be recognized as separate entities as they have distinctively better clinical outcome. More cases, particularly from these two types are needed to affirm our interpretation.
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RUNX2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma
Saba El-Gendi, Mohamed Farouk. Faculty of Medicine, Alexandria, Egypt. Background: The Runx family of transcription factors are implicated in cancer progression, both positively and negatively. Recent studies assigned a role for Runx2 in promoting breast cancer metastasis. However, the role of Runx2 in the early stage of breast carcinoma, and its association with clinical outcome is still unknown. Design: We aimed at assessing the clinicopathological significance of Runx2 expression in a cohort of 84 invasive ductal breast carcinomas. The correlation between the nuclear Runx2 labelling index (LI) in breast carcinoma cells and clinicopathological parameters was assessed. To study the association of Runx2 with patients' outcome, beside treating it as a continuous variable, Runx2 was categorized by the its median value. Optimal cut-off points were determined, by ROC curve analysis, for prediction of disease free survival (DFS) and overall survival (OS). Multivariate Cox regression models were built and best subset regression models were identified to predict the probability of recurrence, metastasis and/or death. Validation was done; and based on the "Predicted R 2 ", the best three models were identified. The interaction between Runx2 and other clinicopathological terms was also tested. Results: Runx2 LI associated significantly only with positive Her-2 status, and did not correlate significantly with other clinicopathological parameters. Although, Runx2 LI, continuous form and when categorized by its median value (65), did not correlate significantly with DFS and OS, yet, after it was categorized using optimal cut-off points, patients with Runx2 LI >45% showed significantly higher event rate and shorter DFS, (P=.047); while patients with Runx2 LI >40% showed significantly shorter OS, (P=.050). Moreover, Runx2 LI effectively contributed to the models built to predict DFS and to a lesser extent to the models built to predict OS. Regarding DFS, the diagnostic performance of Runx2 did not differ according to the clinicopathological characteristics of the tumor. However, among stage IV tumors, the interaction term between Runx2 LI and ER status was a significant predictor of overall survival. In this model, Runx2 was a significant predictor. Conclusions: Runx2 has a role in the biological behavior and affects outcome of invasive ductal breast carcinomas, thus, its inhibition might open a new strategy for therapy. The predictability of Runx2 for OS in stage IV tumors differs with difference of ER status. The pattern of this difference was not studied as the sample size was not sufficient to allow pattern testing. (IG, n = 20) and low nuclear grade (LG, n = 11). 37 women had more than 5-year follow-up (average 10.3 years; range 5.3 to 13.6 years), and 24 of them were treated by breast conservation, (BCT) while 10 women underwent total mastectomy (TM). Among women treated by TM, one woman with extensive DCIS experienced a locoregional invasive recurrence (8/23 axillary lymph nodes) 3 years later and another developed DCIS in the contralateral breast 3 years later. Both had HG DCIS and had not received XRT or tamoxifen (TAM). 14 of 23 patients who underwent BCT also received XRT, including all HG cases (5/5), and none experienced recurrence. The only ipsilateral invasive recurrence occurred in a woman 8 years after a diagnosis of IG DCIS. She also had DCIS in the contralateral breast and did not receive XRT or TAM. Another woman had an ipsilateral recurrence of IG DCIS 6 years after her original diagnosis. She was successfully treated by TM and was alive with no evidence of disease at last follow-up 12.3 years after her original DCIS diagnosis. Among 9 women with < 5yrs follow up, 3 were treated by TM and 6 by BCT (2 also had XRT). To date only 1 women who underwent TM experienced invasive recurrence (1 year after her extensive LG DCIS diagnosis). To date there are no recurrences among women undergoing BCT with or without XRT in the group with less than 5 year follow-up. Conclusions: Invasive recurrence rates following a diagnosis of DCIS at our institution are very low. The decision to use XRT is influenced by grade and size. Two of 3 invasive recurrences occurred in women who had undergone TM, raising the possibility of residual unsampled disease. Most women with smaller LG and IG DCIS can be successfully treated by BCT alone provided negative margins have been confidently achieved. Although the average number of alterations/pt and alteration type (MUT,AMP, DEL) did not differ significantly among breast cancer subtypes, the proportion of genes within specific dysregulated pathways and individual genes varied. The most frequently altered pathways were p53 (70%:57% ER+, 70% HER2, 92% TNBC), RTK/GF (57%:42% ER+, 95% HER2+, 50% TNBC), cell cycle (55%:55% ER+, 50% HER2+, 58% TNBC), and PIK3/mTOR (53%:52% ER+, HER2+50%, 58% TNBC). Among ER+ (n = 40), HER2+ (n = 20) , and TNBC (n = 24) tumors, the most frequent alterations were TP53 mutations (42%, 70%, and 87%), PIK3CA mutations (35%,30%,and 29%) and ERBB2 amplification (0%, 70%, and 8%). Variants of standard biomarkers including 3 HER2 mutations (1 HER2+ and 2 TNBC) and 4 ESR1 mutations were also identified which impacted treatment decisions. Conclusions: Mutational profiling using T-NGS identified potentially actionable alterations in a majority of advanced BC patients, providing novel yet rational therapeutic options and facilitating clinical trial enrollment. In the future NGS results will be used to guide therapy in increasing numbers of BC patients.
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Prevalence Background: Triple negative breast cancers (TNBC), defined by lack of estrogen receptor, progesterone receptor and HER2 expression, comprise about 15% of all breast cancers but are much more common in women with germline BRCA1 mutations. Recent studies have demonstrated considerable heterogeneity of TNBC at the gene expression level; six molecular TNBC subtypes have recently been described. In particular, while some TNBC have basal gene expression signatures others resemble luminal tumors and demonstrate high levels of expression of androgen receptor (AR) mRNA and nuclear AR expression by immunohistochemistry. The frequency of AR positivity in TNBC in relation BRCA1 mutation status has not been well studied. However, given the availability of clinical trials evaluating the efficacy of AR targeted therapies in TNBC and efforts to define appropriate systemic therapy for BRCA1-associated TNBC, the relationship between AR expression and germline BRCA1 mutation status in TNBC is of interest. Design: We studied 197 TNBC: 79 (40.1%) from women with germline BRCA1 mutations (BRCA1+ TNBC) and 118 (59.9%) from women without a BRCA1 mutation (sporadic TNBC). Pathologic features evaluated included histologic type, grade, lymphovascular invasion (LVI), and lymphocytic infiltrates (LI). Tissue microarrays (TMA) were constructed from these tumors (three 0.6mm cores/case) and TMA sections were immunostained for AR as well as for CK5/6, CK14 and EGFR (to define TNBC with basal features). Results: BRCA1 carriers with TNBC were significantly younger (43.4 ±9.1 years) than those with sporadic TNBC (50.9 ±10.8 years; p<0.001). There were no significant differences in histologic type, grade, LVI or expression of CK14 or EGFR between BRCA1+ TNBC and sporadic TNBC (all p>0.19). LI was significantly more frequent in BRCA1+ than in sporadic TNBC (35.9% vs 23.4%; p =0.02). Among all TNBC, 17.8% were AR-positive (defined as at least 1% of cells staining for AR). Sporadic TNBC were significantly more often AR-positive than BRCA1+ TNBC (p=23.7% vs 8.9%; p=0.008). Conversely, BRCA1+ TNBC were significantly more often CK5/6-positive than sporadic TNBC (71.8% vs 54.2%; p=0.02). Conclusions: Sporadic TNBC are significantly more often AR-positive than BRCA1+ TNBC whereas BRCA1+ TNBC are significantly more often CK5/6-positive than sporadic TNBC. These results confirm the heterogeneity of TNBC and, in particular, indicate that AR expression in TNBC varies significantly with BRCA1 mutation status. Motivated by the imperative of healthcare cost containment, we studied the concordance between GHI-RS with online ME RS in breast cancer patients from a large integrated health system to see if the ME method can be used as an alternative to the commercial test. Design: We studied breast carcinomas from a single institution submitted for GHI-RS over a period 4 years. Pathologic parameters included tumor size, Nottingham grade, ER, PgR, Her2 & MIB1 PI. ER, PR were semi-quantitatively scored, an H-score with score >10 considered a positive. Her2 was scored using published ASCO/CAP guidelines. MIB-1 was scored as % positive tumor nuclei [low (<14%) & high (>14%)]. ME scores were generated using the online tool. Pearson correlations between GHI-RS vs ME RS were calculated. Results: A total of 371 cases of breast carcinomas were identified. The average tumor size was 1.68 cm (SD: 0.97, range: 0.3-10 cm, median: 1.5 cm). 
Conclusions:
Overall there was moderate to strong correlation between GHI-RS & all three MEs in our cohort. When reclassifying ME & GHI-RS into 3 groups (low, intermediate, high) , the ME score did not precisely predict the GHI-RS. For high risk tumors, ME is just as sensitive as GHI-RS. This pilot study strongly warrants a longitudinal study of the actual survival / recurrence of our patients & its correlation with the pathologic parameters used to generate ME.
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Can Histopathologic Features of Duct Cell Carcinoma In Situ of the Breast (DCIS) Be Used To Predict Oncotype DX DCIS Score Susan Fineberg, Jana Fox, Nella Shapiro, Adriana Knopfelmacher Couchonal. Montefiore Medical Center, Bronx, NY. Background: The Oncotype DCIS score is a multigene assay used to determine recurrence risk in pts with DCIS treated with excision without radiation (RT). It measures genes involved in proliferation, progesterone receptor and GSTM1. We looked at histopathologic features of cases of DCIS with an Oncotype Score to determine if these could be used to predict score. Design: This study included 46 pts with DCIS and an Oncotype DCIS score. We used our clinical information system to determine clinicopathologic features. We reviewed H&E slide from the block which was sent for testing when available. We counted mitotic figures in all ducts with DCIS on the slide. We noted if a dense chronic inflammatory infiltrate surrounded DCIS. Results: The mean age of our 46 pts was 64. Oncotype score was low in 33 pts (72%) of whom 6 recieved RT. Oncotype was intermediate in 8 pts (17%) of whom 6 recieved RT. Oncoytpe was high in 4 pts (9%) of whom 2 recieved RT, one refused RT and one has no follow-up. In one pt there was a test failure. PR via immunohistochemistry was positive in 40 pts (87%) negative in 4 (9%) and unknown in 1 ( 5%). In 24 pts PR was > 90% and 22 of them (92%) had a low score. PR>90% in DCIS was significantly associated with a low score (p=0.0051). The H&E slide of the block sent for Oncotype was available in 34 pts. The number of mitotic figures in all DCIS glands was 0 in 19 pts of whom 16 ( 84%) had a low score. The number of mitotic figures was > 1 ( range 1 to 8) in 15 pts of whom 7 (47%) had a low score. A mitotic count of 0 for DCIS was significantly associated with a low score ( p=0.03). A dense chronic inflammatory infiltrate surrounded DCIS in 4 pts and 2 of these pts had a high score ( p=0.047). Twelve pts had PR> 90%, 0 mitotic figures and were without dense chronic inflammation around DCIS and all had a low score. 5 pts had a combination of atleast two of the following -negative PR, mitotic count > 1 and / or dense chronic inflammation around DCIS and none had a low score. Conclusions: DCIS with PR >90%, no mitotic figures and absence of dense chronic inflammation around DCIS, as seen in 28% of pts, had a low score in 100% of cases. Conversly none of the 11% of pts with a combination of atleast two of the follwoing : negative PR, mitotic count >1 and/or dense chronic inflammation around DCIS had a low score. These histopatholgic features in DCIS might be useful surrogate for Oncotype score. IT also suggests that mitotic counting in DCIS might be prognostic.
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Tumor (IBC) . A pathologic complete response (pCr) ( RCB-0) or minimal residual disease (RCB-1) is associated with the best prognosis. The immune system appears to play a role in response to NAC and a signficant tumor lymphocytic infiltrate (TIL) may improve response rate. We examined pre chemotherapy( pch) core biopsies (bxs) and correlated TIL with response to NAC. Design: We evaluated pch core bxs in 95 pts with IBC. We visually estimated the % of mononuclear cells both in direct contact with tumor cells and within tumor stroma. We recorded ER, Her2/Neu and the mitotic count score ( Nottingham Score). We used pathology reports from post chemotherapy resections to calculate Residual Cancer Burden (RCB) (www.mdanderson.org/.../calculatore-rcb-pathology). We considered RCB-0 ( pCr) and RCB-1( minimal residual disease) to represent excellent response to NAC. Results: We evaluated pch core bxs from 95 pts with IBC who received NAC. Post chemo resections demonstarted RCB-0 in 21 pts ( 22%), RCB-1 in 15 pts (16%) RCB-2 in 25 pts ( 26%) and RCB -3 in 34 pts (35%). The percentage of TIL in pch core bxs , in either tumor stroma or epithelium was > 50% in 18 pts, <50% and >40% in 6 pts, <40% and >30% in 5 pts and <20% in 66 pts. Of the 24 pts with TIL > 40% , 16 (67%) had RCB-0 or 1. Of the 71 pts with TIL <40%, 20 (28%) had RCB 0 or 1. There was a statistically significant association between TIL > 40% and RCB-0 and 1 (p=.0013). Her2/Neu was + in 31 pts and 16 (52%) had RCB 0 or 1. Her2/Neu was (-) in 62 pts and 20 ( 32%) had RCB 0 or 1. The association between Her2Neu positivity and RCB-1 or 0 was not statistically significant ( p=0.113). ER was + in 44 pts and (-) in 51 pts. 24 of 51 (47%) ER (-) pts had RCB 0 or 1 and 12 of 44 (27%) ER+ had RCB 0 or 1; this difference was not statistically significant ( p=0.06). 34 tumors were triple negative and 14 (41%) had RCB-0 or 1 ( p=0.06). Mitotic count score was 3 in 29 pts and less than 3 in 59 pts, and could not be determined in 7 pts. RCB was 0 or 1 in 10 of 29 (34%) pts with mitotic score 3 and RCB 0 or 1 in 25 of 59 ( 42%) of pts with mitotic score < 3 ( p=0.50).
Conclusions:
We evaluated ER, Her2/Neu , mitotic score and TIL and correlated with response to NAC. Only TIL 40% or greater in pch core bxs was significantly associated with pCr or minimal residual disease . Quantification of the % TIL can easily be done on H and E slides and may be important in the evaluation of IBC when NAC is considered. 
Background:
The diagnosis of ductal carcinoma in situ (DCIS) is rising in number due mammographic screenings, contributing to concerns of over-diagnosis and over-treatment. We aimed to determine the correlation of protein expression with chromosomal copy number alterations (CNAs) as part of an effective risk-stratification for identifying high-risk DCIS with the ultimate goal of improved personalized management for early breast cancer. Design: A tissue microarray (TMA) of samples containing DCIS only versus DCIS with concurrent invasive breast cancer (IBC) was used to assess the correlation of CNAs of 8q24 (BAC clone RP11-1136L8) and 11q13 (BAC clone CTD-2537F6) by fluorescence in situ hybridization (FISH), reported by The Cancer Genome Atlas to be among the most frequent CNAs in IBC, with protein expression of C-MYC on 8q24 (Leica 1472-1) and BCL-1 on 11q13 (Ventana RM-9104-S) by immunohistochemistry (IHC) in the DCIS component of the biopsies. Results: We studied 199 samples diagnosed as DCIS only or DCIS with IBC for IHC and FISH correlation for C-MYC expression and 175 for BCL-1 expression. We found that the number of C-MYC expression positive cases were similar between DCIS only or DCIS with IBC (71 positive of 107 total DCIS versus 67 positive of 92 total DCIS with IBC). However, when we stratified the cases by C-MYC amplification, the presence of the amplification in DCIS with IBC was associated with more than half of the cases with positive protein expression with a sensitivity of 61.2% (41/67) when compared to DCIS alone at 38.0% (27/71), and these differences were statistically significant (P=0.0104 by Fisher's exact test). Many fewer cases of DCIS were amplified for BCL-1 or had BCL-1 expression; however a similar trend was observed where CNAs in DCIS with IBC were more predictive of IHC positivity with a sensitivity of 75.0% (6/8) when compared to DCIS alone at 53.9% (7/13) (P=0.3999 by Fisher's exact test). Conclusions: There is an increased need for risk-adapted management of DCIS and early breast neoplasia. This study demonstrates the potential for combined protein expression and DNA copy number studies for improving the classification of high-risk DCIS.
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Use of 2013 ASCO-CAP Breast Carcinoma HER2 Scoring Guidelines Results in Shifts of Scoring Categories With Slight Change in IHC-FISH Concordance
Regan Fulton, Allen Gown. PhenoPath Laboratories, Seattle, WA. Background: In 2013, revised ASCO-CAP guidelines for immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) HER2 testing and scoring of breast cancers were released. These included changes in the definitions of HER2 1+, 2+, and 3+ IHC scoring. We wished to investigate the effects of the new scoring definitions on the distribution of HER2 IHC scores and the impact on IHC-FISH concordance. Our hypothesis was that the new definitions would lead to increased numbers of 1+ and 2+ IHC cases with minimal impact on IHC-FISH concordance. Design: The results of scoring of all breast cancer specimens received for HER2 IHC and/or FISH testing were tabulated during two parallel time intervals: January-August 2013 (pre-2013 ASCO-CAP) and January-August 2014 (post-ASCO-CAP). A total of 1,813 breast cancer cases received from a wide range of laboratories around the United States had been submitted to PhenoPath for HER2 assessment in the 2013 time period, and 1,447 in 2014. On all cases submitted for primary FISH analysis, nonreported HER2 IHC studies were also performed for quality assurance purposes. All IHC was performed using the SP3 rabbit monoclonal anti-HER2 antibody on a Dako autostainer. All FISH was performed using the PathVysion dual probe kit, assisted by image analysis using the Metasystems Metafer 4 software. Results: Comparing the 2014 to the 2013 IHC data, the percentage of cases scored as 0 decreased from 29% to 21%; the percentage of cases scored as 1+ remained nearly the same (40% v. 42%); the percentage of 2+ cases increased from 23% to 29%, and the percentage of 3+ cases increased slightly from 7.6 to 8.6%. Amongst the IHC 2+ (equivocal) cases, analysis of corresponding FISH results in the 2013 and 2014 revealed that the percent of FISH negative cases increased from 79% to 87%, and the percent FISH positive (³2.0 ratio) decreased from 12% to 9.0%. Among the cases sent in for primary HER2 FISH, the 2013 positive and negative concordance rates for FISH-IHC were 95.7% and 99.7%, respectively; these concordance rates in 2014 were 97.3% and 99.3%.
Conclusions:
The data support our hypothesis that a principal effect of the 2013 ASCO-CAP HER2 scoring guidelines has been a shift in the 'binning' of cases, with a significant number of cases previously scored as 0 shifting into the 1+ category, and cases previously scored as 1+ into the 2+ category. Overall, a slight increase in positive IHC-FISH concordance was noted (95.7% to 97.3%). 2013 ASCO-CAP Guidelines may result in increased overall testing costs owing to these category shifts. Nicola Fusco, Luciano Martelotto, Charlotte Ng, Laetitia Fuhrmann, Joanna Cyrta, Elena Guerini-Rocco, Rita Sakr, Elizabeth Yim, Caterina Marchio, Raymond Lim, Salvatore Piscuoglio, Anne Vincent-Salomon, Sunil Badve, Shu Ichihara, Ian Ellis, Jorge Reis-Filho, Britta Weigelt. Memorial Sloan Kettering Cancer Center, New York, NY; Institut Curie, Paris, France; Indiana University School of Medicine, Indianapolis, IN; Nagoya Medical Center, Nagoya, Japan; Nottingham University, Nottingham, United Kingdom. Background: Adenoid cystic carcinoma (AdCC) of the breast is a rare triplenegative breast cancer (TNBC) harboring the recurrent MYB-NFIB fusion gene. The phenomenon of high-grade (HG) transformation of AdCC and its genetic basis has not been investigated in AdCCs of the breast. Here, we sought to define the repertoire of somatic genetic alterations involved in the progression from AdCC to HG-TNBC. Design: Two breast AdCCs associated with HG-TNBC of no special type (NST) were centrally reviewed by three pathologists. Fluorescence in situ hybridization and RT-PCR were employed to detect the MYB-NFIB fusion gene. DNA samples from each microdissected tumor component and matched normal tissue were subjected to massively parallel sequencing targeting all exons of 490 genes, including the most frequently mutated in breast cancer and actionable cancer genes. Somatic single nucleotide variants were detected by MuTect, insertion and deletions by Varscan2 and Strelka. All mutations were confirmed by Sanger sequencing. Gene copy number profiling was performed using Affymetrix OncoScan arrays. Results: The MYB-NFIB fusion gene and its transcript were detected in all components from each case. Moreover, the conventional AdCC and the HG-TNBC of case 1 shared identical somatic mutations in CHD6, CTNNB1, RPS6KB2 and EP300, whereas mutations in SF3B1 and NOTCH1 were only found in the latter. In case 2, in addition to the MYB-NFIB fusion gene, a KMT2C somatic mutation was present in all components analyzed, whereas mutations of MYB, CDK12 and STAG2 were found only in the HG-TNBC. Gene copy number profiling revealed shared genetic alterations between the AdCC and the HG-TNBC components, but the latter displayed increased genomic complexity in both cases.
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Genetic Events in the Progression of Adenoid Cystic Carcinomas of the Breast To High-Grade Triple-Negative Breast Cancers
Conclusions:
The progression from AdCC to HG-TNBC of NST involves the acquisition of additional genetic alterations. We also documented a subset of HG-TNBC of NST harboring the MYB-NFIB fusion gene, the second recurrent fusion gene identified in TNBCs. Dan Gallagher, Ziyan Pessetto, Wenbo Xu, Jason Rarick, Fang Fan, Andrew Godwin, Ossama Tawfik. Kansas University Medical Center, Kansas City, KS. Background: The discovery of microRNAs (miRNAs) has created new opportunities to better understand the complexity of cancer. miRNAs are non-protein coding genes that regulate gene expression at the translational level. They play a key role in oncogenesis, tumor progression and metastasis. miRNAs have the potential to be oncogenes or tumor suppressors in a given cellular context. While the overexpression of certain miRNAs has been shown to promote metastasis, the overexpression of others correlated with reduced metastatic activity. A better ability to assess the risk of recurrence in breast cancer patients would greatly facilitate clinical decisions in surgical and adjuvant treatment options for breast cancer patients. The development of reliable risk assessment biomarkers will empower oncologists to tailor treatment options that are more effective with less undesirable side effects. Based on several studies demonstrating the role of microRNA miR-139-5p (miR-139), we hypothesize that miR-139 might play a key role in tumor progression and metastasis in breast cancer. Design: miR-139 expression was correlated with tumor grade, type, ER, PR, Ki67 and HER2 status, tumor size, lymph node status, patient's age and overall survival in 74 invasive ductal carcinomas. RNA samples were isolated from the FFPE samples using miRNeasy FFPE kit (Qiagen) per manufacturer's instructions. Concentration of RNA was detected by NanoQuant Infinity Pro200 (Tecan). The miR139-5p specific primers and the SNORD 95 primers were used for RT-PCR in this study. Results: miR-139 expression is associated with aggressive pathologic and clinical features. miR-139 is down regulated in higher grade (grade I vs. grade II, p<0.001, grade II Vs. grade III, p=0.022 and grade I vs. grade III, p<0.001), ER negative (p=0.0008), PR negative (p=0.005), HER2+ (p=0.0537) and highly proliferative tumors (Ki67>15%, p=0.0002). Its reduced expression is not associated with tumor size (>2 cm, p=0.0708) or patient's age (>50 years, p=0.434). When its levels of expression was correlated with local metastasis and overall survival, there was no significant difference in its expression in tumors with nodal status (p=0.264). In contrast deceased patients had significantly lower levels compared to alive patients (p=0.027). Conclusions: miR-139 is differentially expressed in breast carcinomas. Its expression is significantly associated with several clinicopathological parameters and is associated with aggressive tumor behavior and disease progression. Modulation of miRNA expression may serve as an attractive approach for treatment of aggressive and advanced breast carcinomas.
Differential Expression of miR-139 in Breast Cancer
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Glucocorticoid Receptor Expression in Triple Negative Invasive Ductal Carcinoma of the Breast: A Potential Therapeutic Target Alexander Gallan, Gabrielle Baker. University of Chicago, Chicago, IL. Background: Breast cancers which express the estrogen receptor (ER), progesterone receptor (PR), or overexpress HER2 provide actionable therapeutic targets. However, 15-20% of breast cancers are triple negative (TNBC), lacking a therapeutic target, and are associated with a worse prognosis. Activation of the glucocorticoid receptor (GR) has diverse effects depending on cell type. In ER-breast cancer, activation has been demonstrated to inhibit apoptosis of tumor cells, whereas its antagonism is associated with increased tumor cell death. Therefore, GR represents a potential therapeutic target. The current study was undertaken to investigate GR expression and its relation to other pathologic characteristics in previously diagnosed invasive ductal carcinoma (IDC). Design: Consecutive cases of IDC from 2013 with sufficient material in the biopsy specimen for further testing were identified. Immunohistochemistry for GR was performed and results correlated with H&E findings, ER/PR/HER2 status, and demographic data. GR as well as ER and PR status were analyzed as binary results (positive designated as ³1% expression for ER, PR, and GR) and as Allred scores. Data were examined using Student's t-test. Results: A total of 95 cases of IDC (61% African American, 29% non-Hispanic Caucasian, 7% Asian, 3% Hispanic) were analyzed: 12% were grade I, 32% were grade II, and 56% were grade III. ER was expressed in 63% (100% grade I, 83% grade II, 46% grade III), HER2 was overexpressed in 16% (0% grade I, 27% grade II, 13% grade III); 32% were TNBC (0% grade I, 13% grade II, 87% grade III; overall 0% of grade I are TNBC, 13% of grade II are TNBC, 48% of grade III are TNBC). GR was expressed by 88% of IDCs: 93% grade I, 80% grade II, and 82% grade III. 93% of TNBCs and 94% of ER-IDCs expressed GR. Additionally, ER-IDCs had higher GR Allred scores than ER+ IDCs (6.66 vs. 5.88, p=0.03). Age also predicted GR status: women <45 years old were more likely to express GR than women ≥45 (100% vs 87.5%, p<0.01) and to have higher Allred scores (6.78 vs. 6.10, p=0.01).
Conclusions:
The vast majority of our cases of IDC were found to express GR. 93% of TNBC and 94% of ER-IDCs expressed GR, with stronger expression of GR identified in ER-IDCs as compared to ER+ IDCs. Additionally, women <45 years of age have higher expression of GR and would likely derive the most benefit from its antagonism. GR antagonism represents a potential therapeutic target, particularly in TNBC.
Evaluation of the Benefit of Additional Excision in Cases of Papillomas of the Breast Diagnosed on Core Biopsy -Should a Papilloma Be Excised or Not? A Single Institution Experience
Elizabeth Gersbach, Paul Zhang. Hospital of the University of Pennsylvania, Philadelphia, PA. Background: Papilloma of the breast is a common finding on core biopsies that can often account for a mass seen during the patient's imaging studies. Although a benign diagnosis, the patient often undergoes subsequent excision. In our institution, the decision to undergo excision was made variably but more commonly in patients whose clinical suspicion remained elevated for a higher risk lesion, or in those who had the lesion removed for symptom relief and psychological comfort. The objective of this study is to evaluate how many patients had excision of a papilloma diagnosed on core biopsy without atypia, and how many of these patients benefitted from excision because of identification of a more significant lesion in the excision, which would have otherwise not been found. Design: 150 cases of breast core biopsies diagnosed as papilloma without atypia were identified in the surgical pathology archive from 2008 to 2014. It was documented if the patient then had a subsequent procedure (i.e. excisional biopsy or lumpectomy) or if no further intervention was performed. The results of the subsequent excision were evaluated. Results: 79 of the 150 (53%) patients did not have any additional procedures, while the remaining 71 (47%) had a subsequent excision. Of those with additional excisions, 8 (11%) were found to have a higher risk lesion. These lesions included 3 (4%) cases of ductal carcinoma in situ (DCIS), 3 (4%) cases of atypical ductal hyperplasia, 1 (1.5%) case of lobular carcinoma in situ and 1 case (1.5 %) of atypical lobular hyperplasia. Only 2 of 3 of the cases of DCIS (3% of 71 excised cases) involved the papilloma while in the remaining 6 cases (8%) the more significant lesions were found in surrounding breast tissue. Conclusions: There is lack of consensus regarding excision of papillomas diagnosed on core biopsy. Less than 50% of papillomas diagnosed on core biopsy at our institution were excised. Of those excised, the overwhelming majority remained benign but 11% were found to have a more significant lesion. Overall, the incidence of the papilloma harboring a more significant lesion is only 3%. It is important for patient management to be aware of the small risk of finding a more high risk lesion in the subsequent excision for the papilloma. The majority of these excisions may be unnecessary and an effort to eliminate extra surgery based on radiologic and clinical risk factor stratification along with proper patient consulting could further benefit patients.
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Phosphohistone Background: Classification of fibroepithelial tumors (FETs) of the breast relies heavily on assessment of mitotic activity, among other histopathologic parameters. Routine H&E mitotic counts can be subjective and time-consuming. Difficulty may arise in distinguishing mitoses from apoptotic cells and identifying mitoses in a "condensed" state, as can occur with hypoxia and suboptimal fixation. Phosphorylation of histone H3 protein (PPH3) is tightly correlated with mitotic chromatin condensation. PPH3 has been used as an immunohistochemical (IHC) marker of mitoses in multiple tumors/ sites. In this study, we examined the utility of PPH3 in assessing proliferative activity of FETs and compared PPH3 with H&E-determined mitotic counts. Design: 108 FETs including 27 fibroadenomas (FA), 30 benign phyllodes tumors (BPT), 28 borderline phyllodes tumors (BlnPT), and 23 malignant phyllodes tumors (MPT) from 98 patients were identified. Slides were reviewed to confirm the diagnoses. PPH3 staining was performed on 1 unstained paraffin section from each tumor. Mitoses were counted on H&E and PPH3-stained slides in 20 high-power fields (HPFs) (HPF=0.24 mm 2 ), beginning in areas dense in PPH3-stained objects seen at 10x magnification. Statistical analysis was performed. Results: PPH3-stained mitoses were readily identifiable at 10x magnification and allowed rapid identification of mitotic "hot spots." Median mitotic counts/10 HPFs for FA, BPT, BlnPT, MPT were 0.05, 0.74, 4.71, and 13.65, respectively on H&E, and 0.18, 0.78, 5.09, and 16.05, respectively for PPH3. There was a strong positive correlation between H&E and PPH3-determined mitotic counts (r=0.91, P<.001). Both H&E and PPH3-determined mitotic counts were significantly different between tumor grades (P<.001). Based on PPH3-determined mitotic counts, 2 cases would be reclassified, both from BlnPT to MPT. Conclusions: PPH3 mitotic counts correlate with manual H&E counts in FETs. While H&E-determined manual counting remains the gold-standard for assessing mitotic activity in FETs, PPH3 may be helpful as an adjunctive tool in this setting, specifically for identifying mitotic "hot spots." Using PPH3, a small number of cases were reclassified from BlnPT to MPT, for which treatment is similar. Additional study is needed to determine the prognostic significance of reclassifying FETs using PPH3.
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Stability of Estrogen Receptor (ER), Progesterone Receptor (PR), Ki-67 and HER2 Status in Breast Carcinomas After Neoadjuvant Chemotherapy (NAC) Paula Ginter, Himanshu Nagar, Yifang Liu, Sandra Shin, Sonal Varma. Weill Cornell Medical College, New York, NY; Queen's University, Kingston, ON, Canada. Background: NAC is used in the treatment of breast carcinoma to reduce tumor burden. Currently, there are conflicting data regarding stability of biomarker status after NAC. Significant change in biomarker status may affect the post-surgical utility of hormonedirected or HER2-specific therapy. We sought to evaluate this issue at our institution. Design: 47 cases of invasive breast carcinoma with incomplete response to NAC and available pre-and post-NAC tissue samples were identified. Immunohistochemistry was performed for ER, PR, Ki-67 and HER2 on tissue microarray or whole tissue slides. For ER and PR, ³1% nuclear positivity with moderate or strong staining intensity was positive. A case was weakly positive if ³1% but £10% nuclear positivity with weak staining intensity was seen. Ki-67 was "low" if <15% and "high" if ≥ 15% of nuclei stained positive. Pattern and intensity of membrane staining of HER2 was evaluated as: 0 =£10% faint staining, 1+=faint staining in >10%, 2+=weak to moderate staining in >10% or strong circumferential in £10%, 3+=strong complete staining in >10% with interpretation as: 0 and 1+=negative, 2+=equivocal, 3+=positive. Results: A majority of cases showed no change in ER (83%), PR (81%) and HER2 (96%) status. ER changed from negative to positive in 5/47 (11%), all of which were weakly positive. Conversely, 3/47 (6%) changed from a positive to negative; only 1 of which changed from weakly positive to negative. For PR, 5 cases changed from a negative to positive change (11%), one of which had the same change in ER and 2 of which only changed to weakly positive. Conversely, 3/47 (6%) changed from positive to negative, none of which also had the same change in ER. For HER2, 1/47 (2%) changed from negative to positive, confirmed to be amplified by HER2 FISH, while none changed from positive to negative. While in most cases (66%) there was no change in Ki-67 expression, a decrease was seen most often in cases that changed (13/16; 81%). Conclusions: Contrary to the reported trend of decreasing ER and PR expression after NAC, we found a change from negative to positive was more common, possibly due to the inclusion of weakly positive cases, leading to a possible role for hormonal therapy in these patients. A positive change in HER2 was rare which is consistent with the reported finding of HER2 stability after NAC. Ki-67 tendency to decrease after NAC is also in line with published findings and therefore, best assessed in the pre-NAC sample. A prognostic impact was not observed in ER-negative tumors.
Conclusions:
The expression levels of DLC1 in ER-positive breast cancer are associated with both relapse-free and overall survival. These findings suggest that development of strategies for therapeutic restoration of DLC1 could have therapeutic benefit.
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Triple Negative Breast Cancer: Nuclear or Cytopasmic FOX1? Location, Location, Location Abigail Goodman, Russell Tipton, Donna Martin, Jeanne Kowalski, Bill Li, Cynthia Cohen, Gabriela Oprea-Ilies. Emory University, Atlanta, GA. Background: Aberrant protein expression is described in malignat and non-malignat conditions. The aberrant expression may be either nuclear or cytoplasmic. Nuclearcytoplasmic transport is an important aspect of normal cells function. Forkhead-box (FOX) family proteins are DNA binding proteins regulating transcription and DNA repair and normally expressed in the nucleus. FOX1 functions as tissue specific alternative splicing (AS) regulator, stimulates expression of genes involved in cell division, attenuation of oxidative stress and tumor metastasis. FOX1 depletion causes cell death by mitotic catastrophe, often due to aberrant G2 checkpoint control. The aim of the study was to assess the nuclear vs. cytoplasmic immunohistochemical (IHC) expression of FOX1 in human breast cancer in correlation with hormone receptors and HER overexpression status. Design: Invasive mammary carcinomas were grouped into triple negative tumors (TNT) and non-TNT. The non-TNT carcinomas included estrogen and/or progesterone receptor and/or Her2 overexpessing tumors. Tissue microarrays were stained with FOX1 monoclonal antibody. Nuclear staining in more than 5% of cells was considered positive. Cytoplasmic staining was considered positve if more then 3+ in 5% of cells or more then 2+ in 10% of cellls. Age, race, tumor grade and stage were collected and analyzed using Wilcoxon rank sum test for numerical variables and chi-square or Fisher's exact test for categorical variables where appropriate. Results: A total of 388 breast cancer patients were evaluated: 183 were TNT and 205 were non-TNT tumors. The age at diagnosis ranged from 24-90 years of age. TNT patients were significantly younger at the time of diagnosis (p=0.022), with the median age at diagnosis 54 years of age vs. 57 in non-TNT. Nuclear FOX-1 stainin is significantly higher in non-TNT tumors compared to TNT (<0.001), with FOX1 expressed in 178 non-TNT tumors but only in 19 TNT. Cytoplasmic staing was strinkigly more frequent in TNT 59 (49.5%) compared to 79 (38.79%), p<0.01. Race, tumor grade, stage, or age at diagnosis also did not affect FOX1 expression. Conclusions: 1. Cytoplasmic aberrant FOX-1 expression may differentiate breast cancer tumor subtype and explain the more aggressive nature of TNT. Furthemore it may be associated with carcinogenisis and tumor progession in younger women. 2. Targeted inhibition of FOX-1 protein cytoplasmic transport may represent a powerful theranostic agent in the managemnt of a subtype of breast carcinomas with no current targeted therapy.
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Massively Parallel Sequencing Analysis of Acinic Cell Carcinoma of the Breast Elena Guerini-Rocco, Zsolt Hodi, Salvatore Piscuoglio, Charlotte Ng, Anne Schultheis, Caterina Marchio, Leticia De Mattos-Arruda, Nicola Fusco, Emad Rakha, Britta Weigelt, Ian Ellis, Jorge Reis-Filho. Memorial Sloan Kettering Cancer Center, New York, NY; University of Nottingham, Nottingham, United Kingdom. Background: Acinic cell carcinoma (AciCC) is a rare salivary gland-type tumor of the breast, displaying serous acinar differentiation. Despite its triple-negative phenotype, AciCCs are reported to have an indolent clinical behavior. We sought to investigate whether breast AciCCs would be underpinned by genetic alterations found in 254 breast cancer-related genes, and to define whether AciCCs would have a mutational repertoire distinct from that of other triple-negative breast cancers (TNBCs). Design: Three pure and seven mixed breast AciCCs (six AciCC-invasive ductal carcinomas of no special type and one AciCC-metaplastic carcinoma) were included in this study. DNA was extracted from microdissected formalin-fixed paraffin-embedded sections of tumor and normal tissue. In mixed cases each component was microdissected separately. DNA of sufficient quantity was obtained from 2 pure AciCCs, from the AciCC component of 7 mixed cases and from the non-AciCC components of 4 cases. Massively parallel capture sequencing targeting all exons of the 254 genes most frequently mutated in breast cancer was performed. Single nucleotide variants, and insertions and deletions were detected by MuTect, Strelka and VarScan2. Copy number alterations (CNAs) were identified using VarScan2 and GISTIC2.0. Results: Two pure AciCCs and AciCC components from five mixed cases harbored somatic TP53 mutations. One of the TP53 wild-type cases carried a mutation and loss of heterozygosity of MLH1, in addition to somatic mutations in RB1, NF2 and ATR. Additional somatic mutations affecting breast cancer-related genes found in AciCCs included PIK3CA, MTOR, CTNNB1, BRCA1, ERBB4, ERBB3, INPP4B and FGFR2. CNA analysis revealed complex patterns of gains and losses similar to those of TNBCs. Of the 4 mixed cases analyzed, identical somatic mutations were found in the AciCC and non-AciCC component of 2 cases (4 and 7 mutations in common in each case), however additional somatic mutations were identified in the non-AciCC component. In the mixed cases lacking somatic mutations in common, similar patterns of gene CNAs were found in both components of one case. Conclusions: Breast AciCCs display genomic features similar to those reported in TNBCs, harboring complex CNA profiles and TP53 mutations as the most common genetic event. AciCCs may constitute the substrate for the development of more aggressive forms of TNBCs.
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Massively Background: Microglandular adenosis (MGA) is a lesion composed of small infiltrating glands lined by S100-positive, estrogen receptor (ER)-negative epithelial cells and lacking a myoepithelial cell layer. Although classified as a benign epithelial proliferation, there is evidence to suggest that MGA may constitute a non-obligate precursor of triple-negative breast cancer (TNBC). We sought to define the mutational landscape of MGAs and of TNBCs arising in MGA, and to determine whether MGAs may constitute the substrate from which the TNBCs originated. Design: Six cases of MGAs and three of atypical MGAs (AMGAs) associated with in situ or invasive TNBC were collected. DNA from distinct morphologic components and matched normal tissue was extracted from microdissected representative sections and subjected to massively parallel sequencing targeting all coding regions of 273 genes recurrently mutated in breast cancer or related to DNA repair. Single nucleotide variants were detected by MuTect; insertions and deletions were identified by Strelka and VarScan2. Results: MGAs (n=6) and AMGAs (n=3) consistently displayed at least one somatic mutation (range 5-17 and 1-10, respectively), whereas TNBCs (n=4) associated with MGA/AMGA harbored 6 to 11 somatic mutations. Four to 7 mutations identified in MGAs/AMGAs were also detected in their associated invasive TNBCs, and in all cases identical TP53 mutations were found in the MGA and/or AMGA and in the associated TNBC; however the latter harbored additional mutations affecting known cancer genes. In the MGAs/AMGAs lacking TP53 mutations, mutations affecting known driver genes, such as PIK3CA, ERBB3, PTEN, FGFR2 and INPP4B, were identified. Conclusions: MGA is a clonal and neoplastic lesion, harboring recurrent mutations in TP53 and other bona fide cancer genes. Identical somatic mutations were identified in MGAs/AMGAs and matched invasive TNBCs, providing evidence to suggest that these lesions may constitute non-obligate precursors of TNBCs. Grzegorz Gurda, Tadeu Ambrose, Marina Nikiforova, Yuri Nikiforov, David Dabbs, Shannon Puhalla, Rohit Bhargava. University of Pittsburgh Medical Center, Pittsburgh, PA. Background: Women with aggressive, often widely metastatic breast cancers are unresponsive to current chemotherapy, with dim prospects and few therapeutic options. Recent advances in genomic profiling represent a new paradigm of cancer classification, with potential to match patients with targeted therapies. Design: A search of clinical data at our institution yielded 41 advanced breast cancer patients with avg age of 54 (range 31-75). The cancer samples underwent next generation sequencing via Ion Torrent PGM. Specimen characteristics were as follows: 4 (10%) cytology and 37 (90%) surgical specimens; 33 (80%) metastatic and 8 (20%) primary/ recurrent carcinomas; 26 (63%) in-house and 15 (37%) outside/referral. A standard 46 or 50 targetable cancer gene panel with approximately 2,800 mutations was reported. Results: Among 41 patients, 2 (5%) showed no genetic alterations, 15 (36%) showed variants of unclear significance (VUS) only and 24 (59%) showed at least 1 biologically significant variant (BSV)+/-VUS. The samples with VUS only showed an average of 1.85+0.9 alterations and 8/15 (53%) were metastases. The samples with BSV showed a significantly more alterations (3.33+1.4, *p<0.01) and larger fraction were metastases (23/24, 96% *p<0.01). Overall, 110 aberrations were observed in 15 of 50 targeted genes. Every patient had a unique molecular profile. BSV seen in <2 patients within the cohort included genes: TP53 (n=13), PIK3CA (n=13), KRAS (n=3), PTEN, APC, STK11, ERBB4 (n=2). BSV aberrations included 36 point mutations (80%), 3 amplifications (7%), 3 deletions (7%), 2 insertions (4%) and 1 frameshift (2%). The tested samples also showed very high Ki67 index (avg 75%) and were largely (24/39, 62%) hormone receptor and HER2 negative. All of the NGS reports were promptly reviewed (95% within 1 day). Among patients with BSV, 2 of 23 (9%) received targeted therapy. Conclusions: Advanced breast cancers show a patient-unique genetic landscape, though with several recurrent alterations. The majority of tested samples were metastases and both hormone receptor and HER2 negative. From clinical standpoint, NGS reports are promptly reviewed but utilization of targeted therapy is limited.
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Characterization of Molecular Alterations and Clinical Utilization of Targeted Next-Generation Sequencing in Advanced Breast Cancer
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Comparison of Invasive Pleomorphic Lobular Carcinoma With Invasive Classic Lobular Carcinoma: Clinicopathologic and Biomarker Analysis Aparna Harbhajanka, Ihab Lambzabi, Sahr Syed, Richa Jain, Vijaya Reddy, Ritu Ghai, Pincas Bitterman, Mariachiara Mei, Paolo Gattuso. Rush University, Chicago, IL; University of Rome, Sapienza, Italy. Background: Pleomorphic invasive lobular carcinoma (PILC) is a rare, aggressive and distinct morphological variant of invasive lobular carcinoma (ILC) characterized by nuclear atypia and pleomorphism compared to classic ILC (CILC). The aim of this study was to evaluate the clinicopathologic characteristics, tumor biomarkers and prognosis of PILC compared with CILC. Design: We retrospectively reviewed the medical records of 255 patients with ILC and compared the clinicopathologic parameters and Immunohistochemical (IHC) stains for ER, PR, MIB-1 and FISH for HER2 and disease free survival (DFS) of patients with PILC from CILC. Results: Of the 255 cases, 40 cases were PILC and 215 CILC. Seventy six (76/184,41.32%) cases showed axillary lymph node metastases. Our results showed that compared with classic ILC, PILC had a higher T stage, (P < .0001) and larger tumor size. Nodal involvement, lymphovascular invasion, and metastasis of CILC were less frequent compared to PILC with p-value of 0.001, 0.01 and 0.014 respectively.PILC was more commonly positive for HER2(P < .025), and MIB-1(P<.047) while negative for ER and PR compared to CILC. The patients with CILC had better disease free survival compared to PILC (p=0.006, log rank test).
When divided into different strata/catergories, ER positive and PR negative CILC cases showed better DFS than ER positive and PR negative PILC cases(p=0.045,and p=0.001 log rank test)respectively. Similarly, CILC cases in patients >50 years showed better DFS than patients >50 years with PILC (p=0.0001, log rank test). Conclusions: Classical invasive lobular carcinoma is characterized by less nodal involvement, lymphovascular invasion, smaller tumor size, lower metastatic propensity and better disease free survival than PILC. When divided into different strata, ER positive, PR negative and >50 years patient groups with CILC show even significant better DFS than PILC. PILC exhibit an adverse biomarker profile (positive HER2 neu, negative ER and PR and high Ki-67) as compared with classic ILC. These findings suggest that there is biological significance in differentiating PILC and CILC and that this may enhance tumor aggressiveness in certain strata of ILC. Background: Breast is the organ site most frequently associated with surgical pathology report defects. Few studies have investigated the types of error and the mechanisms of error detection specific to these diagnostically challenging specimens. Design: We performed a retrospective study of all revised pathology reports for breast surgical specimens at a large academic medical center over a 5 year period from 2009 to 2013. Reasons for revising a report were classified by utilizing published taxonomies. Special emphasis was placed on characterizing major and minor diagnostic errors. Results: Over the 5 year period, 1% of breast pathology reports were revised (119 of 12,228). The majority of revisions (74%) were due to non-diagnostic issues including changes in specimen identification or laterality (10%), patient registration (14%), or typographical errors (29%). A minority (26%) involved changes in diagnosis. There were 14 major changes that could have had an effect on clinical care and 13 minor changes that were unlikely to alter care. Most of the major changes (9 cases) involved classification of cancer as DCIS or invasive carcinoma. Two involved revision of a diagnosis of DCIS to ADH, 1 misdiagnosis of lymphoma as carcinoma, 1 identification of a lymph node metastasis, and 1 failure to recognize amyloid. Of note, a majority (10 of 14) of the amendments for major changes were discovered during review of immunohistochemical (IHC) studies for receptors, either due to review by a second pathologist or to more obvious diagnostic findings revealed on the deeper levels prepared for the study. Two cases were revised after subsequent surgery revealed more diagnostic findings. The final two cases were revised after the original pathologist requested a second opinion or obtained additional IHC studies. Conclusions: A review of revised reports provides valuable information for quality assurance and improvement within a pathology department. In our practice setting, IHC studies for predictive factors are often reported by a pathologist other than the one who issued the original diagnosis. This is an opportunity for a second opinion on the diagnosis and provided the highest yield for detecting interpretive errors. Our study highlights how evaluation of studies used for prediction of response to treatment, rather than for diagnosis, can be an important mechanism to detect diagnostic errors intradepartmentally in a timely fashion. Background: DNA methylation alterations have been shown to be early events in breast carcinogenesis, however, the relation of such epigenetic alterations to the histopathologic features of DCIS and development of invasive cancer remain unclear. Furthermore, the impact of a biopsy procedure on the epigenetic state of DCIS in future specimens and concordance between the two samples has not been fully evaluated. Design: Whole-genome DNA methylation profiles of estrogen receptor positive DCIS (n=55) from 40 patients within the New Hampshire Mammography Network were measured using the Illumina HumanMethylation450 array. 13 patients subsequently developed invasive cancer with a median clinical follow-up of seven years for this cohort. Central pathology slide review was performed to record DCIS grade and architectural pattern, as well as presence or absence of prominent chronic inflammation, periductal fibrosis, calcifications, and necrosis. DNA was isolated from guided 2 mm cores of paraffin-embedded tissue blocks. Paired biopsy and surgical specimens were available for testing in 15 patients. Results: Using linear regression models fit genome-wide, a CpG island located near the transcriptional start site of the APC gene, a known tumor suppressor gene, demonstrated significant (22 CpG loci at P<0.01) hypermethylation in high grade DCIS compared to low/intermediate grade DCIS. However, no significant enrichment was observed for any of the evaluated histopathologic features in patients that later developed invasive carcinoma compared to those who did not. Linear mixed effects models fit to each of 397,000 CpG sites did not identify significant methylation alterations between paired core biopsy and surgical specimens.
Conclusions:
The identification of significant site-specific hypermethylation in high grade DCIS demonstrates that distinct methylation patterns exist among nuclear grades, which warrants further study. In matched samples, the biopsy procedure does not appear to influence patterns of methylation alterations in DCIS, an important finding for future methylation studies. Background: Neoadjuvant chemotherapy (NAC) in breast cancer to decrease tumor volume for appropriate resection. Prior to NAC, Estrogen (ER) receptor, Progesterone (PR) receptor and Human Epidermal growth factor Receptor 2 (Her-2/neu) status by immunohistochemistry (IHC) and FISH on the core needle biopsy (CNB) are necessary to access sensitivity and for targeted therapy. Biomarkers however, may change after NAC which will alter further adjuvant systemic treatment management. Our study aims to identify the changes in the hormone receptors including ER and PR, Her-2/neu by IHC and FISH and Ki-67. Design: A power path database search of all breast cancer cases between the years 2004 to 2014 was performed for cases with residual tumor after NAC. A total of 93 cases were identified where biomarker studies were performed on both pre-and post NAC specimens. ER and PR were considered positive when the tumor cells were staining >1 % and negative in <1%. The Ki-67 index was categorized into a three-grade system: < 10% (low), > 10-<20% (intermediate), and > 20% (high). Her-2/neu was considered positive when IHC 3+ staining was seen in >10% of tumor cells, 2+ as equivocal and 0 and 1+ were considered negative. FISH amplification cutoff value of >2.0 was positive and <2.0 was negative for amplification. Results: Changes in ER are noted in 12/93 (13%) and in PR 20/93 (22%). The Ki-67 index changes are noted higher to lower values in most of the cases (46%) and were due to decrease in mitotic figures after NAC. Her-2/neu by IHC changed in 18/80 (23%) and by FISH 5 (7%) most commonly from positive to negative. Conclusions: -While tumor heterogeneity cannot be entirely excluded as a cause for variation in biomarker expression, our study showed significant changes in ER, PR, Her-2/neu and Ki-67 after NAC.
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HER2 Results in Breast Carcinomas Following Updated ASCO/ CAP Recommendation Guidelines
-Repeating biomarker studies post NAC for appropriate adjuvant chemotherapy is recommended.
Strong Association of Loss of p27 Expression and c-Myc Overexpression With High Grade Triple Negative Breast Ductal Cancers in African American Women
Farhan Khan, Tammey Naab, Luisel Ricks-Santi, Robert Dewitty. Howard University Hospital, Washington, DC; Hampton University, Hampton, VA. Background: p27 inhibits progression from G1 to S phase. c-Myc plays a key role in cell cycle regulation and apoptosis. The objective of our study was to correlate the expression of c-Myc and loss of p27 by immunohistochemistry (IHC) in the four major subtypes of breast cancer (BC) (Luminal A, Luminal B, HER2, and Triple Negative) in a population of 202 African-American (AA) women with other clinicopathological factors including grade, stage, disease-free, and overall survival. Design: Tissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 AA women. Two separate 1 mm cores represented each case. The polymer-HRP system was utilized for immunostaining. Five micrometer sections were stained with a mouse monoclonal antibody against p27Kip1 (SX53G8, Cell Marque, Rocklin, CA). Additional five micrometer sections were stained with a rabbit monoclonal antibody against c-Myc (EP121, Cell Marque, Rocklin, CA). The sections were evaluated for intensity of nuclear reactivity (1-3) and percentage of reactive cells; an H-score was derived from the product of these measurements. Cases were categorized as having decreased (score <50) or increased (score >50) nuclear expression. Bivariate analysis was done via c2 analysis and survivability data was calculated via the generation of Kaplan-Meier curves (SPSS v19). Statistical significance was assumed if p < 0.05. Results: Loss of p27 expression and c-Myc overexpression showed statistical significance with with ER negative (p<0.0001), PR negative (p<0.0001), triple negative (TN) (p<0.0001), grade 3 (p=0.038), and overall survival (p=0.047). Conclusions: In our study, a statistically significant association between p27 loss and c-Myc overexpression and TNBC with decreased overall survival was found. A recent study found that constitutive c-Myc expression is associated with inactivation of the axin 1 tumor suppressor gene. p27 inhibits CDK2/cyclin A/E. Loss of p27 expression and c-Myc expression detected by IHC strongly suggest that cell cycle dysregulation is critical in the pathogenesis of TNBC in AA women. Axin 1 and CDK inhibitors may represent possible therapeutic targets for TNBC. Background: Ki-67 has increasingly been used in breast cancer (BC). It has variable staining patterns making morphologic interpretation challenging. The purpose of this study was to evaluate various staining patterns, compare them to image analysis, and to correlate the scores with a group of BC that were subtyped based on the PAM50 assay. Design: A total of 22 BCs were molecularly subtyped using PAM50: luminal A (LumA) (n=6), luminal B (LumB) (n=10), HER2 (n=4), basal-like (n=2) and normal-like (n=1). Four one-mm cores from each tumor were randomly assembled in two tissue microarray (TMA) blocks. Ki-67 staining (MIB1, DAKO) was performed on an automated Bond immunostainer (Leica). The slides were manually scored by one breast pathologist. Image analysis (Aperio XT) was performed for all cells first and then using the Genie algorithm that enriched for epithelial cells. Four types of staining patterns were recognized and manually scored: mitotic figure or diffuse chromatin (DC), nucleolar only (Nuc), both nucleolar and chromatin (NC) and weak. A maximum of 500 cells were counted from each core. We evaluated tumor heterogeneity in the luminal types (n=16). The tumor was considered heterogeneous if at not all cores were either below or above the 14% cutoff that was arbitrarily chosen to differentiate LumA from LumB tumors. Tumor infiltrating lymphocytes (TIL) were subjectively scored using a scale from 0 to 3. Results: 76 of 88 (86.4%) cores had at least 500 cells. The cores that had <500 cells were divided among 6 cases. Summing the count of cells in 2 randomly selected cores, 4 cases had <500 cells. The order of the highest percentage of positive Ki-67 was basal-like>HER2>Luminal types. When cases with a TIL score of >1 were excluded, the order of tumor subtypes was not affected. Tumor heterogeneity was seen in 3 LumB and 2 LumA cases. Table1 presents Pearson correlation coefficient between manual and image analysis. Conclusions: When evaluating Ki-67 expression in a TMA setting, a 1-mm core diameter includes at least 500 cells in the majority of the cases. However, more than one core from each case is recommended due to tumor heterogeneity and to maximize the number of cases that include at least 500 cells. Excluding certain staining patterns could improve the correlation between manual scoring and image analysis. The pathologic features were assessed including number of ADH foci, size of largest focus, total number of cores, number of involved cores, size of the biopsy needle, and presence of lobular neoplasia (LN). MRI findings including mass-enhancement vs. nonmass-like-enhancement, and the reason for biopsy were also recorded. An upgrade was considered when the subsequent surgical excision specimen yielded invasive carcinoma (IC) and/or ductal carcinoma in situ (DCIS). Results: The rate of ADH in MRI-guided CNB among all four institutions ranged from 3.3% to 7.1%, with an average of 6%. A total of 15 (15%) cases had upgrade to DCIS (n=12) and IC (n=3). When all cases were included only increased number of involved cores was statistically significant (p=0.02). When cases with associated LN were excluded (n=14), increased number of ADH foci and increased number of involved cores were statistically significant (p=0.002 and 0.009, respectively). Data from a single institution which contributed the highest number of cases (n=61) was analyzed separately. We found that increased number of foci, increased number of total cores and involved cores and larger ADH size predicted upgrade (table).
Conclusions:
The incidence of ADH in MRI-guided CNB is not uncommon. The rate of upgrade of ADH to DCIS or IC is comparable to mammographically detected ADH we previously reported. Therefore, surgical excision is recommended. Similar to mammographically detected lesions, the volume of the ADH predicts the upgrade. This can be used to guide therapy (excision vs. observation) in some clinical situations.
Variables
Upgrade Yes (n=8) Upgrade No (n=53) P value
Number of cores (total) Background: Pathology generated equations using standard morphologic parameters have been introduced to predict Oncotype DX recurrence score (ORS) in breast cancer. Tumor infiltrating lymphocytes (TIL) is known to indicate good prognosis in breast cancer, making the tumor more sensitive for chemotherapy. The purpose of the study is to correlate TIL and other morphologic parameters with ORS. Design: Slides from 416 consecutive breast cancers with available Oncotype DX were reviewed. The following features were graded: Nottingham grade, necrosis (graded from 0 to 3), tumor/stroma ratio, degree of tumor infiltration, degree of TIL (graded from 0 to 3), and percentage of ductal carcinoma in situ. The following data were extracted from the pathology report: tumor size, estrogen receptor (ER) and progesterone receptor (PR) Allred scores, HER2 status, and ORS. Equation was calculated using ER, PR, HER2 and Nottingham grade. Then another equation was calculated using other significant morphologic variables. Results: Table 1 illustrates the correlation between each of the clinical variables and ORS. The concordance rate using our equation that included ER, PR, HER2, and Nottingham grade was 69.61% for overall and 98.62% after excluding the intermediate category. Although multiple morphologic variables were statistically significant, only necrosis and TIL improved the equation. When these two variables were added to the previous equation, these rates became 70.1% and 98.63%, respectively. All patients (n=221) who were categorized as having low ORS had low or intermediate risk using our formula. Three of 44 (6.8%) patients who were categorized as having high ORS had low risk using our formula. However, one of these patients was treated with chemotherapy and developed bone metastases in 28 months. Conclusions: TIL and necrosis are independent factors in predicting ORS. Adding these variables could improve existing equations. More studies are needed to examine the role of TIL in the setting of ORS assay. Is it a contaminant with the extracted tumor cells that falsely increased ORS or a true factor indicating chemo-sensitivity. Results: Cytoplasmic DUSP4 expression was observed. DUSP4 was more frequently expressed in malignant cases than in benign cases (p = 0.024). Mean DUSP4 expression score was signifi cantly higher in malignant cases than in benign cases (p = 0.019). DUSP4 expression was signifi cantly correlated with larger tumor size (more than 2 cm) (p = 0.015). There was no signifi cant correlation between DUSP4 expression and overall survival or disease-free survival in all 266 patients. We evaluated the impact of DUSP4 expression on survival in 120 patients with T1 stage tumor. Interestingly, Kaplan-Meier survival curves revealed a signifi cant effect of DUSP4 expression on both overall patient survival (p = 0.034, log-rank test) and disease-free survival (p = 0.045, log-rank test). In early T stage breast cancer, DUSP4 expression was a signifi cant prognostic factor. Conclusions: DUSP4 is frequently upregulated in breast cancer and may play a role in carcinogenesis and cancer progression and may be a marker of adverse prognosis, especially in patients with early T1 stage cancer.
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Tyrosine The association between DDR expression and the clinicopathological characteristics of patients in our cohort was analyzed by using chi-square or Fisher's exact test. Survival was determined using Kaplan-Meier analyses. Results: In normal epithelial cells and DCIS, DDR1 was expressed in the cytoplasm and cell membrane, while DDR2 was localized to cells at the epithelial-stromal interface. Of the 198 invasive carcinomas, DDR1 was low in 103 (52%), while DDR2 was high in 110 (55.6%). High DDR2 was associated with high tumor grade (p=0.002), and with the triple negative cancer subtype (TNBC) (p<0.0001), where it was accompanied by low DDR1 (p=0.003). The DDR1 low /DDR2
high phenotype was signifi cantly associated with worse overall survival (p=0.007).
Conclusions:
We present the fi rst comprehensive characterization of the concordant expression of DDR1 and DDR2 in breast tissue samples. We identifi ed a previously unknow inverse association between low DDR1 and high DDR2 expression which is associated with survival in patients with breast cancer, and warrants further validation. Our study that may aid in defi ning the potential of DDRs as biomarkers and/or drug targets in specifi c breast cancer subtypes.
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Updated HER2 In Situ Hybridization (ISH) Guidelines in Breast Cancer: Some Equivocal Findings Zuzana Kos, Kenneth Craddock, Hal Berman, Susan Done, Naomi Miller, Bruce Youngson, Anna Marie Mulligan. University Health Network, University of Toronto, Toronto, ON, Canada. Background: With the 2013 updated ASCO/CAP guidelines, dual-probe ISH assays saw a redefi ning of the equivocal category as an average HER2 count of 4-6 signals/cell with a HER2/CEP17 ratio < 2, a new positive category of > 6 HER2 signals despite a ratio < 2 and a cutpoint for positivity of a ratio > 2 (any HER2 count). We evaluated the impact of these changes on our laboratory practice and patient management. Design: HER2 assay data were extracted from the electronic pathology reporting system for all breast cancers that underwent HER2 assessment by ISH since the 2013 update publication. Results: During the study period, 306 tumours were tested by ISH [299 FISH; 4 brightfi eld dual ISH (DISH); 3 BOTH]. Of these, 65 (21.2%) were amplifi ed, 209 (68.3%) were nonamplifi ed and 32 (10.5%) were equivocal for HER2 gene amplifi cation (Table  1) . Of equivocal cases, 1 case of initial ISH testing had subsequent HER2 IHC which (31 vs 32) ; however, only 7 cases were equivocal using both definitions. Overall, 8 (2.6%) patients were now eligible for anti-HER2 therapy who would not have been previously.
Conclusions:
The HER2 guidelines update resulted in a change in HER2 status in 18% of tumours that underwent ISH testing (6.8% reclassified as HER2+) and affected eligibility for anti-HER2 therapy in 2.6% of patients. An increase in equivocal rates was not seen, although, there was little overlap in the cases deemed equivocal using different definitions. While the numbers are small, retesting a second tumour block may reassign 50% of equivocal cases into an amplified or nonamplified category.
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Diagnostic Sensitivity and Utility of GATA3 in Breast Cancer (BC) After Hormonal (HT) and Chemotherapy (CT) Gregor Krings, Yunn-Yi Chen. University of California, San Francisco, CA. Background: GATA3 is increasingly used for BC diagnosis. GATA3 is associated with estrogen receptor(ER) signaling but is also expressed in treatment(tx)-naive triple negative BC(TNBC) and is more sensitive than mammaglobin(MG) or GCDFP15(G15) in all BC subgroups. Neoadjuvant and adjuvant HT and CT may alter BC immunophenotype including ER and downstream genes, but the diagnostic sensitivity and utility of GATA3 with MG and G15 have not been evaluated in the post-tx setting in TNBC or other subgroups. Design: 58 BC were immunostained for GATA3, MG and G15, including 8 pre/postCT HER2+ pairs, 12 pre/postCT TNBC pairs and 26 non-paired postCT TNBC, as well as 12 pre/postHT ER+HER2-pairs. Of 38 CT treated TNBC, 15 were biopsies or fine needle aspirates(FNA) of recurrences or metastases(RM). Any nuclear(GATA3) or cytoplasmic(MG, G15) staining was scored positive. Results: GATA3 was positive in 87% of CT treated BC, compared to 56% MG and/or G15(p=.001). 81% CT treated MG-/G15-BC were GATA3+. GATA3 was positive in 84% CT treated TNBC, versus 49% MG and/or G15(p=.001). 80% CT treated MG-/ G15-TNBC were GATA3+. Results were similar if only including RM. Two(20%) paired TNBC lost GATA3 after CT(p=.32). In CT treated HER2+BC, GATA3(100%) was more sensitive than G15(38%,p=.03) but not MG(75%,p=.47). After CT, GATA3, MG or G15 were positive in 93% BC, including 92% TNBC. 100% HT treated ER+HER2-BC were GATA3+ versus 75% MG+(p=.47) and 67% G15+(p=.48). No changes were seen with HT.
GATA3, MG and G15 in BC After CT or HT Conclusions: GATA3 retains increased sensitivity over MG and/or G15 in CT treated TNBC, including biopsies and FNAs of RM. An immunopanel of MG, G15 and GATA3 shows optimal sensitivity for CT treated TNBC. HT does not alter GATA3 expression or sensitivity in ER+HER2-BC. NCT may change ER, PR or HER2 expression with prognostic implications, suggesting a role for postNCT biomarker retesting. However, systematic evaluation of IS is lacking. We determined the frequency of IS in a large group of NCT treated BC and evaluated differences between subgroups. Design: In 189 pre and postNCT samples, hormone receptor(HR;ER,PR) and HER2 protein expression(PE) were evaluated by immunohistochemistry(IHC) and HER2 amplification(AMP) by fluorescence in situ hybridization(FISH). ER,PR and HER2 scoring was based on ASCO/CAP guidelines. IS of PE was defined as change between + and -for HR and between -/equivocal(eq;0-2+) and 3+ for HER2. IS of HER2 AMP was defined as change between HER2-,eq and +. Results: IS was seen in 29% of BC, including 16% with HER2 and/or ER IS. HR(22%) was more common than HER2(9%) IS (p<.001); PR(15%) was more common that ER(8%) IS (p=.05). Loss was more common than gain for PR(13 v 2%,p<.001) but not HER2(5 v 4%,p=.62) or ER(5 v 3%,p=.29). Of ER+BC, 7% became ER-; 9% ER-BC became ER+. The triple negative(TN) phenotype was lost in 12% TNBC, with 3% switching to HER2+ and 9% to ER+. Of HER2-BC, 6% became HER2+. Of HER2+BC, 27% showed decreased HER2 PE and 16% became HER2-. Of 10 HER2+BC that became HER2 IHC-, 20% switched to FISH-whereas 80% remained FISH+/eq. No differences in IS were identified between BC subgroups(p>.05). Conclusions: IS is common in BC after NCT, including both gain and loss of HER2, ER and PR. BC subgroups show no significant differences in IS. HER2+ BC may selectively decrease HER2 PE compared to HER2 AMP, with implications for assay choice in the postNCT setting.
SATB2 Expression in Metaplastic Carcinoma of the Breast (MCB) With Osseous Differentiation (OD)
Gregor Krings, Yunn-Yi Chen. University of California, San Francisco, CA. Background: SATB2 is a sensitive and specific marker for mesenchymal tumors with osteoblastic differentiation. MCB is a rare aggressive breast cancer (BC) subtype with poor chemotherapy response, which can display heterologous elements including OD. Diagnosis of MCB can be challenging in biopsies or fine needle aspirates (FNA) due to focality of keratin staining and focal or diagnostically subjective heterologous matrix production, including osteoid or bone (OB). SATB2 may be useful in this context but has not been evaluated.
Design: 30 MCB were immunostained with SATB2, including 8 with OD, 13 with chondroid differentiation, and 4 spindle cell carcinomas. 2 MCB with OD were metastases with OB in the primary but not metastatic site; 1 of these was FNA. MCB with OD were also immunostained with cytokeratin (panK) and GATA3. All staining was scored as focal (<10%), patchy (10-50%) or diffuse (>50% Background: Per 2010 ASCO clinical practice guidelines committee and CAP council on scientific affairs, estrogen receptor (ER) or progesterone receptor (PR) with >1% positivity by immunohistochemistry (IHC) should be considered positive, while the cut off value was 10% before. Research revealed that there was no significant difference in overall survival and recurrent-free survival among breast cancer patients with negative ER IHC, ER IHC 1-5% positivity or ER IHC 6-10% positivity. This showed that the relationship between the empirical threshold of ER IHC positivity and true underlying ER biological function was poorly elucidated. To date the RNA expression levels of estrogen receptor (ESR1) have not been completely defined in breast cancer patients. Since correct classification of ER status has clinical implications, we try to investigate the relationship between ER IHC levels and ESR1 expression in a 84-gene based ER signaling pathway to try to find a better way to classify ER status especially breast cancer with low ER IHC. University of Utah School of Medicine, Salt Lake City, UT; ARUP Laboratories, Salt Lake City, UT; University of Minnesota, Minneapolis, MN; University of Utah, Salt Lake City, UT. Background: Estrogen Receptor (ER) expression in normal breast epithelium (NBR) is higher in women with a history of breast cancer (BC) compared to controls. The aim of this study is to quantify ER expression in NBR away from tumor in women with BC and to correlate it with BC subtypes. Design: 204 BC patients were identified for whom NBR away from tumor was available. Tissue microarrays were constructed, stained with ER and scanned using Aperio XT Scan Scope. Normal terminal duct lobular epithelium was manually circled on scanned images and annotations were recorded in separate digital layers. ER was quantitated in marked areas of the electronic image using an optimized scoring nuclear IHC algorithm (Aperio technologies, Inc.). Clinical information and tumor characteristics (menopausal status, ER, HER2 expression, grade, size, number of positive nodes, stage) were recorded. Results: The mean ER positivity in NBR was 16 ± 12.4 % (range: 0-5-5.7%) for all patients with BC, 20.8±13.9% for n=74 postmenopausal (PostM) and 13.4 ±10.9% for n=130 peri+premenopausal patients. ER positivity in NBR from BC patients did not vary by tumor size, positive lymph nodes status, tumor grade, or stage in PostM, and nor in peri+premenopausal women. Older age at diagnosis was significantly associated (p<0.0001) with ER in NBR. In PostM women ER expression in NBR was significantly higher in patients with ER negative or triple negative tumors. Conclusions: This study, based on quantitation from digital images, confirms ER expression in NBR increases with age and menopausal status in women with BC. We report, for the first time, a significant association between ER expression in NBR with ER negative and triple negative cancers in PostM women.
Design:
We compared the ESR1 expression and ER protein levels in 19 triple negative breast cancer patients, 14 patients with ER IHC>50% positivity and 8 patients with ER IHC1%-10% positivity with up to 70 months' follow-up using formalin-fixed, paraffin embedded, blinded tumor samples. They were evaluated for gene expression in ER
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Equivocating on Equivocals -HER2 Status Changes Following Implementation of the 2013 ASCO/CAP Guidelines: A National Reference Laboratory Experience Peng Li, Erinn Downs-Kelly, Rachel Factor, Katherine Geiersbach, H Evin Gulbahce. University of Utah School of Medicine, Salt Lake City, UT; ARUP Laboratories, Salt Lake City, UT. Background: In 2013, ASCO/CAP published new guidelines for HER2 testing. The new guidelines have defined HER2 by immunohistochemistry (IHC) with >10% (previously >30%) strong circumferential membrane staining (CMS) as positive (3+). Equivocal (2+) cases are those with incomplete and/or weak/moderate CMS in >10% of cells or complete, intense, CMS in ≤ 10% (previously ≤ 30%) with reflex to in situ hybridization. We retrospectively reviewed cases submitted to our lab for HER2 testing to assess the effect of the 2013 guidelines on IHC 2+ cases, specifically cases with 10-30% CMS, reflexed to fluorescence in situ hybridization (FISH).
Design: Our lab offers HER2 IHC by Hercept (Dako) or 4B5 (Ventana) antibodies, and dual probe FISH (Abbot Molecular). HER2 IHC & FISH tests performed 1/2010-8/2013, originally scored with 2007 guidelines, were included in the study. IHC was manually read following 2007 guidelines. Intensity (weak, moderate, strong) and the % CMS was also recorded. FISH was manually scored and originally reported per 2007 guidelines. As part of the study, amplification (Amp) rates for IHC 2+ cases were reevaluated using new guidelines by re-assigning cases with HER2/CEP17 ratio of ³2.0 or a HER2 average copy number ≥6/cell as Amp. Background: Radial scar (RS) has been found to be associated with both benign breast lesions and malignant/atypical lesions. The data regarding RS as a risk factor for developing breast cancer are conflicting and it is controversy if an excision will be warranted for patients with radial scar identified on core needle biopsy (CNB). In this study, we investigated the follow-up excision results for patients with radial scar on CNB, but no prior or current high-risk factors. Design: 403 cases of radial scar without any other concurrent or prior histologic abnormalities were included in this study. Follow-up excision (FUE) was performed in 220 (54.6%) cases. Demographic features, radiologic findings and pathologic findings were recorded. The majority of patients (91.5%, 369/403) were rendered a BI-RADS score of 4 and there was no significant difference in radiologic findings including the BI-RADS score between cases with FUE and cases without FUE. Results: Out of 220 cases with radial scar on CNB, only one invasive carcinoma (IC) (0.5%) and one ductal carcinoma in-situ(DICS) (0.5%) were found on FUE. 44 cases (20.0%) were found to have atypical ductal hyperplasia (ADH) and 13 cases (5.9%) were found to have lobular neoplasm (LN) on FUE. We found the upgrade rate is associated with increased age, but not any other variables (clinical presentation, radiologic findings, etc). Conclusions: This is one of the largest studies to evaluate excisional findings on patients with radial scar on CNB. Although the high-risk lesion (HRL) (ADH, LN) upgrade rate of RS following excision is about 26%, the carcinoma (DCIS, IC) incidence is extremely low (1%) in this study. Our data suggest RS is frequently associated with high-risk lesions (ADH, LN), but not carcinoma on CNB. Excision might not be necessary for those who have only RS on CNB and no other known risk factors, although clinical and radiological follow up might be warranted.
Genomic Profiling of Radial Scar Chieh-Yu Lin, Robert Sweeney, Shirley Zhu, Robert West. Stanford University Medical
Center, Stanford, CA. Background: A radial scar in the breast is characterized by a stellate nidus with dense collagen associated with entrapped ducts and lobules. Although the lesion itself exhibits benign cytohistology, previous studies have indicated that the presence of radial scar is associated with concurrent high-risk lesions, such as atypical ductal hyperplasia, carcinoma in situ, or invasive cancer. While the radial scar has been described in the literature for decades, its pathogenesis and the underlying molecular mechanisms that links it to high-risk lesions remain largely unknown. Our lab has previously examined the genomic profiles and transcriptome of other early breast neoplastic lesions. In the current study, we performed transcriptome and exome analyses to understand the molecular mechanisms linking radial scars to high-risk lesions. Design: RNA-sequencing and exome-sequencing were performed on archival FFPE blocks from two pilot cases with radial scar, three hyperplasia lesions, five DCIS, one invasive breast cancer, with 3 paired normal breast tissue. Somatic single-nucleotide polymorphisms and insertion-deletion gene mutations in the radial scar samples were analyzed and annotated by Samtools, VarScans, MuTect, and ANNOVAR. The results are compared with their mRNA expression profiles. Results: Exome-sequencing of radial scars reveals multiple recurring, deleterious somatic mutations that are with high allele frequency and are not present in the paired normal breast tissue. Some of these targets are overlapped with the somatic mutations identified in paired DCIS sample, indicating the clonality. In addition, compared with data from The Cancer Genome Atlas (TCGA) of invasive breast carcinoma, the radial scars share known common mutations occurring in invasive breast cancer. The mRNA expression profiles of the candidate genes are generated, and the unsupervised hieratical clustering analysis shows clustering of radial scar samples. Conclusions: Our study is the first to profile the somatic mutations and mRNA expression profiles of radial scars. We identified recurring somatic mutations, possibly representing the driver mutations in pathogenesis. These findings, together with the results of other high-risk breast lesions, will not only expand our knowledge in disease progression, but also provide novel diagnostic markers for identification of high-risk breast lesion.
Improved Detection for Breast Myoepithelial Cells By A New Clone of Smooth Muscle Myosin Heavy Chain Antibody
Haiping Liu, Sharmini Muralitharan. Thermo Fisher Scientific, Inc., Fremont, CA. Background: Immunohistochemistry (IHC) of myoepithelial cell (MEC) markers is routinely used in breast pathology for detecting the presence or absence of an invasive carcinoma. Smooth muscle myosin heavy chain (SMMHC) and p63 are among the most commonly used MEC markers and often used together as a panel. However, reduced SMMHC expression in MECs bordering the tumor cell nests in the ductal carcinoma in situ (DCIS) has been observed in several studies where clone SMMS-1, was applied. Our preliminary study showed that a rabbit monoclonal antibody against SMMHC, clone EPR5336(B), was highly sensitive and specific in in detecting MECs in breast lesions compared to clone SMMS-1. Design: Clones EPR5336(B) and SMMS-1 were first optimized for IHC on FFPE human breast tissue sections; then they were compared on individual and microarray breast tissues. The microarrays consisted of normal mammary glands, benign lesions, carcinoma in situ and invasive carcinomas. Further analysis was done to compare clone EPR5336(B) with clone SMMS-1 on breast carcinoma in situ cases, with p63 antibody clone 4A4 as reference marker for MECs, on 16 cases of DCIS and 2 cases of LCIS. Results: Clone EPR5336(B) produced more intensive staining than clone SMMS-1 in all breast tissues tested. While both clones stained almost all MECs in normal breast tissues and hyperplasias, clone EPR5336(B) produced much stronger staining intensity. In MECs bordering carcinoma in situ (CIS), SMMS-1 staining became very weak or even negative while the staining by clone EPR5336(B) was always a notch stronger. In 18 breast CIS cases that were stained by the two SMMHC clones and p63, clone EPR5336(B) demonstrated outstanding capability of highlighting MECs around the lesions. Clone EPR5336(B) stained MECs with complete circumference bordering CIS in 11/18 cases, with partial circumference in 6 cases. In contrast, clone SMMS-1only demonstrated complete circumference staining of MECs in 2 cases and partial circumference in 10 cases. There was only one case of CIS where MECs were not stained with clone EPR5336(B) while clone SMMS-1 failed to detect MECs in 6 cases. Although p63 was able to stain MECs around lesion of CIS in all cases, only 7 achieved staining of complete circumference.
Conclusions:
The study demonstrates that clone EPR5336(B) of SMMHC antibody is more sensitive than clone SMMS-1 in detecting breast MECs.
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The (Table 1 ). There was a major re-shuffling of the equivocal category. 19 of 25 results in the 2007 equivocal category, defined by a HER2/CEP17 ratio between 1.8 and 2.2, were re-assigned as either positive (13) or negative (6). Only six 2007 equivocal results remained equivocal when 2013 guidelines were applied. Since the update designates specimens with HER2 signal/nucleus ratio of 4.0-6.0 as equivocal, 35 previously negative cases became equivocal in the 2013 scheme, 12 of these with 1+ immunohistochemistry. One negative patient was reclassified as HER2 positive with low HER2/CEP17 ratio and HER2/nucleus=6. We evaluated the clinicopathologic features of BC in a large cohort of patients with PIK3CA mutations. Design: Tumors from patients with locally advanced or metastatic breast carcinoma were tested for PIK3CA mutations using the Sequenom or MSK-IMPACT platforms for a clinical study at our institution. Clinicopathologic features reviewed included patient age at diagnosis, primary tumor histologic subtype, grade, size, lymphovascular invasion (LVI), receptor status, nodal status, and time interval to distant metastasis. Results: A total of 513 tumors were tested between 02/13 and 03/14. Receptor status was known for 422 BC: 297 (70%) were ER/PR+, HER2-; 55 (13%) ER/PR+, HER2+, 11 (3%) ER/PR+, HER2 equivocal (by IHC and FISH); 33 (8%) ER/PR-, HER2+; 26 (6%) ER/PR/HER2-. A total of 78 cases harbored PIK3CA mutations, including H1047R (38), E545K (16), E542K (12), H1047L (4), N345K (4), E545A (2), C420R (1) and H1047Y (1). Among cases with PIK3CA mutation, the primary BC was ductal (61), lobular (11), or mixed ductal and lobular (6). Tumor size ranged from 0.25-8.5 cm (average 2.9). Tumor grade was known for 41 BC, including 1 (2%) grade 1, 20 (49%) grade 2, 20 (49%) grade 3. LVI was present in 32/78 (41%). Lymph node status at diagnosis was known in 51 patients; 37 (73%) were node positive. We found no unique morphologic feature(s) associated with PIK3CA mutation. The time interval to metastasis ranged from 0-226 months (average 59 months). Receptor status was known in 68 BC with PIK3CA mutation: 51 (75%) were ER/PR+, HER2-; 5 (7%) ER/ PR+, HER2+; 3 (4%) ER/PR+, HER2 equivocal (by IHC and FISH); 6 (9%) ER/PR-, HER2+; 3 (4%) ER/PR/HER2-. The distribution of specific mutations according to the receptor status is summarized in Table 1 . One of the hotspot mutations E545K was detected only in ER/PR+, HER2-tumors in this cohort. Among BC without PIK3CA mutation, 13 cases harbored AKTE17 mutation. Conclusions: PIK3CA mutation did not correlate with any specific morphologic features in the primary tumor. Response to PI3K inhibitors in this cohort of patients is under investigation.
Folate Receptor Alpha (FRA) Expression in Pregnancy Associated Breast Cancer (PABC)
Tracy Lundberg, Sagar Dhamne, Luis Blanco, Kalliopi Siziopikou. Northwestern University, Feinberg School of Medicine, Chicago, IL. Background: Folate is required for cell metabolism, DNA synthesis and repair. The folate receptor regulates cellular folate homeostasis and cellular proliferation. Folate receptor alpha (FRA) is expressed in breast cancer; its expression is often associated with triple-negative (TN) phenotype and worse prognosis. Pregnancy associated breast cancers (PABC), which are diagnosed during or after a pregnancy, are also more likely to be TN cancers with a poor prognosis. In this study we evaluated FRA expression in PABC and correlated its expression with clinicopathologic features in this aggressive breast cancer subtype.
Design: 23 patients diagnosed with PABC within 2 years of pregnancy (mean age 35.8, range 26-48). Age-matched nulliparous women with breast cancer served as controls (mean age 37.5, range 29-51). Pathologic tumor features including histologic type, tumor grade, tumor markers (ER, PR, HER2) and lymph node (LN) status were assessed. Extent of FRA expression by immunohistochemistry (0=<1%, 1=1-25%, 2=26-50%, 3=51-75%, 4=76-100%), staining intensity (0=absent, 1+=weak, 2+=moderate, 3+=strong) and product score (extent x intensity) were calculated. Staining pattern was noted as luminal, cytoplasmic, membranous or perinuclear. Results: Overall, PABC cases were more likely than controls to have greater extent of FRA staining (3 staining: 26% vs 7%), to have strong staining (3+: 35% vs 20%) and to be associated with a TN phenotype (33% vs 7%). All (7/7, 100%) of the TN PABC cases showed strong FRA staining. Of interest, 30% of the PABC cases showed a membranous staining pattern, while none (0%) of the control cases did so. Furthermore, membranous staining PABC cases had a higher product score than non-membranous staining PABC cases (mean 7.57 vs 2.25, p = 0.0013). Finally a higher % of the membranous staining PABC cases were grade 3 tumors, had TN phenotypes and had positive LN compared to non-membranous staining PABC cases (85% vs 63%, 43% vs 25% and 86% vs 44% respectively). Background: Adenoid cystic carcinomas (ACC) of the breast are rare tumors of excellent prognosis, with characteristic histology, and molecular features consisting in a recurrent chromosomal translocation t(6;9)(q22-23;p23-24), responsible for the fusion of MYB with NFIB, and overexpression of MYB. Basaloid salivary gland-like tumors, include basal adenomas (cylindromas), and basaloid carcinomas, which are possibly related to ACC. The aims of this study were to define the clinicopathologic features of these tumors and the diagnostic utility of MYB IHC. Design: Twenty-five breast tumors, previously diagnosed as ACC or basaloid tumors, were reclassified histologically, and graded according to the degree of cytologic atypia, mitotic activity and growth pattern. Clinical data obtained included age, tumor size, lymph node status, and follow-up. IHC included stains for estrogen/progesterone receptors, HER2, p63, c-kit and MYB. Results: Thirteen cases were classified as ACC, two as basal cell adenomas, and ten as basaloid carcinomas. Median age was 59.2 years (range. 34-78 years), median tumor size was 24.9 mm (range, 12-45 mm). All cases were triple negative; MYB IHC was positive in 13 (100%) ACC, two basal cell adenomas were positive but in scattered cells, and six (60%) basaloid carcinomas were positive. p63 was positive in all ACC and basal cell adenomas, and in four basaloid carcinomas. c-kit was positive in all the tumors. Lymph node metastases were present in one ACC (pN1a), and one basaloid carcinoma (pN1mi), two basaloid carcinomas were pN0 i+. One ACC developed brain metastases and died. One patient with basaloid carcinoma is alive with pleuropulmonary metastases.The remaining cases are alive without evidence of disease. Conclusions: Tumors with basaloid features in the breast, including ACC, basal cell adenomas, and basaloid carcinomas, are within the same histological spectrum, and are probably genetically related. MYB stain was positive in a high percentage of cases. The prognosis of these tumors is good, with little tendency to lymph node metastases, but occasional cases may develop distant metastases. Background: Cellular angiolipoma is a rare entity in the breast that may present with a mammographic abnormality or palpable mass. To date, there are only sixteen cases reported in the literature with the largest study including 14 cases. Per the reports lesions were either in the breast parenchyma or subcutis of the breast. Design: We searched the pathology database for all examples of angiolipoma of the breast, and reviewed the clinical presentation, imaging studies and follow-up data of those classified as cellular angiolipoma. Results: A total of 116 cases of angiolipoma of the breast were retrieved from our surgical pathology archives for the period from1990 to 2014. Of these, four cases were classified as cellular angiolipoma (3.4%), all of which were from females. Comparatively, for the same time period, there were 1752 cases of extramammary angiolipoma, of which seven were classified as cellular angiolipoma (0.39%, P<0.0001). All seven extramammary cases were from the arm or chest. The demographic, clinical, and follow-up data are summarized in Table. The morphology in all of our four cases was typical with cellular spindle cell areas and vascular proliferation in a background of mature adipose tissue with characteristic intravascular fibrin thrombi and low mitotic rate (< 1 per 10 HPFs) and absence of necrosis and nuclear pleomorphism. Immunohistochemically they are positive for CD34, but negative for desmin and HHV-8.
Conclusions
Conclusions: Cellular angiolipoma is rare, but in our experience is more common in the breast than at other sites. They may be encountered as needle biopsies, but close attention to the morphologic features and use of ancillary studies will assist in distinguishing these lesions from Kaposi's sarcoma or angiosarcoma. Background: Approximately 15% of all patients with metastatic breast cancers have symptomatic brain metastases (BM), with a median survival of less than one year. The androgen receptor (AR) is expressed in many primary and metastatic breast cancers, and there is data that anti-androgen therapy may show promise in treating patients with AR+ disease. However, AR expression in brain metastases from breast cancer has not been well characterized. Design: Tissue microarrays from a well-annotated cohort of breast cancers metastatic to the brain were evaluated for AR expression by IHC (clone SP107, Ventana Benchmark Ultra). AR positivity was defined as >=10% staining in tumor nuclei. Differences in AR expression between the breast and metastatic tumor were assessed in the subset of patients with matched tissue. Gene expression profiling was performed using macro-dissected FFPE material on Affymetrix HTA 2.0 arrays, and PAM50 subtypes were derived. AR expression was then correlated with ER/HER2 status and PAM50 molecular subtype. Results: Overall, 29 of 67 BM (43%) were AR+. AR positivity was seen at a higher rate in patients with ER+ and/or HER2+ BM as opposed to patients who were ER-/ HER2-(see table 1 When AR status was segregated by PAM50 molecular subtype, AR positivity was seen more often in the luminal A (65%) and B subtypes (67%) than in the ERBB2+ (25%) and basal (5%) subtypes. Interestingly, of the 15 cases with matched primary and metastatic tissue, 11 cases (73%) showed the same AR result for both the primary and BM (6 +/+, 4 -/-), while 4 cases (27%) showed a change from AR+ in the primary cancer to AR-in the metastases.
Conclusions: These findings demonstrate that many brain metastases from breast cancer express AR. AR positivity is seen more often in patients with ER+ and luminal cancers as determined by routine IHC parameters and molecular profiling. When comparing AR+ matched primary breast cancers with corresponding brain metastases, loss of AR expression in the brain metastasis is identified in close to a third of patients. The results indicate that targeted anti-androgen therapy may be a reasonable option for patients with brain metastases from breast cancer and that AR testing should be performed on the metastatic tissue.
Clinical Utility of ER and CK5 Separately or as a Cocktail in Separating ADH and Low Grade DCIS From UDH
Anthony Martinez, Xiaoxian Li, Krisztina Hanley, Cynthia Cohen. Emory University, Atlanta, GA. Background: Previous studies have looked at the use of high molecular weight cytokeratins (HMCKs) such as CK5 to help distinguish between usual ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH) and low grade DCIS. Low grade atypical proliferative lesions generally have diffuse estrogen receptor (ER) expression. Few studies, however, have looked at the utility of combining a HMCK with ER to differentiate ADH or low grade DCIS from UDH. The goal of this study is to assess the utility of CK5 and ER each as a single stain or as a cocktail, in separating ADH and low grade DCIS from UDH. In addition, the utility of Bcl-2 and PR expression was assessed. Design: Archived pathology files identified the following study cases: 13 ADH, 10 low grade DCIS and 22 UDH. Tissue blocks were stained for ER, CK5, PR and Bcl-2. Nuclear staining for ER and PR was scored as diffuse (≥80%), focal (<80%), and negative (0%). Cytoplasmic staining for CK5 and Blc-2 was scored as diffuse (≥60%), focal (<60%), and negative (0%). Differences in staining between the study groups and the sensitivities and specificities were calculated.
Results: ER, CK5, and PR expression patterns were significantly different in ADH and low grade DCIS versus UDH (p<0.001). For ER: 10/13 (77%) ADH and 10/10 (100%) DCIS cases showed diffuse staining (sensitivity 87%, specificity 100%); none of the 22 UDH cases showed diffuse staining with ER. The combination of ER and CK5 versus either alone increased the sensitivity of identifying low grade atypical proliferative lesions to 91.3%. The expression patterns of either CK5 or ER between ADH and low grade DCIS were not significant (p=0.265, p=0.061). For CK 5: 11/13 (85%) ADH and 7/10 (70%) low grade DCIS cases were negative for CK5; all 22 UDH cases had diffuse staining (sensitivity 100%, specificity 91.3%). Interestingly, 2 ADH cases showed diffuse staining with CK5. The first case had cautery artifact and the second case showed both diffuse ER and CK5 staining. For PR: 5/13 (38%) ADH cases and 6/10 (60%) DCIS cases showed diffuse staining; none of the 22 UDH cases showed diffuse staining. Bcl-2 showed no statistical significance in expression pattern between UDH, ADH and DCIS (p=0.815). Conclusions: While morphology remains the gold standard for the diagnosis of UDH, ADH and low grade DCIS, the combined use of ER with CK5 may increase the sensitivity of distinguishing ADH and low grade DCIS from UDH when compared to either stain alone. PR staining may also play a role in the differential diagnosis whereas Bcl-2 does not appear helpful. Background: GATA-3 is a transcription factor demonstrated in gene expression profiling experiments to be highly expressed in breast cancer, where it was shown to correlate with estrogen receptor (ER)-positivity and favorable prognosis, and urothelial carcinoma. GATA-3 immunohistochemistry (IHC) has emerged as a key marker in the diagnosis of ER-positive breast cancer and urothelial carcinoma. It is at least as, if not more, sensitive than the traditional breast cancer markers ER and PR, with the advantage that it is not expressed in Müllerian tract tumors. It is nearly twice as sensitive as GCDFP-15 and mammaglobin. GATA-3 would be especially useful as a marker of ER-negative breast cancers, but, unfortunately, data are conflicting, with reported rates of GATA-3-positivity ranging from 12.5-71% (median 48%). Some of this variation may be due to choice of antibody clone. Design: GATA3 IHC was performed on tissue microarrays of 200 ER-negative and 23 ER-positive breast cancers, using two monoclonal antibodies (L50-823, Biocare; HG3-31, Santa Cruz). Tumors were arrayed in triplicate. Extent (%) and intensity (0, 1+, 2+, 3+) of staining were assessed and an H-score (extent x intensity) calculated. An average H-score >5 was considered positive. Two-tailed Fisher's Exact Test and Wilcoxon matched-pairs signed-ranks test were used as appropriate, with p<0.05 considered significant. Results: Strong GATA3 expression (average H-score 292) was detected in 100% of ER-positive breast cancers, regardless of clone. GATA3 expression was detected in 78.6% (average H-score 168) and 67.2% (average H-score 136) of ER-negative breast cancers with the L50-823 and HG3-31 clones, respectively. Both the frequency and extent of GATA3-positivity were greater with L50-823 than with HG3-31 (p<0.0001). Detailed expression data are presented in the Table. Conclusions: Immunopositivity with monoclonal antibodies to GATA-3 is retained in the vast majority of ER-negative breast cancers, suggesting this as a key diagnostic marker in this tumor type, particularly useful in metastases. The L50-823 clone appears more sensitive and produces a more robust signal in this setting.
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GATA3 Is Frequently Expressed By Estrogen Receptor-Negative
GATA3 Expression in Breast Cancer Stratified by ER Status
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Mucocele-Like Tumors of the Breast: A Clinical Outcome and Histologic Analysis of 102 Cases From the Mayo Benign Breast Disease Cohort
Annie Meares, Ryan Frank, Amy Degnim, Marlene Frost, Lynn Hartmann, Robert Vierkant, Daniel Visscher. Mayo Clinic, Rochester, MN. Background: Mucocele-like tumors (MLT) of the breast are classically defined as cyst-like lesions in which mucin distends lumens and extravasates through the lining epithelium into surrounding stroma. MLT are accompanied by a variety of epithelial proliferations, with an increased frequency of associated atypical ductal hyperplasia. There are no long term follow-up studies to assess whether MLT confer risk for subsequent development of breast cancer. Design: Our benign breast disease (BBD) cohort is comprised of 13,434 women who underwent biopsy between 1967-2001. Archival slides were reviewed in a blinded, retrospective fashion. MLT were categorized as classic (with mucin extravasation), nonclassic (without extravasation), or mechanically disrupted (MD). Cases were classified as MD when mucin was present at the edge of the biopsy or there was a defect in the tissue causing mucin extravasation. MLT were also analyzed for associated proliferative and atypical lesions (including flat epithelial atypia (FEA)), and for incidence of breast cancer in follow-up; the mean follow-up is 14.8 years.
Results:
The cohort had 102 MLT (0.7%); 79 were classic, 9 were non-classic, and 14 were MD. Columnar epithelium, coarse calcifications, and abundant mucin were common to MLT. At time of diagnosis, 42% of patients were greater than 55 years, 41.2% were 45-54 and 16.7% were less than 45. MLT were more often associated with atypical hyperplasia (AH) compared to the overall cohort (26% vs 5%, p<.0001). FEA was present in 8.8%. To date, 13 patients with MLT (12.7%) have developed breast cancer, with a mean interval between BBD biopsy and cancer diagnosis of 14.8 years. This breast cancer frequency is only slightly higher than the population expected rate (SIR 2.28, 95% CI 1.21-3.91), and not significantly different from women with proliferative breast lesions other than MLT, or columnar cell change. The mean age at cancer diagnosis was 65.8 years. Six cancers developed in the same breast as the MLT, 6 in the contralateral breast, and one bilaterally. Two had FEA in the BBD biopsy and 3 had AH. Four of 17 women under the age of 45 with MLT developed cancer, a frequency which is higher than the population expected rate (SIR 5.16, 95% CI 1.41-13.23). Conclusions: MLT are a subset of columnar cell change which, for unclear reasons, are often associated with co-existing AH. Our data suggests that, overall, MLT do not appear to be unstable precursor lesions; however, MLT occurring in patients under age 45 may represent a high-risk subset.
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Metastatic Breast Cancer: Can Bone Biopsy Be Used To Evaluate Hormone Receptor and HER2 Status? Diana Montezuma, Carla Bartosch, Nuno Coimbra, Paula Lopes, Renata Vieira, Elisabete Fernandes, Fernanda Silva, Joana Vieira, Teresa Sarmento, Noemia Afonso, Conceicao Leal, Mariana Afonso. Portuguese Oncology Institute of Porto, Porto, Portugal. Background: Differences in hormone receptor (HR) and HER2 status between primary and metastatic breast cancer (BrCa) have been reported. Although bone is the preferential metastatic site, most data derives from studies of non-bone metastases, since decalcification is believed to impair immunoreactivity. We assessed the impact of decalcification in HR/HER2 status in bone metastases and therapeutic/prognostic implications of HR conversion. Design: Material from bone (n=148) and visceral (n=120) BrCa metastases was clinicopathologically reviewed and compared with primary tumor for HR (immunostaining intensity/ positivity percentage) and HER2 status. In 34 primary BrCa, alongside with routine fixation, a parallel tissue sample was decalcified. Statistical analysis: McNemar's, Wilcoxon signed-rank, Chi-square tests and Cox proportional hazard model.
Results: Comparison of HR/HER2 expression between bone and visceral metastases
Regarding decalcified primary tumors, when considering only positive cases, there was no significant change in HR status, but there was a significant (ER: p=0.005; PR: p=0.001) reduction in the median intensity of the HR expression. Patients with positive-to-negative ER conversion had a worse survival (HR:1.95,p=0.03) compared with those that remained ER positive in the metastasis. PR conversion showed a similar trend (HR:0.90,p=0.156). Conclusions: Bone is traditionally considered inadequate for HR/HER2 reevaluation but our results show that HR/HER2 immunoexpression is feasible and reliable in bone specimens, as it is not substantially influenced by decalcification. Importantly, careful evaluation of low intensity staining is mandatory and decalcification procedures must be standardized. Since bone may be the first and/or only BrCa metastatic site, and HR/ HER2 conversion may impact treatment, validation of these results may significantly change clinical approach to metastatic BrCa.
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Impact of 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
Kristen Muller, Laura Tafe, Heather Steinmetz, Jonathan Marotti. Dartmouth-Hitchcock Medical Center, Lebanon, NH. Background: HER2 testing is recommended for all newly diagnosed invasive breast cancers and metastases to assess prognosis and suitability for targeted therapy. At our institution, we perform fluorescence in situ hybridization (FISH) as the primary assay to identify HER2 amplification. The 2013 ASCO/CAP guideline updates lowered the threshold for HER2 positivity and altered the equivocal category. The goal of this study was to evaluate the impact of these changes on the distribution of HER2 FISH status in breast cancer and, examine the utility of reflex HER2 immunohistochemistry (IHC) for FISH equivocal cases. Design: We retrospectively identified all primary invasive breast cancers and metastases with HER2 FISH results during the 12 months before (10/2012-09/2013) and after (10/2013-09/2014 ) the HER2 guideline updates were implemented. All cases analyzed for HER2 via dual-probe FISH (PathVysion) were included. The distribution of HER2 FISH positive, equivocal, and negative cases was determined for each time period. Reflex HER2 IHC (clone 4B5) results were recorded for HER2 FISH equivocal cases. HER2 results were interpreted based on the guidelines that were in place at the time of testing. Results: The distribution of HER2 FISH results before and after the guideline updates are listed in Table 1 . There was a significant increase in the number of FISH equivocal results after the guideline updates (4.9% vs 1.4%, p= 0.0087) that was independent of specimen type (core vs. surgical, p= 1.0). Four of 5 FISH equivocal cases before the update would have been classified as positive using the new recommendations. Sixteen of 17 FISH equivocal cases after the updates had reflex HER2 IHC: 2/16 (12%) were positive, 11/16 (69%) remained equivocal and 3/16 (19%) were negative. Six FISH equivocal biopsy cases after the guideline updates had repeat FISH on the subsequent surgical specimen: 2 remained equivocal and 4 were negative. (n=28), benign PTs (n=19), borderline PTs (n=15) and malignant PTs (n=7) from 57 patients were retrieved from the files of our Department. Lesions were classified according to the criteria set out in the current World Health Organization classification. Two pathologists with an interest in breast pathology reviewed all available slides and selected areas representative of the lesions and normal breast tissue for microdissection. DNA samples were extracted from each lesion and adjacent normal breast and subjected to Sanger sequencing using primers encompassing the MED12 exon 2 coding sequence and the exon-intron boundaries. Forward and reverse sequence reactions were performed in duplicate. Sequencing results were analyzed using the DNAStar LaserGene software with the observers blinded to the diagnosis of each lesion. Results: MED12 exon 2 somatic mutations were found in 64%, 79%, 87% and 14% of FAs, benign PTs, borderline PTs and malignant PTs, respectively. Thirty somatic single nucleotide variants and 17 insertions and deletions affecting MED12 were identified. Seven patients had multiple lesions; in 3 cases all lesions were found to harbor identical somatic MED12 mutations, in 2 cases all lesions harbored MED12 mutations but these varied from lesion to lesion, in 1 case of bilateral FA, one harbored a MED12 mutation and the other was MED12 wild-type, and in the last case both malignant PTs were MED12 wild-type. Although we observed a step-wise increase in the frequency of MED12 mutations from FAs to borderline PTs, malignant PTs significantly less frequently harbored MED12 exon 2 somatic mutations (p<0.005, Fisher's exact test). Conclusions: MED12 exon 2 somatic mutations are found in the majority of FAs, benign and borderline PTs, but are significantly less common in malignant PTs. Although MED12 is likely the driver of most FAs and PTs, our results suggest that genetic alterations other than MED12 exon 2 mutations may constitute the driving genetic events of malignant PTs.
Strong Correlation of c-Myc Expression With High Grade Triple Negative Breast Ductal Cancers in African American Women
Tammey Naab, Luisel Ricks-Santi, Farhan Khan. Howard University Hospital, Washington, DC; Hampton University, Hampton, VA. Background: c-Myc is a proto-oncogene that regulates the expression of many target genes involved in cell proliferation and cell cycle regulation. Constitutive expression of mutant c-Myc can result in cell cycle dysregulation and uncontrolled cell proliferation. The significance of c-Myc expression and cell cycle dysregulation in breast carcinogenesis is poorly understood. The objective of our study was to correlate the immunohistochemical expression of c-Myc in the four major subtypes of breast carcinoma (Luminal A, Luminal B, HER2, and Triple Negative) in a population of 202 AA women with other clinicopathological factors including grade, stage, disease-free, and overall survival. Design: Tissue microarrays (TMAs) were constructed from FFPE tumor blocks from primary ductal breast carcinomas in 202 AA women. Two separate 1 mm cores represented each case. The polymer-HRP system was utilized for immunostaining. Five micrometer sections are stained with a rabbit monoclonal antibody against c-Myc (EP121, Cell Marque, Rocklin, CA). The sections were evaluated for the intensity of nuclear reactivity (2-3) and the percentage of reactive cells; and an H-score was derived from the product of these measurements. Cases were categorized as having decreased (score <50) or increased (score >50) c-Myc expression. Bivariate analysis was done via c2 analysis and survivability data was calculated via the generation of Kaplan-Meier curves (SPSS v19). Statistical significance was assumed if P < 0.05. Results: c-Myc expression was associated with ER negative (p=0.001), PR negative (p=0.031), triple negative (p<0.0001), and grade 3 (p=0.04). c-Myc expression was marginally associated with disease-free survival (p=0.085), but not overall survival.
Conclusions: Our study finding of enhanced c-Myc expression in high grade triple negative breast cancers supports the role of c-Myc breast carcinogenesis in AA women. A recent study has found that c-Myc stabilization by selective phosphorylation results in c-Myc with enhanced oncogenic activity due to inactivation of the axin 1 tumor suppressor gene, an important regulator of survival, growth, and stress pathways. Axin 1 may represent a possible therapeutic target for TNBC, a subtype without specific therapeutic options.
Nuclear Transcription Factor Sox10 Is Expressed in a Subset of Metastatic Triple Negative Breast Carcinomas Emily Nelson, Rajni Sharma, Pedram Argani, Ashley Cimino-Mathews. Johns Hopkins
Hospital, Baltimore, MD. Background: Sox10 is a nuclear transcription factor expressed primarily in tumors of neural crest origin, such as nerve sheath tumors and melanoma. However, we and others have previously demonstrated Sox10 labeling immunohistochemistry (IHC) in primary breast carcinomas, particularly in triple negative carcinomas (Human Pathol 2013; 44:959-965) . However, the expression of Sox10 in metastatic breast carcinoma has not been previously reported. Here, we investigate the labeling pattern of Sox10 in paired primary and metastatic breast carcinomas from 26 patients with known estrogen receptor (ER), progesterone receptor (PR) and Her2 status. Design: Tissue microarrays (TMAs) containing samples of paired primary breast carcinoma (PBC) and surgically-resected metastatic breast carcinoma (MBC) from 26 patients (5-10 cores per tumor) were labeled with IHC for Sox10. The extent of nuclear Sox10 labeling was scored by percentage labeling as follows: 0 (0%), 1+ (1%-25%), 2+ (25%-50%), 3+ (50%-75%), and 4+ (>75%). Clinicopathologic data were recorded. The carcinomas were invasive ductal (n=23) or lobular (n=3), and consisted of 16 luminal A (ER+/PR+/Her2-), 8 triple negative (ER-/PR-/Her2-) and 2 Her2+ (ER-/PR-/ Her2+) phenotypes. The metastases were solitary per patient and were located in the brain (n=11), lung/pleura (n=8), gastrointestinal tract (n=3), liver (n=2), ovary (n=1) and paraspinal soft tissue (n=1). Results: Nuclear Sox10 labeling was seen in 3 (12%) MBC, all of which were Elston grade III, triple negative ductal carcinomas metastatic to the brain (n=2) or lung (n=1). Overall, 38% triple negative MBC were Sox10 positive, as compared to 0% luminal A and Her2 MBC (p=0.045). The Sox10 labeling intensity was 1+ weak in 2 cases, and 4+ moderate-strong in 1 case. The Sox10 labeling in these 3 MBC was increased (n=2) or stable (n=1) relative to the matched PBC, which displayed 0, 1+ and 2+ weak labeling. The remaining PBC were all Sox10 negative. Conclusions: Sox10 labeling is seen in over a third of metastatic triple negative breast carcinomas, which like melanomas and nerve sheath tumors can also be S100 positive. The findings in this study support our previous observation that Sox10 is rarely seen in ER+ or Her2+ carcinomas. The differential diagnosis of a S100+, Sox10+, ERhigh-grade malignancy of unknown origin should include both melanoma and poorly differentiated breast carcinoma. An immunopanel containing more specific markers, such as cytokeratin or p63 for carcinoma and HMB45 or melan A for melanoma, should be employed in this setting.
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Micro-Intratumoral Heterogeneity and Multiple Tumor Cell Subtypes of HER2-Positive, ER-Positive Breast Cancers
Hiroaki Nitta, Brian Kelly, Wenjun Zhang, Mike Farrell, Eslie Dennis, Shinobu Masuda. Ventana Medical Systems, Inc., Tucson, AZ; Nihon University, Tokyo, Japan. Background: HER2 and ER status are the most relevant predictive factors in determining treatment for breast cancer patients. Therefore, we compared HER2+/ER+ breast cancers cases with other breast cancer subtypes to investigate the relationship between HER2 protein expression, HER2 gene amplification, and ER protein expression and segment these cases in terms of intratumoural heterogeneity. Design: Thirty-four selected HER2 IHC 3+ and 2+ breast cancer cases were examined using a brightfield HER2 and ER multiplex assay for the following pathological features: 1) HER2 phenotypic intratumoral heterogeneity, 2) HER2 genotypic intratumoral heterogeneity, 3) HER2 phenotypic and genotypic micro-intratumoral heterogeneity, and 4) HER2 and ER micro-intratumoral heterogeneity. The study cohort consisted of 11 HER2+/ER+, 9 HER2+/ER-, 12 HER2-/ER+, and 2 HER2-/ER-breast cancer cases. Results: HER2 phenotypic intratumoral heterogeneity was defined as the identification of two or more HER2 protein expression levels (3+ to 0) within the same tumor tissue section. Phenotypic heterogeneity was observed mainly in HER2+/ER+ (7/11, 64%) and HER2-/ER+ (7/12, 58.3%) types and was also detected in HER2-/ER-breast cancer cases (2/2). Phenotypic intratumoral heterogeneity was observed in only one of nine HER2+/ER-cases (11%). HER2 genetic intratumoral heterogeneity was defined as the presence of tumor cells with a HER2/CEN17 ratio higher than 2.2 in 5-50% of the tumor cells. HER2 genetic heterogeneity was observed in HER2-/ER+ (5/12, 41.7%), HER2+/ER+ (2/11, 18.2%), and HER2-/ER-breast cancer cases (1/2). HER2 phenotypic and genotypic micro-intratumoral heterogeneity was defined as individual tumor cells containing amplified HER2 gene without HER2 overexpression. HER2 phenotypic and genotypic micro-tumoral heterogeneity was observed with HER2+/ ER+ (8/11, 73%) and HER2+/ER-(3/9, 33%) types. Simultaneous analyses of HER2 and ER status demonstrated 4 types of tumor cell populations: 1) HER2 gene+/HER2 protein+/ER+; 2) HER2 gene+/HER2 protein+/ER-: 3) HER2 gene+/HER2 protein-/ ER+; and 4) HER2 gene+/HER2 protein-/ER protein-. Conclusions: Frequent HER2 phenotypic intratumoral heterogeneity and HER2 phenotypic and genotypic micro-intratumoral heterogeneity were observed in HER2+/ ER+ breast cancer cases. Four distinct types of HER2 and ER micro-intratumoral heterogeneity were identified among HER2+/ER+ breast cancers. Those data suggest that the intratumoral heterogeneity of HER2 and ER status at individual cell levels may be an approach to segment breast cancer cases. Sharon Nofech-Mozes, Yunxia Sui, Zhengyu Pang, Dan Wang, Kela Liu, Kashan Shaikh, Mayan Murray, Alison Cheung, Gina Clarke, Robert Filkins, Martin Background: Biomarker Multiplexing is an emerging technology to study expressions and co-localizations of multiple molecules of interest within a morphological context. We have previously described the development of a novel prototype of a micro-fluidic flow cell with an automated dye cycling strategy for repeated stain-image-bleach sequences, established cut offs and demonstrated good correlations with conventional immunohistochemistry (Clarke et.al., Histopathology, 64(2), 242-255, 2014) . Quantification of signal intensity allows measuring biomarkers expression on a single cell and provides an opportunity to assess intratumoral heterogeneity. Design: A total of 230,671 cells from 105 breast cancers were assessed for ER, HER2, Ki-67, and ALDH1. Signal intensity of each biomarker across all cores on the TMA was log transformed. Using an unsupervised K-median clustering algorithm, individual cells were grouped based on their biomarkers profiles.
Intratumoural Heterogeneity Assessed By Biomarker Multiplexing and Cluster Analysis
Results:
In an analysis based on 4 clusters, our analysis produced clusters that approximated to intrinsic molecular subtypes: two triple-negative clusters that are Ki67-or +, a Luminal A like cluster (ER+/HER2-) and HER2+ (HER2+/ER-). Individual cells within each cluster were mapped back to their corresponding TMA core demonstrating that almost all cores exhibit various levels of intratumoural biomarker heterogeneity. Interestingly, the extent of heterogeneity was significantly lower for cores consisting of HER2+/ER-cells, as 90-100% of cells within those cores are HER2+/ER-. Although individual cells didn't coexpress ER and HER2, there were three cases that consist of ER+ and HER2+ populations representing Luminal B tumors. Clustering into more than 4 groups yielded similar molecular profiles, with additional clusters further defining within each intrinsic subtype. Conclusions: Biomarker multiplexing combined with cluster analysis is a powerful tool for quantifying biomarker expressions of individual cell in a tumour and for determining the extent of intratumoural biomarker heterogeneity. Analysis of a larger cohort will allow us to better understand the basis of heterogeneity within each subtype and potentially improve treatment planning and outcome. (Rakovitch, SABCS 2014) showing prediction of risk of an ipsilateral local recurrence (LR). Here we evaluate the correlation between the DS and clinicopathologic features, and whether DS provides independent LR risk information in pts treated w/ breast conservative surgery (BCS). Design: Pathology was centrally reviewed for: focality (multifocality=at least 2 foci of DCIS 5mm apart), size, grade, subtype, comedo necrosis & clear margins, (CM=no ink on tumor). The DS was obtained by quantitative RT-PCR. Cox modeling was used to determine the relationship between independent covariates, DS (hazard ratio (HR)/50 units) & LR. Results: DCIS Score was evaluated in 718 women w/ DCIS tx with BCS alone (571 w/ CM). With a median follow-up of 9.4 years, 100 BCS alone w/ CM cases developed LR (44 DCIS, 57 invasive). In the primary analysis, among 571 pts treated by BCS alone with CM the continuous DS was significantly associated with LR in ER+ pts (HR 2.26; 95%CI 1.41,3.59; P=0.001) and in all pts (HR 2.15; 95%CI 1.43,3.22; P=<0.001). Univariable analyses showed that the DS, multifocality, size, histologic subtype, grade, and comedo necrosis were statistically significant predictors of LR risk. 10 yr Kaplan-Meier LR rates (95%CI) for all BCS pts alone w/ CM were: low risk DS 12.7% (9.5%, 16.9%); int risk DS 33.0% (23.6%, 44.8%) & high risk DS 27.8% (20.0%, 37.8%). In multivariable analysis, hazard ratios for factors associated with LR were: multifocality: 1.97 (95% CI 1.27-3.02); size: 2.07 (1.16-3.83); age<50: 1.75 (1.07-2.76); DS/50: 1.69 (1.08-2.62) & tumor subtype: solid vs. cribriform, 1.63 (0.97-2.88). Patients with low DS and non-multifocal disease have a 9.7% risk of any local recurrence (4.3% for DCIS and 5.6% for invasive) at 10 yrs. DCIS Scores were widely distributed within each subgroup defined by the clinical and pathology characteristics. TheDS is only moderately correlated w/ grade, comedo necrosis and size (Spearman correlations <0.48). Conclusions: For DCIS pts treated with BCS alone the DCIS Score, focality, tumor size and histologic subtype provide independent LR information. Pts with low DCIS score and non-multifocal disease may be considered for BCS alone.
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Significance of Percentage of 2+ IHC Positive Cells for the Prediction of HER2 Amplification Status in Breast Cancers
Onder Onguru, Paul Zhang. TUBITAK and GATA, Ankara, Turkey; University of Pennsylvania Medical Center, Philadelphia, PA. Background: According to recent 2013 CAP/ASCO guideline, Her2 status is classified as equivocal when 2+ staining observed >10% of invasive tumor cells for which a reflex FISH is recommended. However, significance of 2+ cells ≤ 10% is unclear. The aim of this study is to investigate HER2 amplification by FISH in breast cancers with IHC 2+ staining and emphasize on the significance of percentage of IHC 2+ tumor cells, particularly the £10% category in final Her2 status. Design: As a routine QA practice, database of both HER2 IHC and FISH test details was kept in the IHC lab of Hospital of the University of Pennsylvania. 180 cases of breast cancer with 2+ Her2 staining were identified in the data from 2009 to 2014. HercepTest was performed on Dako autostainer with Link 48 (Dako). The % of 2+ IHC stained invasive tumor cells were determined by visual estimation for % and intensity at the time of the diagnosis and categorized into three groups: £10%, 10-50% and >50% for this review. FISH was performed in all cases by using Vysis dual colored DNA probe (PathVysion) and data was scored according to 2013 ASCO/CAP criteria for this review. Results: There were 22 cases (12.2%) in >50% IHC 2+ group, 102 (56.7%) in 10-50% group and 56 (31.1%) in £10% group. Overall, Her2 amplification by FISH was 25.5%. Her2 was amplified by FISH in 12 (54.5%) cases in >50% group; 26 (24.5%) in 10-50% group and 8 (14.3%) in £10% group; while not amplified in 9 (40.9%), 68 (66.7%) and 41 (73.2%), respectively, in each group. The remaining 16 cases (8.8%) were FISH equivocal. Conclusions: Most of breast cancers (56.7%) with IHC 2+ Her2 expression contain moderate amount (10-50%) of 2+ positive cells. Although overall, 25% of all 2+ cases were Her2 amplified by FISH, Her2 amplification probability significantly increased to 54.5% in cases with >50% 2+ positive cells and decreased to 14% in 2+<10% cases. Currently the 2013 ASCO/CAP guidelines defined IHC 2+>10% as equivocal result but lacked clear classification for 2+£10%. Our data showed a relatively small but non-neglectable number (14%) of 2+ £10% cases was Her2 amplified by FISH which approaches to the overal incidence of Her2 overexpression (15-20%) in breast cancer. IHC Her2 result of 2+£10% should be regarded as equivocal and reflex FISH should be performed in cases with 2+£10% as recommended by the 2007 ASCO/CAP guidelines.
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Correlation 
FOXP3
+ Tregs blood count had no relevance. Supported by Grants FIS 10/00082, AP-172/10, FCVI-HGUA (2010/PC-04 and 2011/ PC-03) .
Nuclear TAZ Protein Expression Associates With the TripleNegative Phenotype in Breast Cancer
Jose Palacios, Juan Diaz-Martin, Maria Angeles Lopez-Garcia, Laura Romero-Perez, Maria Atienza-Amores, Maria Angeles Castilla-Moro, Juan Manuel Rosa-Rosa. Hospital Universitario Ramón y Cajal, IRyCIS, Madrid, Spain; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain. Background: The Hippo signaling pathwayhas emerged as an important regulatory pathway in cancer. The final transducer effectors of this pathway are the oncoproteins TAZ and YAP1, transcriptional coactivators of target genes involved in cell proliferation and survival. TAZ has been previously reported to have a role in tumorigenesis in breast cancer, but detailed analyses in the different breast cancer phenotypes have not been conducted so far. Design: We have analyzed TAZ expression by immunohistochemistry in a retrospective series of 640 invasive breast carcinomas, comprising estrogen/progesterone receptor positive, HER2 positive, and triple-negative tumors. In a subset of 51 frozen tumors, we analyzed the mRNA expression of TAZ by q-PCR, and we inspected the DNA methylation status of TAZ-encoding locus by using the Sequenom MassArray ® MALDI-TOF platform. Amplification of TAZ was analyzed by FISH in 30 triple-negative tumors. Cox's regression analyses, which included the classical parameters, were performed to evaluate TAZ IHC expression as a prognostic biomarker in breast cancer. Results: We found a striking association of TAZ nuclear expression with the triplenegative phenotype (60.5% TAZ positive, p<0.001), which was even strengthened when stratifying into the basal-like subtype (70.8% TAZ positive, p<0.001). We observed similar low methylation levels of TAZ locus both in triple-negative and estrogen/ progesterone receptor positive tumors. Gene amplification was observed in 6.45% of triple-negative tumors analyzed. These data were further confirmed in a panel of breast cancer cell lines and in the TCGA dataset. Finally, patients with strong TAZ expression showed poorer clinical outcome regarding both recurrence and overall survival. Multivariate analysis showed that strong TAZ IHC expression had prognostic value for breast cancer specific survival, independent from classical factors (hazard ratio, 2.191; p=0.044). Background: Breast cancer (CA) metastases are often sampled by fine needle aspiration allowing the diagnosis of lesions using a minimally invasive technique. Cell blocks (CB) with adequate cellularity are crucial for ancillary studies. A recent study at our institution showed that an optimized CB protocol had the same or better cellularity and reliable ER and HER2 immunohistochemistry(IHC), while still complying with the ASCO/CAP guidelines. The aim of this study was to evaluate the HER2 status using chromogenic dual in-situ hybridization (Dual-ISH) in comparison with fluorescent insitu hybridization (FISH) in paired CB using the prior established method (old method) and the new optimized CB method (new method). Design: Twelve CB from 6 breast CA specimens with known 3+ HER2 IHC were prepared using the old and new methods. H&E slides were examined for cellularity. HER2 Dual-ISH (Ventana) and FISH (IQFISH pharmDx™, Dako) were done on all CB. New CB method included adding 5-10ml of 95% ETOH into formalin fixed cells and an additional centrifugation step. Dual-ISH slides were examined by light microscopy (60x) and FISH slides by fluorescent microscopy under oil (100x). Results: All cases with detectable nuclear signal showed amplification (HER2/CEP17 range 3.5-17) and the ratio was similar for Dual-ISH and FISH. New CB method showed better cell aggregation without significant nuclear overlap. In 5 out of 6 cases (old CB method), < 20 nuclei (range 0-3) were detected with FISH and considered a failure. Results are summarized in Figure 1 .
Conclusions:
TAZ enhanced expression in the triple-negative/basal phenotype is a relevant observation that contributes to gain a better understanding of the complex biology of this breast cancer type. Moreover, TAZ could represent a potential selective therapeutic target for triple-negative/basal breast cancer
Accurate HER2 results are essential to guide therapy. The new CB method for Dual-ISH and FISH was more successful in identifying the amplification within CA cells due to improved cellularity and cell aggregation when compared to the old method. The advantage of Dual-ISH compared to FISH for CB is that CA cells are more easily identified at low power with better morphological detail, whereas scant and scattered cells may not be easily detected by FISH. Standard FISH protocols for tissue may be too harsh for scantier CB specimens leading to absence of cells. In this study of CB specimens, HER2 Dual-ISH proves to be of similar accuracy and an easier alternative for amplification detection compared to FISH.
Androgen Receptor Expression in Breast Cancer and Correlation With Pathological and Immunohistochemical Features
Asawari Patil, Nupur Jadhav, Sangeeta Desai, Tanuja Shet, Rajendra Badwe. Tata Memorial Hospital, Mumbai, Maharashtra, India. Background: Androgen Receptor (AR) expression in breast cancer is associated with increasing age, lower tumor grade, smaller tumor size and ER, PR, Her2/neu expression. AR is potential therapeutic target for AR antagonists, especially in subset of triple negative AR positive tumors. The aim of this study is to evaluate AR expression in breast cancer patients in India and to correlate with histological features and ER, PR, Her2/neu expression. Design: We planned to study AR expression in therapeutic subgroups, based on ER, PR, Her2/neu expression viz. (1) ER(+) -ER positive, Her2/neu negative, (2) Her2(+) -Her2/neu positive, irrespective of ER, PR expression, (3) TNBC -Triple Negative. We identified patients in each subgroup during period from January 2005 to December 2009. Slides and blocks were retrieved, slides were reviewed and tissue microarray (TMA) were prepared from representative tumor block. Immunohistochemical studies for AR, ER, PR and Her2/neu were performed on each TMA. Tumor was considered AR positive when > 1% cells show nuclear expression. ASCO/CAP guidelines were used for ER, PR, Her2/neu evaluation. Clinical data was obtained from electronic medical records.
Results: Total number of cases selected were 109 in ER(+), 67 in Her2(+) and 92 in TNBC group. The frequency of AR expression in each subgroup in summarized below. Although AR expression was more frequent in ER (+) group in our series, we found fewer ER (+), AR ( Background: Phyllodes tumor of the breast is an uncommon neoplasm with a spectrum of behavior ranging from a benign fibroepithelial lesion to a sarcomatous entity with hematogenous metastases. Although historically described to be more common in women of Hispanic origin, few studies have examined the correlation between race and incidence. In this retrospective study, we reviewed the medical records of histologically confirmed phyllodes tumors diagnosed in our tertiary care institution over the past ten years, and characterize the incidence by race. Design: Our study consists of 62 patients with benign, borderline, and malignant phyllodes tumors diagnosed between September 2004 and September 2014. As of 2013, our patient population of 183,744 consisted of 78,431 Hispanics (42.7%), 76,728 Whites (41.8%), 26,461 Blacks (14.4%), and 2,124 Other (1.1%). Data collected included patients' race, age, tumor grade, and tumor size. Results: Of the 62 patients with phyllodes tumors in our study, there were 44 Hispanic patients (71.0%), 12 Blacks (19.4%), 5 Whites (8.1%), and one Asian (1.6%). Mean age at diagnosis was 43 in Hispanics, 39 in Blacks, and 41 in Whites. The correlation between race and histologic grade of the phyllodes tumors is illustrated in Table 1 . Tumors were benign in 75%, borderline in 5%, and malignant in 20%. However, no significant correlation between race and malignant behavior was found (p = 0.938731), in contrast to previous reports in the literature. Conclusions: Racial differences in the incidence of phyllodes tumors do exist. In this multi-institutional review, we found a significant disparity in the proportion of phyllodes tumors by race, with a substantially higher number of phyllodes tumors diagnosed in Hispanic women (p<0.00001). No correlation between race and tumor grade was found (p = 0.938731). Understanding the reason behind these findings will require further investigation into genetic predisposition, geographic influence, and socioeconomic factors.
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The Relationship Between Quantitative HER2 Gene Expression By the 21-Gene RT-PCR Assay and Adjuvant Trastuzumab (H) Benefit in NCCTG (Alliance) N9831 Edith Perez, Steven Butler, Amylou Dueck, Frederick Baehner, Farid Jamshidian, Diana Cherbavaz, E Aubrey Thompson, Steven Shak, Peter Kaufman, Nancy Davidson, Julie Gralow, Yan Asmann, Karla Ballman. Mayo Clinic, Jacksonville, FL; Genomic Health, Inc., Redwood City, CA; Mayo Clinic, Scottsdale, AZ; University of California, San Francisco, CA; Norris Cotton Cancer Center, Lebanon, NH; University of Pittsbugh Cancer Institute, Pittsburgh, PA; Mayo Clinic, Seattle, WA; Mayo Clinic, Rochester, MN. Background: There is considerable interest in developing HER2 testing criteria for adjuvant H. We used the 21-gene assay to examine the relationship of HER2 mRNA to benefit from H. Design: N9831 compared adjuvant chemotherapy AC-T to concurrent chemotherapytrastuzumab AC-TH in stage I-III HER2+ breast cancer. Recurrence Score (RS) and HER2 mRNA expression were determined by Oncotype DX (neg<10.7, equiv 10.7 to <11.5, pos ³11.5 log2 expression units). Cox regression was used to assess the association of HER2 expression with H benefit for distant recurrence. Results: Median follow-up: 7.4 yrs. Of 1940 total pts, 901 had consent and sufficient tissue. HER2 by RT-PCR was neg in 130 (14%), equiv in 85 (9%) and pos in 686 (76%) pts. Concordance between HER2 assessments was 95% for RT-PCR vs central IHC (>10% + cells = +), 91% for RT-PCR vs central FISH (³2.0 = pos) and 94% for central IHC vs central FISH. In the primary analysis, the association of HER2 expression with H benefit was marginally non-significant (P=0.057). In hormone receptor pos pts (local IHC) the association was significant (P=0.002). The association was nonlinear with the greatest estimated benefit at lower and higher HER2 mRNA expression levels. The observed treatment benefit in low HER2 pts was not due to imbalance between arms in RS and individual gene expression values. Conclusions: Concordance among HER2 assessments by central IHC, FISH and RT-PCR was high. Association of HER2 mRNA expression with H benefit was marginally non-significant. A consistent benefit of trastuzumab irrespective of mHER2 levels was observed in the pts with either IHC+ or FISH+ tumors. Benefit was observed in pts with high HER2 by RT-PCR but also observed for the small groups of pts with negative results by quantitative RT-PCR or FISH. Plausible mechanisms for this observation will be discussed. (HER2) and triple negative(TN). ER and PR were considered positive when ³10% of cells were stained. HER2 was determined according to ASCO-CAP guidelines(2007) . Data were compared using Chi2 and Fisher's exact tests and multivariate analysis of variance, as appropriate. Statistical analysis was performed with SPSS version 15. Results: pCR(ypT0/pTis ypN0) was achieved in 29 cases(13.3%). Taking into account only breast-pCR, 36 patients(15.9%) achieved ypT0 and 25(11.1%) ypTis. Breast-pCR rates were significantly different between surrogate subtypes: 3.6% in LA, 11.7% in LB, 29.4% in LBHER2, 60.6% in HER2 and 33.3% in TN. Of 133 patients with positive axillary nodes at diagnosis, 48(36%) became ypN0. Axillary-pCR rates were significantly different between surrogate subtypes: 12.5% in LA, 15.9% in LB, 77.3% in LBHER2, 66.7% in HER2 and 27.6% in TN. On univariate analysis, factors associated with ypT0 were RE-, RP-, HER2+, Ki67>20%, grade and surrogate subtype (p<0.001). On multivariate analysis only surrogate subtype was found to be statistically significant(p<0.001). In the subgroup of patients with positive lymph node at diagnosis, HER2+, molecular subtype and breast-pCR were predictive of ypN0. On multivariate analysis, HER2+ was the only predictive factor of Axillary-pCR (p<0.001).
Conclusions:
In this multivariate analysis, the strongest predictive factors of breast-pCR were surrogate subtype and HER2+ whereas HER2+ was the only positive predictor of axillary-pCR. Further molecular studies will help us to better select those patients who benefit most of neoadjuvant chemotherapy.
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Genomic Abnormalities Correlated With Histologic Grade of Invasive Ductal Carcinoma of the Breast Zheng Ping, Dejun Shen. University of Alabama, Birmingham, AL. Background: Pathologic grade is one of the most important prognostic biomarkers in the patients with invasive breast cancer (IBC). The most clinically used Nottingham grade is based on three histologic features: tubule formation, nuclear pleomorphism and mitotic activity. However, little is known about the genomic basis of IBC histologic grading. Design: We hypothesize that mutations in some breast cancer genes determine the histologic grade of invasive breast cancer. Whole genome sequencing data were analyzed in 1061 cases of invasive breast cancer. Specific genetic abnormalities were correlated with histologic grade of invasive ductal carcinoma. All sequencing data and corresponding pathology information were from The Cancer Genome Atlas (Invasive Breast Cancer, TCGA provisional) and were analyzed via cBioPortal bioinformatics tools. Results: A total of 1323 mutated genes are identified in 976 IBC cases. Among the most frequently mutated genes are PIK3CA (316, 32.4%), TP53 (295, 30.2%), CDH1 (105, 10.8%), GATA3 (97, 9.9%) and MAP3K1 (70, 7.2%). Multiple mutations are found significantly associated with Nottingham histologic grade, including PIK3CA and TP53. The tumors with TP53 mutation are mostly histologically higher grade, but those with PIK3CA mutation often show a low to intermediate grade. The PIK3CA mutated tumors with a synchronous TP53 mutation show a significantly higher histologic grade compared with those without TP53 mutation. However, the TP53 mutated tumors with a synchronous PIK3CA mutation show a slightly lower histologic grade compared with those without a PIK3CA mutation. The results suggest that TP53 gene mutation alone may be sufficient to lead to a high histologic grade phenotype in IBC. While most tumors without TP53 mutation show a moderate histologic grade, those tumors with a PIK3CA mutation do show a significant lower histologic grade. These data suggest that a mutated PIK3CA gene may be an earlier event than TP53 mutation in breast cancer progression. Conclusions: Mutations in TP53 and PIK3CA genes play important roles in defining histologic grade of invasive breast cancer.
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Hedgehog Signaling in Immunophenotypes of Breast Carcinoma: A Gene Expression and Clinicalpathological Study Eloy Pomares-Navarro, Ariadna Perez-Balaguer, Elena Sanmartin, Fernando OrtizMartinez, Leire Andres, Jose Ponce, Hortensia Ballester, F Aranda, Enrique Lerma, Gloria Peiro. University General Hospital, Alicante, Spain; Hospital de Cruces, Barakaldo, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Background: The Sonic Hedgehog (Hh) signaling is a key developmental regulatory pathway. It is recognized as a primary driver of oncogenesis in some types of human cancers. However, its involvement and prognostic relevance specifically in patients with breast carcinoma (BC) has not been studied extensively. Therefore, our aim was to analyze the expression of several Hh associated-genes in a clinical series of BC. Design: FFPE samples of 186 BC were classified immunohistochemically into Luminal A and B/HER2-(43%), HER2+ (29%) or TN/BL (28%) phenotypes. qRT-PCR method was performed using PUM1 as housekeeping. Relative mRNA expression of Hh genes (GLI1, GLI2, GLI3, SMO, PTCH and BOC) was determined using the 2 ∆∆CT method and expressed as relative quantification (RQ) unit. The gene expression results were correlated with clinico-pathological factors and outcome of the patients. Results: Significant association was found between several clinicopathological factors and gene expression, such as histological grade (for GLI1, GLI2, GLI3 and BOC), vascular invasion (for SMO and PTCH), lymph-node status (for GLI1 and SMO), necrosis (for GLI1, GLI2, GLI3 and BOC), and phenotype (all p<0.05, Kruskal-Wallis and Mann-Whitney Tests). Survival analysis showed that patients whose tumors expressed GLI3 in low levels had increased recurrences, especially among those with TN/BL phenotype (p= 0.034). Overall survival was shorter in patients whose tumors expressed GLI1 and SMO, predominantly in HER2 phenotype (p= 0.043 and p= 0.01, respectively). Interestingly, lymph-node negative patients with high tumor levels of SMO had poorer survival (p= 0.034) (Kaplan-Meier; log-rank test). Conclusions: Several genes of the Hh pathway are expressed in all phenotypes of BC, supporting their involvement in this neoplasia. GLI1, GLI3 and SMO expression stratified patients at risk of recurrence and/or death in TN/BL and HER2 phenotypes. Therefore, these facts make those genes as potential candidates for a therapy targets. Supported by Grants FIS 10/00082 and FCVI-HGUA 2012/C-08. 
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Reflex Repeat HER2 Testing of Grade 3 Breast Carcinomas at Excision: Core Biopsy Parameters Including HER2 Immunohistochemistry & Dual In Situ Hybridization May Refine Case Selection Susan Prendeville, Linda Feeley, Michael Bennett, Fionnuala O'Connell, Tara Jane Browne. Cork University Hospital, Cork, Ireland. Background: The updated ASCO/CAP guidelines (October 2013) for HER2 testing in breast cancer recommend repeat testing at excision of all grade 3 tumors that were HER2 negative on core needle biopsy (CNB). This has cost, time and workload implications. The aim of this study was to identify the rate of HER2 discordance between CNB and excision in this cohort of tumors. Design: All Grade 3 HER2 negative cases diagnosed on CNB at a single institution over an 11 month period (Oct 2013 -Sept 2014) had reflex repeat HER2 testing at excision. Post-neoadjuvant therapy tumors were excluded. Histologic parameters including tumor subtype, grade and HER2 result for biopsy and excision were recorded. HER2 testing was performed in accordance with CAP guidelines using immunohistochemistry (IHC, Ventana 4B5) and dual in-situ DNA hybridisation (Dual ISH, Ventana INFORM) on cases with equivocal (2+) IHC results. All cases were dual reported by specialised breast pathologists.
Results: Diagnostic CNB and HER2 testing was performed on 520 breast cancers during this period.67 Grade 3 HER2 negative cases had repeat HER2 testing on excision. Tumor subtypes comprised invasive ductal carcinoma (n=59), invasive lobular carcinoma (n=5) and carcinoma with mixed ductal and lobular features (n=3). 22/67 were upgraded from grade 2 on CNB to grade 3 on excision. 63 cases (94%) showed concordant HER2 status on repeat testing on excision. In 4 cases (6%), the HER2 result changed from negative on CNB to positive on excision (table 1) . 3 of these 4 cases showed equivocal HER2 IHC result on CNB and HER2 heterogeneity on excision. The 4 th case was upgraded from grade 2 on CNB to Grade 3 on excision. Conclusions: Our findings suggest that criteria for repeat HER2 testing at excision of grade 3 tumors that were HER2 negative on CNB may be refined to target tumors that were HER2 equivocal by IHC on CNB or were upgraded on excision, features indicating possible tumour heterogeneity. This could have significant cost and workload savings for busy laboratories. Gross margin status on the specimens did not show significant differences for close margins (<2mm): 9% for conventional lumpectomies and 12.5% for RSL lumpectomies. Interestingly, there is a markedly increased percentage of close margins (<2mm) for invasive lobular carcinoma (25%), compared to invasive ductal carcinoma (10.4%). All percentages are reported per likelihood of having involved or close margins per one margin.
Conclusions: This study looked not only at direct involvement of inked surfaces, but also at close or very close margins, since surgeon/institutional preference varies in regards to the definition of a positive margin. As was shown before, no significant differences are seen for the marginal status for either RSL or CWL lumpectomy specimens taken out for invasive carcinoma. This project shows that this finding is valid at three typical cut offs used for margin assessment.
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Reporting the Greatest Linear Extent of Ductal Carcinoma In Situ on Needle Core Biopsy Emily Reisenbichler, Omar Hameed. Vanderbilt University, Nashville, TN. Background: Regardless of size, ductal carcinoma in situ (DCIS) of the breast has a pathologic stage of pTis; however extent of DCIS correlates with local recurrence rates and the likelihood of close or positive margins. As a result, DCIS extent influences patient management and is therefore an important element in the College of American Pathologists tumor summary checklist for excision specimens. There are no recommendations regarding routine reporting of DCIS extent on needle biopsy and to our knowledge, no systematic studies have evaluated the impact of reporting this in needle biopsy material. Design: Consecutive cases of DCIS, with or without microinvasion, performed or reviewed at our institution were identified by pathology report search over a 7 year period. The greatest linear extent of DCIS on needle core biopsy was compared to the estimated DCIS extent in the excision specimen. Cases with > 1mm invasion identified on excision were excluded.
Results: Of 241 total cases, there were 157 (65%) cases in which the DCIS extent on biopsy was smaller, 13 (5%) cases in which the sizes were equal, and 70 (29%) in which the size on biopsy was greater, including 30 (12%) cases with no residual tumor on excision. The mean extent of DCIS on excision was greater than that on core biopsy (16.0 vs 5.7 mm; Figure 1A) ; however the opposite was seen when only small tumors (£10 mm final size) were considered (4.5 vs. 3.6 mm; Figure 1B ). There was very strong linear correlation between the size change (excision size minus biopsy size) and the final pathologic size (Figure 2) .
Conclusions:
In a significant number of cases, the extent of DCIS on core biopsy was larger than that estimated in the excision. Due to the potential impact on clinical management, DCIS extent should be reported on all needle biopsy material, particularly in the setting of small tumors, when the biopsy specimen frequently represents the best overall approximation of DCIS size.
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Increased Anti-Phospholipid Antibody Titers in Invasive Ductal Carcinoma Vs. Ductal Carcinoma In Situ: Implications for Surveillance Elizabeth Richards, Evan Himchak, James Szymanski, William Bivin, Elaine Lin, Qiang Liu. Montefiore Medical Center, Bronx, NY. Background: Understanding the role of anti-phospholipid (aPL) antibodies in tumor progression is important in breast cancer. Coagulopathic complications are common in patients with these cancers and patients with venous thromboembolism have a higher risk of mortality. Elevated aPL antibody titer has been observed clinically within a variety of malignant tumors. However, previous studies have not examined the relationship between aPL titers in pre-malignant verses invasive cancers. With the increase in DCIS diagnoses, questions regarding surveillance for malignancy are increasingly relevant. We propose that a higher aPL titer in invasive ductal carcinoma (IDC) vs DCIS may point to a potential utility monitoring DCIS patients. Design: Patient serum samples with a diagnosis of DCIS (n=29) and IDC (n=47) were run on a Bio-Rad Autoimmune EIA using anti-cardiolipin IgM and anti-B2 glycoprotein I IgA test kits. Patients with titer levels greater than 11 anti-B2 glycoprotein I IgA units or greater than 20 anticardiolipin IgM units were considered positive for the respective antibody, according to criteria established by international consensus. All other results were considered negative. Results: Anti-cardiolipin IgM titers were found to be positive in 0/29 DCIS patients and 8/47 IDC patients. Using Fisher's Exact test, the differences between these two categories is significant (P=0.021). However, anti-B2 glycoprotein I IgA titers were positive in 20/29 DCIS patients and 30/47 IDC patients. With 69% of DCIS and 64% of IDC patients positive for anti-B2 glycoproteinI IgA titers, the antibody is present in similar rates between these two groups. Conclusions: There was a significant positive correlation between anti-cardiolipin IgM titers and IDC vs titers in DCIS. Further investigation is necessary to determine the causality of the relationship. One possibility is that the tumor cells may induce increased aPL antibody production, which induces other angiogenic factors and promotes tumor survival. Alternatively, high titers of aPL antibody may induce invasive transformation of pre-malignant lesions, pointing to a possible utility of routine aPL antibody testing in DCIS patients. No correlation was found between anti-B2 glycoprotein I IgA and IDC as compared to DCIS. However, both DCIS and IDC had high titers of anti-B2 glycoprotein I IgA compared to the incidence of aPL in the general population (3%). This raises the interesting question of whether anti-B2 glycoprotein I IgA levels may rise even earlier in the path to tumorigenesis than anti-cardiolipin IgM.
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Genomic, Transcriptomic and Prognostic Caracterisation of Medullary Breast Carcinoma in Comparision With Basal-Like Breast Carcinoma
Pierre Romero, Vanessa Benhamo, Frederique Berger, Jaydutt Bhalshankar, Nadege Gruel, Laetitia Fuhrmann, Gaetan McGrogan, Xavier Sastre-Garau, Roman Rouzier, Olivier Delattre, Anne Vincent-Salomon. Institut Curie, Paris, France; Institut Bergonie, Bordeaux, France. Background: Medullary breast carcinoma (MBC) is a rare entity (< 2 % of all invasive breast cancers). We previously showed that MBC was a triple-negative and a basal-like carcinoma but displayed distinguished genomic features from grade 3 non-medullary basal-like carcinoma (BLC). Here we tried to identify transcriptomic and pan-genomic alterations using massively paralell RNA sequencing from MBC and compare MBC prognosis with BLC prognosis. Design: We retrospectively selected 19 MBC and 36 BLC with available frozen samples. We then performed a pan-genomic analysis on SNP array 6.0-Affymetrix. A transcriptomic analysis (Affymetrix 133 + 2) and tumor RNA sequencing (HiSeq 2000 Illumina; algorythms TopHat-fusion v2.0.4/defuse v0.6) were then performed on 19 and 6 MBC respectively. Overall survival (OS) and progression free survival (PFS) data were compared between MBC and BLC. Fluorescent In Situ Hybridation was used to confirm amplification. Results: Unsupervised analysis of transcriptomic data identified two dinctinct groups, one inculded 75 % of MBC and the other 97 % of BLC. Statistical analysis (Welch test; fold change >3; p value ≤ 0.05) showed significant overexpression of 92 genes and underexpression of 154 genes (GeneOntology: up-regulation of genes involved in hypoxia signaling pathway, MAPK, immune response, apoptosis and down-regulation of genes involved in cell adhseion). Tumor RNA sequencing allowed the identification of ten fusion transcripts, nine of them were validated with RT-PCR. One of the fusion involved ETV6. Pan-genomic profiles from MBC and BLC were similar but 23 losses of heterozygocity, 4 gains and 21 losses specific to MBC were identified (≥ 40 % of the cases). Three regions with amplifications, specific to MBC (16 % vs 6 % of BLC), were located on chromosome 10p, and the most frequent located in the surroundings of ETV6 at 12p (26 % vs 17 % of BLC). Confirmation of ETV6 amplification by FISH is being processed. Median follow-up was 79 months. OS and PFS (8.6 years vs 4.3 years, p = 0.0562) were longer in MBC group than BLC group. Conclusions: We show that molecular alterations can define MBC as a genomic and a transcrioptomic sub-category of basal-like carcinoma with the dysregulation of expression of genes involved in cell adhesion or immune response. We identify fusions which reccurrence among the whole MBC cohort is being verified by RT-PCR. Prognosis of MBC is better than BLC. other benign breast findings may lead to unnecessary excisional biopsy. This study categorized PASH in CNB as diffuse vs. focal to determine if this correlates with the presence of a PASH nodule which may necessitate surgical excision. Design: A search for PASH cases on CNB from January 1, 1992 to December 31, 2012 identified 271 cases which were reviewed by two observers. On review, 216 were confirmed as PASH. These cases were subclassified as diffuse: PASH involving 2 adjacent lobules and focal: PASH in multiple non-contiguous lobules. Surgical follow up on the 217 cases was reviewed. Twenty one CNB with a concomitant pre-malignant or malignant diagnosis that would have led to surgical resection were excluded from surgical review. The surgical cases were classified as diffuse vs. focal PASH, using the same criteria. A PASH nodule on surgical excision was defined as a mass that could be measured grossly. Results: The 216 PASH CNB were categorized as follows: 78 focal and 138 diffuse. Of these, 48 cases (22%) had surgical biopsies. 47 surgical excisions were reviewed (1 case not available) and 0/48 had a premalignant or malignant diagnosis. 75% (15/20) of focal PASH on core biopsy were focal on excision while 93% (25/27) of diffuse PASH cases were diffuse on excision. 2 (7%) cases of diffuse PASH were downgraded to focal on excision while 5 (25%) cases of focal PASH were upgraded to diffuse on excision. Fibroadenomas involved by PASH found on excision were considered concordant with a core diagnosis of diffuse (5 of the 25 cases) and discordant with a core diagnosis of focal (2 of the 5 cases). Of the remaining discordant cases (2 diffuse and 3 focal on core biopsy), sclerosing adenosis and stromal fibrosis were seen on excision. Using a Fisher's exact test the two-tailed P value is less than 0.0001 which is statistically significant. Conclusions: When PASH is diffuse on CNB as defined by this study, diffuse PASH is present in the majority of excisions (93%). This finding in our study correlates with the presence of a mass lesion. Although the clinical and radiologic features may drive surgical resection, our findings support watchful waiting of focal PASH.
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Assessing Mitotic Activity in Breast Spindle Cell Lesions Using Whole Slide Imaging: Comparison To Glass Slide Analysis J Jordi Rowe, Andrea Dawson. Cleveland Clinic, Cleveland, OH. Background: Mitotic activity in breast spindle cell lesions (BSCL) is important for accurate classification. These lesions are commonly seen in consultation, including digital consultation. It is unknown whether mitotic activity in BSCL can be accurately assessed using whole slide imaging (WSI). This study compares mitotic counts in BSCL in WSI vs glass slide analysis (GSA). Design: 25 BSCL were selected from the files that included a variety of benign to malignant lesions. One slide per case was WSI scanned at 20x, 40x (Aperio) and set aside for GSA. For 25 cases two observers counted mitoses on 10 high power fields (HPF) on the WSI 20x and 40x scans and glass slide and recorded the time it took to complete each count . Areas that were counted were mapped. HPF on WSI was defined using the Aperio method. One observer counted contiguous fields and the second counted scattered fields on WSI. The mitotic counts and median time was averaged for both observers. Results: Mitotic counts were highest for the GSA(98), followed by the 40x scan(74) and then the 20x scan (48). The differences were significant for WSI20x vs GSA (p value 0.001) and not significant for WSI40x vs GSA (p-value 0.033) indicating that 20x scanning for HPF analysis is the inferior method. The median mitotic count time for 10 HPF was: 1.32 min. (GSA), 5.77 min. (WSI40x) and 2 min. (WSI20x). The average total time for 25 slides was: 35.4 min (GSA), 151.1 min (WSI40x) and 52.8 min (WSI20x) indicating a four-fold increase in mitotic count time from GSA to WSI40x. The two field selection patterns yielded different mitotic counts (GSA: 116 vs 80), (WSI40x: 84 vs 64) (WSI20x: 67 vs 29) which was not statistically significant with a p-value of 0.2. Conclusions: Mitotic activity can be assessed in BSCL using WSI with slides scanned at 40x but may not be as accurate as GSA. Slides scanned at 20x for HPF analysis may lead to inaccurate classification of BSCL in a digital consultation practice. Accuracy, and a four-fold increase in time to perform mitotic counts at WSI40x, should be taken into account when developing a breast digital consultation practice. Ozlen Saglam, Feng Dai, Seema Husain, Gokce Toruner. Moffitt Cancer Center, Tampa, FL. Background: FOXA1 gene is located in human chromosome 14q and has a role in hormone-dependent cancers. FOXA1 is amplified in ER-positive breast cancer and it partly regulates AR activity. FOXA/AR-dependent WNT pathway activation leads to nuclear accumulation of beta-catenin and eventually HER3 induction. ER, AR, beta-catenin and HER3 levels were studied in invasive lobular carcinoma (ILC) and pleomorphic subtype of lobular neoplasia (PLN) by immunohistochemistry. In addition, mutation hotspots on 50 oncogenes and tumors suppressor genes were sequenced using Ion AmpliSeq Cancer Hostspot Panel v2 kit using Personalized Genome Machine. Design: A total of 25 breast biopsies and resection specimens were retrieved from surgical pathology files. Fifteen out of 25 cases were ILC and 10 cases were pure PLN (40%). ILC group had 10 grade 2(67%) and 5 grade 3(33%) cancers. There was associated PLN in 14 ILC cases. Pleomorphic nuclear features were observed as a dominant component in one ILC case and focally in another. A combined ductal and lobular features was present in one of the invasive cancers. H-scores of ER, AR, HER3, beta-catenin and FOXA-1 expression were recorded separately for ILC, PLN and normal breast epithelium. and p53 (DO-7), (Ventana, Roche) after 2009. Criteria for positive staining for ER/PR and p53 is 1% and >10% positive staining respectively. The KI is categorized into low, intermediate and high (table 1) 
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FOXA1 Expression in Invasive and In Situ Lobular Carcinoma
Conclusions:
The ER+/PR-phenotype was associated with significantly lower ER expression, higher tumor grade, increased KI and p53 over-expression compared to the ER+/PR+ phenotype. Absence of PR may be a marker of aberrant growth factor signaling and may explain relative resistance to anti-hormonal therapy in this group.
The Clinical Utility of Alternative CEP17 Probes in Cases of Equivocal HER2 FISH Results
Mary Ann Sanders, Alvin Martin. University of Louisville, Louisville, KY; CPA Laboratory Norton Healthcare, Louisville, KY. Background: Anti-HER2 targeted therapy in combination with traditional chemotherapy regimens has been shown to improve outcome for breast cancer patients with HER2 positive tumors. ASCO/CAP recently issued new guidelines for HER2 testing in an attempt to capture as many breast cancer patients who are eligible for HER2 targeted therapy, and this included new cutoff points for HER2 FISH results as well as the use of alternative CEP17 probes for resolving equivocal HER2 FISH cases. The goals of this study are to determine the effect that the new guidelines have had on the number of HER2 equivocal cases and the clinical utility of alternative CEP17 probes as a reflex test for equivocal HER2 FISH results in clinical practice. Design: Our data base was searched for consecutive cases of breast cancer where HER2 FISH was performed from October 2013 to September 2014. The HER2 copy number, CEP17 copy number, alternative CEP17 (TP53) copy number, HER2/CEP17 ratio, HER2/TP53 ratio, and amplification status based on both the 2007 and 2013 guidelines were recorded. PathVysion Kit (Her2neu/ CEP17 probes) and Vysis LSI TP53 probe were purchased from Abbott Molecular (Abbott Park, IL) and FISH was performed according the manufacturer's instruction. Results: A total of 689 cases were identified. Three cases (3/689; <1%) were HER2 FISH equivocal by the 2007 guidelines whereas 20 cases (20/689; 3%) were equivocal using the 2013 guidelines. All 20 of these cases were reflexed to TP53 FISH resulting in 13 cases that were HER2 not amplified, 7 cases that were HER2 amplified and zero cases that were HER2 equivocal. Conclusions: Equivocal HER2 results can make patient management decisions difficult when deciding if a patient will benefit from anti-HER2 targeted therapy. Since the implementation of the new HER2 guidelines, we have found about a 7 fold increase in the number of HER2 equivocal cases by FISH at our institution and use of an alternative CEP17 probe as a reflex test has resolved 100% of these cases. Therefore, our data supports routine use of alternative CEP17 probes as a reflex test for equivocal HER2 FISH especially with increased numbers of equivocal cases under the new ASCO/ CAP guidelines. Elena Sanmartin, Fernando Ortiz-Martinez, Eloy Pomares-Navarro, Leire Andres, Jose Ponce, Hortensia Ballester, Enrique Lerma, F Aranda, Gloria Peiro. University General Hospital, Alicante, Spain; Hospital de Cruces, Barakaldo, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Background: The CD44 transmembrane receptor mediates communication and adhesion between cells and extracellular-matrix. Recent research suggests that stimulation of CD44 induces FOXP3 expression in regulatory T-cells (Tregs), which are involved in the immune suppressive response. Moreover, FOXP3 has been identified as a tumor suppressor gene that regulates tumor development. However, the relationship between CD44 and FOXP3 in breast cancer (BC) is unknown, and there is no conclusive data of their involvement in tumor progression. Our main objective was to study the association between CD44 and FOXP3 gene expression in BC specimens and cell lines, and to correlate the results with clinico-pathological variables and patients' outcome. Design: We analyzed the mRNA expression of CD44 and FOXP3 by qRT-PCR in 264 BCs (38,6% Luminal, 28,4% HER2+, 33% Triple Negative/Basal-Like [TN/BL]). Relative quantification was calculated by the 2 -∆∆Ct method, using PUM1 and ACTB as reference genes and normal mammary tissue as the calibrator sample. FOXP3+ Tregs were counted in 3 high power fields (x400) within the tumor and/or immediately adjacent stroma. Additionally, CD44 activation was performed by treatment with Hyaluronan in cell lines BT474, representing BC subtypes, to study the changes in FOXP3 and CD44 mRNA expression. Results: LowerCD44 expression was seen in tumors with necrosis (p=0.020), vascular invasion (p=0.011) and grade 3 (p=0.002; Mann-Whitney U and Kruskal-Wallis tests). We found a positive correlation between CD44 and FOXP3 mRNA expression (r=0.175, p=0.004) as well as between FOXP3 mRNA expression and Tregs content (r=0.144, p=0.032; Spearman's Rank Correlation). Moreover, activation of CD44 by Hyaluronan in cell lines showed an increase in FOXP3 expression, confirming their positive correlation. Survival analysis revealed that patients with tumors showing low levels of CD44 expression had increased recurrences (p=0.039; Kaplan-Meier; log-rank test). Conclusions: Our findings in a clinical series of BC and in vitro indicate that CD44 induces FOXP3 expression. Furthermore, increased CD44 expression is associated with good prognostic factors and better patients' outcome. Supported by Grants FIS 10/00082, AP-172/10, FCVI-HGUA (2010/PC-04 and 2011/ PC-03) . Filipa Santos, Ana Felix, Ana Carvalho, Patricia Machado, Saudade Andre, Fatima Vaz. Instituto Portugues de Oncologia, Lisboa, Portugal. Background: Male breast cancer (MBC) is a rare entity and its management has been extrapolated from female counterpart. BRCA2 mutations confer increased risk of breast carcinoma, bilateral breast carcinoma (BBC) and other malignancies. BRCA2 founder mutations have been identified, including the previously reported c.156_157insAlu of portuguese origin.We aim to characterize a cohort of MBC with studied BRCA2 gene and analyze its clinicopathological features. Design: We studied 25 non-related MBC cases with BRCA2 gene status evaluation. Medical charts and histological slides were reviewed. "Intrinsic" subtype was classified using immunohistochemical staining for hormonal receptors, HER2 and Ki67.
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CD44 Is Associated With FOXP3 Expression and Favorable Outcome in Patients with Breast Carcinoma
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BRCA2 Mutation in Male Breast Cancer
Design: Archives at our institute were analyzed for primary squamous carcinomas (PSC) of breast and 27 tumors where no demonstrable duct components were selected for further review. In addition 28 metaplastic carcinomas with only squamous differentiation (MCS) were retrieved along with case files for analysis. Results: Of the 27 patients with PSC, 14 underwent modified radical mastectomy, 6 lumpectomy and 7 patients were initially misdiagnosed as benign cysts and underwent cyst excision. Of the PSC 18 were moderately differentiated, 8 poorly differentiated and one was a well differentiated squamous carcinoma. Interestingly though none of patients had a duct component, duct carcinoma in situ was identified in 4 patients and in two of them this in situ carcinoma showed squamous differentiation. A comparison with MCS revealed that lymphovascular emboli were not seen in any PSC but were noted in 7/28 MCS. Nodal metastases was significantly more in MCS (12/27) as opposed to PSC( p -0.051). Most metaplastic carcinomas presented with 2 to 5cm sized tumors while most squamous carcinomas were 5 to 10 cm in size( p-0.020). DCIS was seen in 4/27 PSC while 11/28 metaplastic carcinomas showed DCIS (p-0.040) While half of squamous carcinomas were circumscribed with a fibrous border they showed no intratumoral fibrosis, however most MCS showed infiltrating edges with dense intratumoral fibrosis. Disease free survival (DFS) for MCS was 64% while overall survival (OAS) was 72.7% at 5 years. PSC had a DFS of 39.8% and OAS of 66.7%. The extent of squamous differentiation impacted DFS with best behavior for metaplastic carcinomas showing < 40% squamous differentiation and worse for pure squamous carcinomas (p -0.043). Age had an impact on DFS in PSC with better survival in patients >50 years of age while no such impact was seen in MCS. Conclusions: Primary squamous carcinoma of breast has unique histopathological features that make diffrentation from MCS easier. PSC however is an aggressive disease as compared to MCS especially those with <40% squamous differentiation.
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Impact of Tissue Decalcification on Immunohistochemical Detection of Breast Carcinoma Markers
Jianhui Shi, Vivian Xu, Haiyan Liu, Fan Lin. Geisinger Medical Center, Danville, PA. Background: Application of an immunohistochemical (IHC) assay on decalcified tissues is frequently performed in an anatomic pathology laboratory. It has been documented that tissue decalcification (decal) may have a negative impact on an assay for certain antigens. In this study, we investigated the impact of decal on the detection of commonly used breast carcinoma markers using cultured breast cancer cell lines. Design: Three breast cancer cell lines were obtained from the American Type Culture Collection. A set of IHC markers as listed in the Table were tested on each cell line on a cell block. Three cell lines collectively expressed all target markers. The cell pellets containing a mixture of the 3 cell lines were first fixed in 10% neutral buffered formalin for 8 hours and then decalcified in Decalcifier B (Fisher Healthcare, item #23245683) for the following durations: 0 minutes (no decalcification), 30 minutes (min), 60 minutes, 3 hours, 6 hours, 1 day, 3 days and 1 week. A tissue microarray (TMA) block containing these tissue/cell line cores with the different decal times was constructed. The aforementioned IHC markers were applied to the TMA sections using the Ventana Ultra staining platform. The staining intensity was recorded as strong (S) Conclusions: These data demonstrate that tissue decal 1) has a significant negative impact on HER2 detection and on Ki67 and p53 detection after 60 min and 30 min of decal, respectively; 2) has no negative impact on ER detection following 60 min of decal and minimal impact following 1 week's decal; 3) has no negative impact on the detection of PR, GATA3, GCDFP15, CK7, TFF1, and TFF3 following 1 week's decal. Design: In order to understand the mechanism by which KLK6 can affect breast cancer pathogenesis, we examined the effect of KLK6 reconstitution on miRNA expression, followed by bioinformatics analysis of the predicted target of the significantly dysregulated miRNAs. Results: KLK6 over-expression resulted in up and down-regulation of a number of miRNAs in breast cancer cell lines. miR-34a and miR-888 were among the significantly down-regulated miRNAs, whereas miR-146a and miR-106a were up-regulated. Target prediction, pathway analysis, and experimental confirmation identified convergent miRNA networks targeting the MYC and MAPK and other signaling pathways. KLK6 overexpression resulted in down-regulation of miRNAs such as miR-34a, which led to up-regulation of their targets, including MAPK signaling genes (MAPK13, MAP2K1), CDKN1C and other cell cycle genes, and the oncogene MYC. We identified differential KLK6 expression in the molecular subtypes of breast cancer. Our data demonstrates breast cancer molecular subtype variations of KLK6 expression (in Her-2, Basal-like, Luminal A and Luminal B), with associated alterations of downstream miRNAs such as miR-34a, and their signaling targets in these subtypes. Long term patient survival outcomes were significantly reduced with altered KLK6 expression and high (KLK6+MYC+CDKN1C)-MUC1 scores. Conclusions: We provide evidence that KLK6 dysregulation in breast subtypes affects MYC expression as well as MAPK signaling pathway genes through miRNAs networks, mediated at least partially through an alteration of the miRNA biogenesis machinery with differential patient outcomes in these groups.
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Are Radial Scars at Core Biopsy High Risk Lesions? A 10-Year Single Institution Study and Literature Review Bart Singer, Thomas Lawton. University of North Carolina, Chapel Hill, NC. Background: The core biopsy literature considers radial scars (RS) a high risk lesion based on studies showing a high chance of finding associated malignancy on excisional biopsy. These studies have significant shortcomings, and recommendations for or against surgical excision are variable. With the advent of a new imaging technique known as tomosynthesis (3D mammography), studies have shown at least a 2-fold increase in the detection of RS. Thus, determining the true risk potential of these benign lesions is becoming more critical. Design: We identified 15 published studies from 1999-2014 that analyzed the rate at which benign RS on core needle biopsy (CNB) are upgraded after surgical excision. All of the studies had at least one of these confounding factors: [1] no radiologic-pathologic concordance of CNB results and/or including discordant cases in their series, [2] including CNBs with RS plus another risk lesion (e.g. ADH), [3] including risk lesions (e.g. ADH) as upgrades, [4] no comment on the distance of the upgraded lesion from the biopsy site, leaving the possibility that the upgraded lesion was unrelated to the RS, and [5] no histologic review of biopsies by a breast pathologist. To date, there is no study of RS that controls for all of these variables. Therefore, with IRB approval, we performed a computer-based search of all breast CNB performed at UNC from July 1, 2004 -June 30, 2014. All of the above factors were addressed in our study. Results: Adjusting for the aforementioned confounding factors, 53 RS were followed up with surgical excision over the 10-year period. No concordant cases were upgraded on excision (0/53). Our literature review identified a total of 831 RS, of which 38 (4.6%) had reported upgrades to malignancy on excision. However, after applying all of the above criteria to each study, only 3 cases documented upgrades to malignancy, with the distance of the malignancy to the biopsy site ranging from 3 mm to 1 cm. By adding our study to the previously published cases, we find an upgrade rate to malignancy of <0.5% (3/884). Conclusions: Our institutional data and a thorough review of the literature suggest that benign RS, when concordant and adequately sampled, do not pose a "high risk" of discovering malignancy on excisional biopsy. Since discovery of these benign lesions is likely to increase as tomosynthesis becomes more widely adopted, eliminating the label "high risk lesion" for radial scars and strict adherence to radiology-pathology concordance in each case can prevent a large number of unnecessary surgical excisions. Baljit Singh, Yang Zhan, Yanfeng Qi, Xichun Liu, Haitao Zhang, Rachel Broddy, Yan Dong, Rosemary Wieczorek, Peng Lee. New York University Langone Medical Center, New York, NY; Tulane University, New Orleans, LA. Background: The androgen receptor (AR) and its pathway have been implicated in tumorigenesis and progression of breast cancer. Recent studies identified at least 15 splicing variants of AR (AR-Vs). Structurally, AR-Vs have insertions of cryptic exons downstream of the exons that encode the DNA-binding domain or deletions of the exons encoding the ligand-binding domain, resulting in a disrupted AR open reading frame and expression of ligand-binding-domain-truncated AR proteins. In prostate cancer, some of the AR-Vs are associated with aggressive disease. The AR-V expression in human breast cancer specimens has not been studied. We aimed at studying the expression of AR-Vs in breast cancer specimens and present the data on AR-V1, AR-V7, AR8, and AR v567es , particularly in AR-positive triple negative breast cancer (TNBC). Design: Nine cases of TNBC were tested in this preliminary study. Cancer areas were macrodissected from formalin fixed paraffin embedded sections with total RNA extracted by using the PureLink® FFPE RNA Isolation Kit (Invitrogen). Reversetranscription was performed by using the SuperScript® III Reverse Transcriptase Kit (Invitrogen). AR-V expression was presented as cycle number difference to housekeeping gene (delta CT) for real-time PCR or as absolute copy number for digital PCR. Results: AR-V7 was expressed in all 9 cases with delta CT values varied from 0.14 to 7.84 with mean as 3.75. AR-V1 and AR-V4 were expressed in 4 of 9 cases (overlapping in 2 cases) with copy numbers ranging from 7.4 to 36. AR8 and AR v567es were expressed in 2 of 9 cases with copy numbers ranging from 10.8 to 52.
Splicing Variants of Androgen Receptor in Breast Cancer
Conclusions:
We report expression of different patterns of AR-V in triple negative breast cancer. These data are encouraging and warrant a study in a larger cohort of cases. AR maybe useful for both prognosis and targeted therapy in triple negative breast carcinoma. The CAP/ASCO guideline recommendations for HER2 FISH testing in breast cancer were updated in 2013. The guidelines recommend that a tumor with a dual probe HER2/CEP17 ratio ≥ 2.0 or an average HER2 copy number ≥ 6.0/cell be considered HER2 positive (HER2+) and a dual probe HER2/CEP17 ratio < 2.0 with average HER2 copy number ≥ 4 and <6/cell be considered HER2 equivocal (HER2e). The new guideline also eliminates the dual probe HER2/CEP17 ratio equivocal category. Background: RNA-sequencing (RNA-seq) is an alternative method for the analysis of gene expression, and may be used to overcome difficulties that are inherent to RNA microarray technology. Also, RNA-seq has a higher dynamic range compared to conventional gene expression techniques and therefore may be advantageous for the quantification of gene expression. We have compared routine immunohistochemistry (IHC) results obtained on breast core biopsies with gene expression by RNA-seq, and analyzed discrepant results. Design: Fresh frozen tumor tissue was collected from core cut biopsies of 267 cases of primary invasive breast cancer, after obtaining informed consent. RNA-seq was performed using generation sequencing (NGS). Routine IHC was performed on the core biopsies for ER, PgR, and HER2 expression on a fully automated system (Ventana), and validated primary antibodies. In case of HER2 2+ results, HER2 amplification was determined by CISH. Intrinsic subtypes were calculated according to clustering for RNA-seq. Discrepant cases were subjected to further analysis. Results: A high concordance rate between IHC and RNA-seq was observed for hormone receptor-(HR-) positivity, with a calculated accuracy of 94.7%. Discrepant cases that were HR-positive by IHC (irrespective of HER2-status) fell into HR-negative clusters by RNA-seq in 7.5%, but only 0.5% HR-negative cases were clustered as HR-positive by RNA-seq. With HER2, the accuracy rate for RNA-seq was calculated as 91.2%, with 4,9% false positives and 4,5% false negatives. For triple-negative cases by IHC, the calculated concordance (accuracy) was 95.8% when compared with the respective cluster as determined by RNA-seq. Further analysis that included the IHC from resection specimens showed that some but not all of the discrepancies could be explained by heterogenous antigen expression or by low hormone receptor positivity in IHC in cases that were non-luminal by RNA-seq. Further possible sources of discrepancies could include non-representative tissue for RNA-seq.
RNA-seq appears to be a reliable method for predicting positive ERand HER2-status, with an overall accuracy rate of 93,6% in the whole cases series. Discrepancies occurred due to low hormone receptor expression on IHC, because of HER2 heterogeneity, or sampling issues.
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Biomarker (2013) 24 (9): 2206-2223). Results: We found 343 MBC from 330 women (11 had 2, one had 3 different metastases) at a median age of 62 (mean 61, range 21-92). The most common sites were liver (27%), brain (17%), lung (13%), bone (13%), skin (13%), followed by soft tissue (4%), ovary (4%), pleura, mediastinum, adrenal, omentum, peritoneum, pericardium, dura, colon, vagina, parotid, and submandibular gland. Most specimens were biopsies (89%); 38 were excisions and 2 FNAs. ER testing was performed on 321 (93%) specimens, PR on 308 (90%) and HER2 on 311 (91%); all 3 biomarkers were available for 286 (83%) tumors. Conclusions: HER2+ and luminal B BC is more frequent in metastatic than in primary setting; the opposite is true for luminal A and PR+ BC. Brain metastases are more likely to be HER2+ or TN. Bone is a very uncommon metastatic site for HER2+ BC. Laboratories should account for these variations when analyzing biomarker rates against recommended benchmarks as part of quality assurance activity. Elzbieta Slodkowska, Sharon Nofech-Mozes, Guangming Han, Fang-I Lu, Wedad Hanna. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Background: While the classic forms of fibroepithelial lesions (FEL) do not pose any diagnostic challenge, there are some that defy classification. The aim of this study was to review the morphologic spectrum of FEL in relation to outcome. Design: We searched our files for phyllodes tumors (PT) and atypical fibroadenomas (aFA, size >5cm, moderate cellularity, mitoses >3 per HPF, leafy architecture, irregular border, ddx of FA vs. benign PT (BPT). All available slides were examined for border, architecture, stromal overgrowth, mitoses, necrosis, heterologous elements, and margin status. FEL were classified based on 2013 WHO book. Follow up (FU) was obtained from electronic medical records. Results: We found 189 FEL in 177 patients (pt) at a median age of 43 y. There were 55aFA, 59BPT, 29 borderline (BoPT) and 46 malignant PT (MPT). Slides were available for 130 of them (45aFA, 42BPT, 20BoPT, 23MPT). FU was available for 143 pt (median 51m, range 3-264m); 3 died of disease (DOD, all MPT), 5 were alive with disease (AWD, 4 with metastatic MPT, 1 with recurrent BPT) and 135 had no evidence of disease (NED). Local recurrence rate was 14%. 11PT recurred with the same grade (8BPT, 2BoPT, 1MPT) and 3 as more aggressive (1BoPT-MPT, 2BPT-MPT); for 6 the original PT was unknown. Of 15 FEL with FU and positive margin 13 recurred and 2 had NED (p=<0.0001). The border of 13 PT with available slides that recurred was infiltrative in 9, pushing in 1 and indeterminate in 3 (p=0.0001). MI and ≥50% myxoid stroma were only predictive of recurrence in BPT (p=0.0278 and p=0.001). Among 31 aFA and BPT with pushing border that were enucleated none recurred (median 57m). Necrosis (31%) and heterologous elements (7%) were only seen in MPT; necrosis was predictive of metastatic event (p=0.002). Only MPT metastasized at 21% rate (at median 8m). Background: According to WHO Classification of Tumors of the Breast 2013 the usual mitotic activity per 10 HPF is none to rare in fibroadenomas (FA), low at <5 in benign phyllodes tumor (BPT), frequent at 5-9 in borderline phyllodes tumors (BoPT) and abundant at ³10 in malignant phyllodes tumors (MPT ). The same authors also suggest that the mitotic count be related to the size of the field diameter (x40 objective and x10 eyepiece, 0.196mm 2 ). The aim of this study was to review the spectrum of mitotic activity in fibroepithelial lesions (FEL). Design: After ethics approval we searched our records for excision specimens of PT with available slides. In addition we included 'atypical FA' (aFA, size >5cm, moderate cellularity, mitoses >3 per HPF, leafy architecture, irregular border, ddx of FA vs. BPT). Two mitotic counts were recorded: the highest mitotic score per 10 HPF from the pathology report and the highest mitotic score counted in a single most mitotically active 1.96 mm 2 area that was chosen after meticulous review of all available slides. Follow up (FU) was obtained from electronic medical records. Results: We found 130 FEL with median of 6 slides per FEL (range 1-28). There were 45 aFA, 42 BPT, 20 BoPT and 23 MPT. The median tumor size was 3.7cm (range 0.7-24). When assessing MI in the most active area 17/45 (38%) of aFA had >3MF per 10HPF, 19/42 (45%) BPT had >5MF per 10HPF, 11/20 (55%) BorPT had >10MF per 10HPF, while only 5/23 (22%) MPT had <15 MF per 10HPF. The median FU was 55m (range 3-173m), during which 16 FEL recurred. MI was only predictive of recurrence for BPT, regardless of counting method (p=0.0278 using cut-offs 3 and 10, respectively). Background: In addition to conventional histopathological parameters, the assessment of proliferation is a major factor in treatment decision in breast carcinoma patients. Heterogeneity for ki67 is not well documented in the literature. The aim of this study was to assess weather ki67 heterogeneity in invasive breast carcinomas could have an impact over treatment decision. Design: Immunohistochemistry for ki67 was evaluated in large tumor sections from resection specimens (mastectomies/lumpectomies) of 131 consecutive invasive breast carcinomas. Heterogeneity was defined as the presence of a low (less than 17%) and high (more than 35%) proliferative activity within the same tumor in the same histologic section. The rest of the cases were defined as homogenous. Clinical-pathological features of the cases were also analyzed. Results: 107 (81.67%) of the cases were homogenous and 24 of 131 cases (18.32%) showed heterogeneity as defined above. Among these, 10 (41.6%) cases showed a gradient of increasing staining toward the tumor edge and 14 (58.4%) cases showed hot spots. In general, the proliferative activity varied from 1 to 90% in different areas of the tumor. A higher incidence of breast carcinoma was observed after menopause in both groups (83.33% in heterogeneous cases and 79.43% in homogeneous cases) (p=0.783). These groups were similar as far as the most frequent histological tumor types were concerned: NST type (95.83% vs. 56.07%)(p=0.0001). Tumor histological grade, T and N stage were similar in both groups. We noted a higher proportion of stage N3 cases in the heterogeneous tumor group (54.16% vs. 34.57%)(p=0.14). Prognostic markers analysis in the heterogeneous cases revealed 100% positivity for hormone receptors, (compared to 94.65%) and a much higher proportion of HER2 negative cases (87.5% vs. 73.83%)(p=0.19). Conclusions: Ki67 heterogeneity can be seen frequently in breast carcinomas. Clinicalpathological features are similar in both groups analyzed, but with an increased prevalence of NST, more advanced clinical stages (N3) and more HER2 negative cases in the heterogeneous group. As ki67 value could have an impact on clinical decisions, it is mandatory to evaluate the whole specimen and not only the core biopsy specimen and to correlate it with mitotic count. Background: Despite advances in prognostic factors in female breast cancer, data regarding the impact of different prognostic parameters including molecular markers is limited in male breast cancer. The objective of this study is to evaluate clinic-pathological parameters in correlation with overall survival (OS) to identify unfavorable independent prognostic parameters in male breast carcinoma. Design: All male patients diagnosed with invasive breast cancer in three different international institutions between 2008-2013 were identified by searching laboratory databases. Parameters analyzed included age, clinical and pathological stage, histological tumor type and grade, molecular biomarkers, treatment and overall survival (5 year OS). Results: 33 cases were identified. Mean age of patients was 64 (range: 45-81). Most of the cases were of NST histological type (69.69%), G2 histological grade (60.6%), T2 (63.63%), N2 (30.3%), M0 (93.93%) and Luminal A molecular subtype (64%). 25 patients received chemotherapy (CT), 9 of them received CT associated with hormone therapy (HT), 1 case only HT and 1 case-CT followed by radiotherapy (RT). Follow-up information was available in all patients ranging from 10 to 84 months. Median survival was 48 months. 21 patients are alive and free of disease (all of them received HT), 2 cases have metastatic disease and 11 patients are deceased. In univariate analysis a higher T status and the presence of axillary lymph node metastases was associated with worse median survival (p=0.014, respectively p=0.03) while in multivariate analysis we found that survival is independently influence by age (over 70 years unfavorable) (p=0.028, 95% CI=1.208-26.383). Among the deceased patients, the majority was treated only with CT while none of them received HT. Conclusions: Older age is the only statistically significant unfavorable independent prognostic parameter in multivariate analysis in male breast carcinomas. While not statistically significant, all male breast cancer cases analyzed in this study had uniform expression of molecular markers (ER/PR positive-93.93%, HER2 negative-96.97%) and an excellent response to HT, which highlights its role in prognosis and survival.
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Cancer Stem Cell and Epithelial-Mesenchymal Transition Markers Predict Worse Outcome in Triple Negative Breast Cancer Puay Hoon Tan, Aye Aye Thike, Valerie Koh, Yvonne Boey. Singapore General Hospital, Singapore, Singapore. Background: Triple negative (TN) breast cancers, defined by the absence of estrogen receptor, progesterone receptor and c-erbB2 (HER2) expression, have more aggressive clinical behavior, poorer prognosis, and lack targeted therapy options. Tumors with stem cell properties are able to self-renew, harbor a higher cancer recurrence rate and are more resistant to therapy, while epithelial-mesenchymal transition (EMT) predicts tumor progression, metastasis and drug resistance. We investigate immunohistochemical expression of cancer stem cell (CSC) and EMT markers in TN breast cancers. Design: The study comprised 696 TN breast cancers (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) from the Department of Pathology, Singapore General Hospital. Antibodies to basal (CK14, 34βE12), EGFR, CD44 and EMT markers (E-cadherin and Snail2) were applied to tissue microarray sections, using the streptavidin-biotin method. CK14, 34βE12, EGFR, CD44 and Snail2 expression was defined as staining of 1% or more of tumor cells, with cytoplasmic decoration for CK14 and 34βE12, cytoplasmic membrane staining for EGFR, CD44 and E-cadherin, and nuclear reactivity for Snail2. Loss of membranous E-cadherin occurred when ≤70% of tumor cells expressed membranous staining. Disease free survival (DFS) and overall survival (OS) were calculated as time from diagnosis to recurrence or death respectively. Results: Expression of CD44 and Snail2, loss of membranous E-cadherin was observed in 354 (51%), 215 (31%) and 274 (39%) tumors respectively. Histologic grade significantly associated with CD44 (p=0.007), Snail2 (p<0.001) positivity, loss of E-cadherin membranous expression (p=0.007). CK14, EGFR and 34βE12 confirmed 85% of cases to be basal-like, with similar correlation (CD44 positive, p<0.001; Snail2 positive, p=0.026; and E-cadherin loss, p=0.045). Positive Snail2 (p=0.007), loss of E-cadherin (p<0.001) were associated with syncytial growth pattern. CD44 positive tumors harbored pushing borders (p=0.001). Median follow up was 83 months, with a maximum of 236 months. A combinational phenotype (loss of E-cadherin, Snail2 and CD44 positivity) was observed in 57 (8%) tumors. Cases with this phenotype (p=0.013) and CD44 positive tumors (p=0.024) disclosed poorer OS. Multivariate analysis confirmed statistically significant association of the combinational phenotypewith unfavorable OS (HR 1.768, 95% CI 1,032-3.029, p=0.038).
Conclusions:
We conclude that enrichment of CSC and EMT markers in TN breast cancers correlated with aggressiveness and basal-like phenotype, which may provide new insights for therapy.
Immunohistochemical Protein Expression of Chemokine Receptor Cxcr4 and Vegf Predicts Histological Grade and Poorer Outcome in Breast Phyllodes Tumors
Puay Hoon Tan, Aye Aye Thike, Jeffrey Lim. Singapore General Hospital, Singapore, Singapore. Background: Phyllodes tumors of the breast are uncommon fibroepithelial neoplasms which present challenges for grading and prognostic assessment. To date, there is no consensus regarding the role of biomarkers in these unusual tumors. Inhibition of CXCR4, a chemokine receptor, is believed to decrease vascular endothelial factor (VEGF) expression and angiogenesis in vitro and in vivo. The aim of this study was to evaluate protein expression of VEGF and CXCR4 in a series of phyllodes tumors and correlate the expression of these markers with clinicopathological parameters and outcomes. Design: The cohort comprised 158 phyllodes tumors diagnosed at the Department of Pathology, Singapore General Hospital between 2005 to 2009, incorporating 107 (67.7%) benign, 39 (24.7%) borderline and 12 (7.6%)%) malignant tumors. Antibodies to CXCR4 and VEGF were applied to sections cut from tissue microarray blocks (2mm cores, 3 cores per case), using the streptavidin-biotin method. Immunoreactivity was assessed in stromal cells of tumors. Positive biomarker expression was defined as staining of mean percentage or more of stromal cells, with cytoplasmic membrane staining for CXCR4, and cytoplasmic decoration for VEGF. Disease free survival (DFS) and overall survival (OS) were defined as time from diagnosis to recurrence or death respectively, and correlated with protein immunohistochemical expression. Results: Positive immunohistochemical expression of CXCR4 and VEGF was seen in 58 (36.7%) and 62 (39.2%) cases respectively. Stromal expression of CXCR4 and VEGF was significantly correlated with high histologic grade (p=0.001, p<0.001), permeative borders (p=0.025, p=0.003), stromal cell atypia (p=0.021, 0.001), and high mitotic score (p<0.001, p<0.001). CXCR4 expression was significantly associated with stromal hypercellularity (p=0.036), and VEGF was more expressed in larger tumors (p=0.019). At a maximun follow up duration of 75 months (mean and median 36 months), 11 patients developed recurrences, with three succumbing from phyllodes tumors. Patients whose tumors expressed CXCR4 and VEGF disclosed poorer OS (p=0.015, p=0.034 respectively). Conclusions: Determination of CXCR4 and VEGF provides significant biological insight into breast phyllodes tumors. These markers may promote new therapeutic paradigms especially for the malignant group of phyllodes tumors.
Conclusions:
RT-PCR testing has clinical utility in identifying pts who may be HER2(+) by central FISH/IHC & therefore candidates for HER2 targeted therapy. The QA program identifies rare cases where IS is HER2(+) & IBC is HER2(-). Ping Tang, Huijiao Chen, Jianmin Wang, Kristin Skinner, Michelle Shayne, Marilyn Ling, Bradley Turner, David Hicks, Hong Bu, Zhang Zhang Design: 560 patients with ER positive tumors, clinical follow-up and diagnosed between 1997 and 2012 in our institution were included. Modified ERS from all three equations, which used the Nottingham grade (3-9), modified H-score of ER and progesterone receptor (PR) (average staining intensity X percent positive tumor cells, 0-300), HER2 status (negative, equivocal, positive), tumor size (cm) and % labeling for Ki-67, were calculated from each case. A mean modified ERS of each case was used for statistical analysis. Results: For this cohort, the mean age was 60 years, the mean tumor size was 2.17 cm, 71% were histologic grade 1 and 2, 63% were node negative. All patients were ER positive, 85% were PR positive, and 10% were HER2 positive. The Modified ESR was not associated with patient age, tumor size, or histological grade; but it was associated with nuclear grade and expression of ER, PR, HER2 and Ki-67. Although nodal status was not included in calculations in these equations, a high Modified ERS (>30) was strongly associated with positive node. Among the three components of Nottingham grading, only nuclear grade showed a significant association with Modified ERS. Only 4% of ER 71-100%, 2% of PR 71-100%, 8% of HER2 negative, and 5% of Ki-67<15% had Modified ERS >30. Also, Modified ERS was significantly associated with progression free survival in these 560 patients (p-value=0.0031) and in node negative subgroup of these patients (p value=0.0069), but not in node positive patients (p value=0.8697). Conclusions: Modified ERS can effectively stratify ER positive patients into different prognostic subgroups. It may be used to guide clinical decision making for patients with ER positive tumors, in conjunction with other clinical-pathologic factors. Ping Tang, Wei Bing, Jianmin Wang, Sara Xu, David Mills, Hiba Iqbal, Kristin Skinner, David Hicks, Hong Bu. University of Rochester Medical Center, Rochester, NY; West China Hospital, Sichuan University, Chengdu, China; RTI Health Solutions, Research Triangle Park, NC. Background: Progesterone receptor (PR) is an estrogen receptor (ER)-regulated gene and has critical roles in both normal mammary and breast cancer development. Loss of ER expression in breast cancer is associated with older patients, larger tumors, higher grade tumors, and tumors over-expressing HER2. We previously showed that loss of PR expression predicts for higher Recurrence Scores (RS) for the 21-gene assay (ODX) and higher risk for bone metastasis. Recently, a 20% or less PR was proposed as a classifier to separate Luminal B from Luminal A subtype of breast cancer. Limited information is known for PR in ductal carcinoma in situ (DCIS). Here, we intend to study the relationship between the different levels of PR expression and various pathologic features in DCIS of the breast. Design: 886 cases of primary DCIS of the breast from our institution and diagnosed between 1997 and 2013, had an exact percentage documented for ER and PR IHC scoring, were included in the study. The clinicopathological features, including patient age, tumor size, nuclear grade and expression of ER and PR, were collected for each case. The relationships between the different levels of PR expression (<1%, 1-20%, 21-50%, 51-70% and 71-100%) and these pathologic features were analyzed. Results: Among the 886 cases of DCIS, the mean age was 85.5 years, mean tumor size was 2.4cm, 84.5% were positive for ER, and 76.2% were positive for PR. 24%, 14%, 13, 11%, and 38% of these DCIS had PR expression of <1%, 1-20%, 21-50%, 51-70% and 71-100%, respectively, similar in distribution as was seen in IDC (data not shown). Significant differences in patient age, nuclear grade and ER expression were observed only between the PR<1% and PR 1-20% subgroups, with less PR expression associating with younger patients, higher nuclear grade and lesion ER expression in DCIS; these difference was not observed between the PR 1-20% and PR 21-50% subgroups, the PR 21-50% and 51-70% subgroups, and the PR 51-70% and PR 71-100% subgroups. In ER positive tumors, the only significant difference noted between different PR subgroups was nuclear grade. Conclusions: The significant pathological difference observed in between PR<1% and PR 1-20% suggests the cutoff of 1% for PR appears to be biologically important. Further studies are warranted to investigate the roles of PR in local/regional of DCIS of the breast.
Modified Magee Equations Predict Clinical Outcome for Breast Cancer Patients
Pathological Features of DCIS of the Breast According To the Expression of Progesterone Receptor
increased by 23.5% (OR=1.235, p=0.010). With each additional year of age, the odds of choosing cx decreased by 5.3% (OR=0.947, p=0.058). The decision to treat with adjuvant cx did not correlate with menopausal status, oncologist, size or grade of the tumor. Of note, 3 of 3 patients with N1mi nodal status were treated with cx , and the 1 patient with N0(i+) nodal status was treated with hormonal therapy alone. Background: Survivin is a member of the inhibitor of apoptosis gene family and has dual roles in promoting cell proliferation and preventing apoptosis. It is one of the 16 genes tested in Oncotype DX, an RT-PCR assay used to predict additional benefit from chemotherapy in estrogen receptor positive, lymph node negative breast cancer patients. We set out to investigate the prognostic significance of Survivin in triple-negative breast cancer, the most aggressive subtype currently lacking targeted therapies. Design: With Queen's University Research Ethics Board approval, a cohort of 348 breast cancer patients with 5-12 years of follow-up was assembled. A rich clinical database was created and tissue microarray was constructed. ER-/PR-/HER2-tumours were defined as triple-negative. The immunohistochemistry-based subtype definitions were luminal (ER+ or PR+/HER2-), luminal/HER2+ (ER+ or PR+/HER2+), HER2+ (ER-/PR-/HER2+) and triple negative, including the basal (ER-/PR-/HER2-/CK5+ or EGFR+) and non-basal (ER-/PR-/HER2-/CK5-/EGFR-) subgroups. Proliferation index was assessed using Ki-67 and Survivin stains. Nuclear staining for Survivin was scored based on the percentage of positive cells as follows: 0, 1-10%, 10-50% and >50%. Results: There were 53 triple-negative (15%) patients (including 43 basal, 8 non-basal and 2 unclassifiable cases), 213 luminal (61%), 21 luminal/HER2+ (6%), 24 HER2+ (7%) and 37 (11%) unclassifiable breast cancers. Survivin was not differentially expressed in the luminal subtypes. Overall survival was lower in triple-negative cases versus the rest of the cohort. Unadjusted univariate analysis showed that high Survivin expression (>50% positive cells) versus low (<50% positive cells) Survivin expression predicted for lower overall survival (p=0.004). Survivin expression in >10% cells was associated with lower recurrence-free survival (p=0.049). Conclusions: Increased expression of Survivin at the protein level merits further study as a possible prognostic factor in triple-negative breast cancer patients. Background: ER and PR have traditionally been assessed on whole sections of excisional specimens (EXS) for breast cancer to determine eligibility for hormone therapy. Clinicians now ask that ER and PR be reflexively assessed on all core needle biopsy specimens (CNBX) showing ductal carcinoma in situ (DCIS), despite the fact that these results do not impact the next step in therapy; namely, surgical excision. However, a subset of EXS performed for DCIS diagnosed on CNBX will harbor IDC which would need to be retested for ER/PR. Moreoever, because ER and PR labeling is often heterogeneous, many recommended that negative results for these markers on small CNBX be repeated on EXS. We have previously demonstrated that reflex ER/PRHer2 testing of invasive mammary carcinomas (IMC) on CNBX unnecessarily increases costs due to the need to repeat negative results in EXS (Mod Pathol 2014;27(S2): 86A). We now examine the added cost associated with reflex ER/PR testing of DCIS on CNBX. Design: We reviewed all cases of CNBX showing pure DCIS which also had a resulting EXS at our institution over a period of 2 years. Cases in which ER or PR were inadvertently not ordered on CNBX were excluded. EXS lesions which could not be definitively matched with the DCIS on CNBX (e.g. some EXS with multiple tumors) were excluded. The number of cases in which the EXS harbored IMC, as well as the number of cases in which ER/PR was negative on the CNBX, was assessed. The cost of each test was calculated as both the technical and pro-fee bill combined. Results: A total of 63 cases of DCIS meeting the study criteria were identified. 6 (10%) only had benign pathology on EXS, 44 (70%) had pure DCIS, 4 (6%) had DCIS with microinvasive carcinoma (MI), and 9 (14%) had DCIS with IMC. The 13 cases with MI or IMC (20% overall) required repeat ER and PR testing of the invasive component in the EXS. Of the 44 cases with pure DCIS, 4 were negative for both ER and PR on CNBX which also merited repeating testing on EXS. The total increased cost of repeat testing on these cases was $10,656 dollars. Conclusions: Reflex ER/PR testing of DCIS on CNBX unnecessarily increases health care costs. Extrapolating our cost of $201 per DCIS diagnosis on CNBX to 50,000 new cases of DCIS in the United States each year, reflex ER/PR testing would increase costs by over $10 million dollars. As with IMC, we recommend that ER and PR not be reflexively ordered on CNBX specimens containing DCIS, but instead be routinely performed on EXS. Sonal Varma, Victoria Hoskin, Abdi Ghaffari, Yolanda Madarnas, Sandip SenGupta, Bruce Elliott. Queens University, Kingston, ON, Canada; Queen's University, Kingston, ON, Canada. Background: Over-expression of the metastasis-associated protein ezrin has been identified in many invasive cancer types including breast, but has not yet been associated with a specific breast cancer (BC) subtype. Furthermore, recent studies have indicated a link between ezrin and drug resistance. However, very few studies have been conducted for BC, or have assessed whether ezrin is associated with treatment response. Design: Using an open access gene expression database (KM Plotter), we looked at ezrin expression with overall survival (OS) and distant metastasis-free survival (DMFS) in estrogen receptor positive (ER+) and negative (ER-) BC patients. To understand the role of ezrin in drug resistance, we over-expressed or silenced ezrin expression in MCF-7 and ZR-75-1 BC cells, which have low and high ezrin levels, respectively and show differential intrinsic sensitivity to various chemotherapeutic agents. Cytotoxicity assays were performed on cells treated with doxorubicin (Dox). Western blotting was performed on whole cell lysates to assess changes in the PI3K and NF-kB survival signaling pathways which have previously been linked to ezrin. Results: Based on the KM Plotter analysis, high ezrin expression was associated with a lower OS and DMFS in a cohort of ER+, but not ER-, BC patients. In vitro assessment of high vs low ezrin expression revealed that over-expression of ezrin in MCF-7 cells which are sensitive to Dox, increased resistance to the cytotoxic drug, while ezrindepletion in ZR-75-1 cells which exhibit intrinsic resistance to Dox, resulted in increased sensitivity to Dox treatment. Biochemical analysis demonstrated that over-expression of ezrin increased phosphorylation of Akt, p65 NF-kB, and expression of its downstream target, survivin. Furthermore, ezrin-depletion reduced p65 NF-kB phosphorylation and survivin expression, but did not alter Akt phosphorylation. Conclusions: High ezrin expression may be a prognostic marker for poor outcome in ER+ BC patients. Furthermore, high ezrin expression is associated with increased drug resistance and NF-kB/survivin signaling, which may provide important survival signals for the ezrin-mediated drug resistance phenotype. Analysis of our locally accrued breast tumour cohort (n=348) is in progress to validate the ezrin pathway as a potential predictive marker of treatment response. . All components and their peritumoral normal tissue were retrospectively microdissected on frozen tissue sections for DNA extraction. Paired-end whole-exome sequencing was performed (average depth of coverage 70X; uniquely mapped reads). Single-nucleotide variants (SNVs) were identified with SAMTools and GATK. After evaluation of their putative functional impact (PolyPhen-2 and GERP scores), SNVs were validated with Sanger sequencing. Copy-number genomic profiles were determined from whole-exome datas (The Control-FREEC algorithm). To determine if SNVs identified in only one component could be detected in the others, targeted ultra-deep sequencing was performed. Results: SNVs in PIK3CA and CBFB were identified in all tumor components of both patients. For patient 2, SNVs in genes such as TP53, EIF4A1, ABCD3 and GATA3 were identified in all tumor components. Ultra-deep sequencing revealed that all 10 SNVs initially observed in only one tumor component only, were present in all tumor components. Strikingly, two SNVs in CDKL1 and in CNTNAP2 genes were identified at much lower allelic frequencies in IDC compared to that of DCIS and N+. Furthermore, for patient 2, somatic copy number alteration profiles revealed a X chromosome subclonal loss in DCIS and a clonal loss IDC, verified by FISH but was not present in the axillary lymph node metastasis. Conclusions: Our study showed that despite X chromosome loss visible in 100% of the IDC cells, the N+ cells harbored no X chromosome loss, suggesting that metastatic cells could derive from subclones of the DCIS component and not from IDC in this patient. The mutational profile was also consistent with this observation. These whole-exome sequencing data refined the mutation repertoire of DCIS and showed that DCIS, IDC and N+ from a same patient harbored identical but also private somatic genomic alterations and highlighted inter-tumoral as well as intra-tumoral heterogeneity.
Conclusions
High Ezrin Expression Is Linked To Poor Prognosis and Drug Resistance in Estrogen Receptor-Positive Breast Cancer
